
<html lang="en"     class="pb-page"  data-request-id="dace0480-7e39-48bc-910f-1663bad7b4c5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm401490p;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases" /></meta><meta name="dc.Creator" content="James D.  Clark" /></meta><meta name="dc.Creator" content="Mark E.  Flanagan" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Telliez" /></meta><meta name="dc.Description" content="The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammat..." /></meta><meta name="Description" content="The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 23, 2014" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401490p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401490p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401490p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401490p" /></link>
        
    
    

<title>Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401490p" /></meta><meta property="og:title" content="Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0012.jpeg" /></meta><meta property="og:description" content="The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401490p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401490p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401490p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401490p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401490p&amp;href=/doi/10.1021/jm401490p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5023-5038</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401430e" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm401516c" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+D.++Clark">James D. Clark</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Flanagan">Mark E. Flanagan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Telliez">Jean-Baptiste Telliez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Pfizer Immunosciences, 200 CambridgePark, Cambridge, Massachusetts 02140, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Center for Chemistry Innovation and Excellence, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="corresp-info"><strong>*</strong>Telephone: 860-441-0205. E-mail: <a href="/cdn-cgi/l/email-protection#412c20332a6f246f272d202f2026202f013127283b24336f222e2c"><span class="__cf_email__" data-cfemail="4924283b22672c672f252827282e282709392f20332c3b672a2624">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401490p&amp;href=/doi/10.1021%2Fjm401490p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5023â5038</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 13, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 September 2013</li><li><span class="item_label"><b>Published</b> online</span>23 January 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 June 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401490p" title="DOI URL">https://doi.org/10.1021/jm401490p</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5023%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BD.%2BClark%252C%2BMark%2BE.%2BFlanagan%252C%2BJean-Baptiste%2BTelliez%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D12%26contentID%3Djm401490p%26title%3DDiscovery%2Band%2BDevelopment%2Bof%2BJanus%2BKinase%2B%2528JAK%2529%2BInhibitors%2Bfor%2BInflammatory%2BDiseases%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5038%26publicationDate%3DJune%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401490p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">13774</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">255</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401490p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;D. Clark&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Flanagan&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Telliez&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;5023-5038&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401490p&quot;},&quot;abstract&quot;:&quot;The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401490p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401490p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401490p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401490p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401490p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401490p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401490p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401490p&amp;href=/doi/10.1021/jm401490p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401490p" /></input><a href="/doi/pdf/10.1021/jm401490p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26pmid%3D24417533%26genre%3Darticle%26aulast%3DClark%26date%3D2014%26atitle%3DDiscovery%2Band%2BDevelopment%2Bof%2BJanus%2BKinase%2B%2528JAK%2529%2BInhibitors%2Bfor%2BInflammatory%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jmcmar.2014.57.issue-12/production/jmcmar.2014.57.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0012.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus kinases or JAKs are a family of intracellular tyrosine kinases that function as hubs in the signaling process of many cytokine receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The JAKs play a critical role in both innate and adaptive immunity as well as hematopoiesis, making them attractive targets for a number of therapeutic indications.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Consequently, since their discovery in the early 1990s, the JAKs have steadily garnered interest as targets for new medicines.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> There are now multiple chemical entities in the clinic across various indications including myeloproliferative diseases and various inflammatory diseases. Because of the volume of clinical activity in recent years, this review will focus on the inhibition of the JAK enzymes for the treatment of inflammatory diseases.</div><div class="NLM_p">The etiology of many inflammatory and autoimmune diseases is not fully understood but involves a combination of genetic predispositions and environmental and lifestyle triggers. The pathogenic inflammatory state often involves a break in T- and B-cell tolerance against self-antigens leading to undesirable autoimmune responses. When antigens from affected tissues are presented on antigen presenting cells (APCs) to naive T-helper cells (Th0) along with co-stimulatory factors, cytokines, which are low molecular weight (â¼30 kDa) protein or glycoprotein signaling molecules, are secreted leading to activation, differentiation and expansion of Th0 cells to distinct T-helper phenotypes (e.g., Th1, Th2, Th17). These activated T-cells themselves secrete cytokines that activate other cells of the immune system, such as macrophages, NK cells, and neutrophils that infiltrate the targeted tissue, causing the damage associated with these diseases. Therefore, by orchestrating the intercellular communication in this process, cytokines play a central role in the inflammatory response.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cytokine receptor superfamilies and associated signal transduction pathways. Protein kinases feature prominently as mediators in signal transduction. The complex nature of these signaling pathways lead to redundancies in some cases. However, there are no known compensatory pathways around JAK/STAT. Furthermore, many cytokine receptors lack intrinsic kinase activity, instead relying on associated tyrosine kinases, such as the JAKs to transmit signals from the extracellular environment to the nucleus. Consequently, many cytokines and growth factors important for a variety of immune, inflammatory, and hematopoietic functions signal through JAK/STAT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cytokines signal through a variety of receptor superfamilies (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> By binding to the extracellular domain of the receptor, the cytokine induces changes that are detected at the intracellular domain, triggering signal transduction events ultimately leading to changes in gene expression.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Protein kinases are key players in signal transduction pathways for these receptor superfamilies. As a consequence, many of these kinases have been targeted in an effort to modulate the inflammatory response. However, because of the complex network of these signal transduction pathways, which can be redundant, some of these kinases make better drug targets than others.</div><div class="NLM_p">The JAKs associate with the intracellular domain of receptor subunits of the class I and class II receptor superfamily.<a onclick="showRef(event, 'cit1a'); return false;" href="javascript:void(0);" class="ref cit1a">(1a)</a> The class I receptors all bind ligands with a common four helical structure and share a common WSXWS motif extracellularly and, although divergent intracellularly, have a conserved membrane proximal region for associating with JAKs. The class II receptors bind interferons and the IL-10 family and are structurally related to the class I receptors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The activation step occurs when a cytokine binds to its receptor, inducing a multimerization (dimerization or higher order complexes) of receptor subunits. This brings the JAKs associated with each subunit proximal to one another, triggering a series of phosphorylation events ultimately resulting in the phosphorylation and activation of signal transducers and activators of transcription (STAT) proteins. A phosphorylated STAT dimer then translocates to the nucleus of the cell where it binds to target genes modulating their expression (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Importantly, since there are no known compensatory pathways around JAK/STAT, the JAK enzymes are essential in regulating the cytokines that signal through these pathways. Furthermore, many of the cytokines that signal through the class I and class II receptors are implicated in the pathogenesis of autoimmune diseases, adding to the attraction of the JAKs as drug targets.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytokine signaling through the JAK/STAT pathway. Cytokine binding to the receptor leads to JAK activation and phosphorylation of the JAKs and associated receptors. Phosphorylation of the receptors in turn initiates recruitment of the STATs via their SH2 domains and subsequent phosphorylation of STAT proteins. The phosphorylated STAT homodimers or heterodimers then translocate to the nucleus where they bind to specific DNA binding sites regulating gene transcription that leads to changes in cellular function.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are currently several biologics available that have clearly demonstrated the benefits of inhibiting cytokine activity in the treatment of inflammatory diseases.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The majority of these are monoclonal antibodies that derive their activity by binding to and blocking the cytokine receptor or the cytokine itself. For example, biologic tumor necrosis factor (TNF) inhibitors have been available for over 10 years and used to treat patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, and inflammatory bowel disease in which nonbiologic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), are insufficient.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, RA patients often require therapy for decades, and recent data show that after 2 years, only about half of patients remain on their first TNF inhibitor.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Thus, additional treatment options are needed. Moreover, many patients are reluctant to self-inject or undergo iv infusions required for administration of biologics. JAK inhibition with an orally available small molecule represents an alternative approach to biologic therapies. Since the JAK enzymes associate with the intracellular domains of the class I and class II cytokine superfamilies, they cannot be readily targeted by biologics with the current state of the art but can be accessed and inhibited with a small molecule possessing the appropriate physicochemical properties.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Small molecules also offer the potential advantage of oral dosing, adding to the attraction of this approach. In addition, unlike biologics that generally act by binding to individual cytokines or receptors and nearly completely inhibiting an individual cytokine for prolonged periods of time, JAK signaling is downstream of multiple cytokines implicated in the pathogenesis of inflammatory diseases, and therefore, efficacy can be observed at doses that partially and reversibly modulate the signaling of multiple pathways. Higher doses that fully inhibit multiple pathways may drive greater efficacy but would likely be immunosuprpressive.</div><div class="NLM_p">There are four members of the JAK family: JAK1, JAK2, JAK3, and TYK2. The four JAKs possess two kinase domains, a true kinase domain, and a likely inactive pseudo-kinase domain. Thus, they get their name from Janus, the two-faced Roman god of doors and new beginnings. An important element of JAK function is the pairing of the JAK kinases, which are associated with the intracellular domains of different subunits of the receptor. The biological significance of signaling through different JAK combinations is illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The pairing of the JAKs with a given cytokine receptor is determined by their association with specific receptor chains. For example, JAK3, being coupled to the Î³-common chain, is always paired with JAK1 and in this arrangement controls the signaling for the six known Î³-common cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 primarily associated with adaptive immune functions.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> JAK1, however, also pairs with JAK2 and TYK2, regulating the signaling through a wide array of cytokine receptors and therefore affecting several proinflammatory cytokines associated with the innate immune response, such as IL-6 and the type I interferons. JAK2 is the only member of the JAK family that pairs with itself. In this combination JAK2 controls the signaling of various cytokines and growth factors, such as IL-3, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), and thrombopoietin (TPO). Consequently, since specific cytokines may be implicated in the pathogenesis of certain diseases, while modulation of others may result in undesired side effects, striking the appropriate selectivity balance for inhibition within the JAK family continues to represent both an opportunity and a challenge for drug development.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biological significance of signaling through different JAK combinations. Cytokine signaling is mediated by specific JAK and STAT combinations due to preferential binding to the intracellular domains of the individual cytokine receptor chains. For example, JAK3 only associates with the Î³-common chain and therefore only mediates IL-2, -4, -7, -9, -15, and -21 signaling, whereas JAK1 plays a broader role in cytokine signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">JAK3 was among the first of the JAKs targeted for therapeutic intervention in this regard.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This is due to strong validation following characterization of human JAK3 deficiencies.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Inactivating mutations in JAK3 confer a severe combined immune deficient (SCID) phenotype in humans that is phenotypically indistinguishable from the Î³-common chain deficiency, demonstrating the link between this receptor chain and JAK3.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In patients with two mutated JAK3 alleles, enzymatic activity is completely abrogated, disrupting the signaling of multiple cytokines that would ordinarily signal through this pathway and that are important for T-cell and NK cell activation, development, and homeostasis. While these patients have a profoundly impaired immune system, they are otherwise normal and can be rescued by bone marrow transplantation, providing good genetic validation for JAK3 as a therapeutic target for selective immune modulation limited to the hematopoietic system. Heterozygous parents of the SCID patients did not exhibit an immunocompromised phenotype, suggesting that partial inhibition could be used to modulate the immune response. This has important implications in a number of clinical settings, such as prevention of transplant rejection and treatment of various autoimmune disorders. Importantly, while complete inhibition of JAK3 and/or JAK1 would result in immunodeficiency, clinical experience has taught that partial and reversible inhibition of multiple JAKs, including JAK3, during the course of a day can provide safe and effective treatment in a number of therapeutic settings.</div><div class="NLM_p">The homology within the JAK family combined with the fact that JAK family crystal structures have only recently become available made it challenging to target JAK3 selectively. As a consequence, early JAK clinical candidates, such as CP-690,550 (<b>1</b>), now known as tofacitinib, inhibit a combination of JAK enzymes, the implications of which will be discussed in subsequent sections.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> To date, there is no evidence of human deficiencies in JAK1 and JAK2. This is consistent with perinatal and embryonic lethality in phenotypes of JAK1 and JAK2 KO mice, respectively.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> JAK2 activity is essential for hematopoiesis, and JAK1 signaling is required across many of the type I and type II cytokine receptors.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Type I receptors contain conserved Cys residues and a WSXWS extracellular motif. Type II receptors are related to the type I receptors but do not contain the WSXWS motif. Like JAK3, TYK2 mediates a smaller number of cytokine pathways. To date, two human patients with TYK2 deficiency have been described with distinct but overlapping phenotypes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Both patients appear to have impaired but not abolished resistance to viral and bacterial pathogens consistent with defects in IFNÎ³, IFNÎ±/Î², IL-12, and IL-23 signaling.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Differences in the phenotype of the two patients, the phenotype of TYK2 deficient mice and inconsistencies between the effect of TYK2 deficiency and cytokine deficiencies thought to be mediated by TYK2 suggest that TYK2 dependent signaling is not yet fully delineated.</div><div class="NLM_p last">There are currently at least seven JAK inhibitors in clinical development for inflammatory diseases and potentially many more being profiled preclinically. The following sections will take a deeper look into the nature of the JAK enzymes and a more detailed examination of the entities in the clinic that show potential for the treatment of inflammatory diseases.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">JAK Enzyme Structure and Signaling</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The JAK enzymes are relatively large proteins (120â130 kDa) of the tyrosine kinase family.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> There is a high degree of sequence homology across the JAK family with the highest homology observed within the catalytic domain. These enzymes contain seven distinct homologous regions comprising four structural domains (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). One characteristic feature of the JAKs is the two structurally related domains JH1 and JH2.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> JH1 is the active kinase catalytic domain, while JH2 is termed the pseudo-kinase domain that is not functional catalytically but is thought to play a key regulatory role in concert with JH1.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Interestingly, recent work has shown that the JH2 domain of JAK2 might negatively regulate JAK2 function by phosphorylating key residues within the JH2 domain.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The JH3 and JH4 domains are believed to primarily play a structural role in stabilizing the confirmation of the JAKs, while the domains JH5-JH7 (FERM domain) have been shown to interact directly with the intracellular domain of the cytokine receptor as well as interact with the JH1 domain.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Upon cytokine binding and conformational changes the JAKs are activated and become phosphorylated notably on tyrosine residues in the activation loop of the kinase (JH1) domain. Activated JAKs phosphorylate specific tyrosine residues in the intracellular domain of the receptor, creating recruitment sites for STATs. Recruitment of STATs to the receptor in turn allows JAKs to phosphorylate STATs, leading to their dimerization and subsequent migration to the nucleus where they bind to specific DNA binding sites, regulating gene transcription that leads to changes in cellular function.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic of JAK structural domains. The JAKs all contain seven homology regions (JH) and four structural domains. A characteristic feature of the JAKs is the presence of a pseudo-kinase domain JH2 that exerts regulatory function over the catalytic kinase domain JH1. The SH2 and FERM domains provide structural and regulatory control over the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mutations in JAKs are associated with various cancers, myeloproliferative disorders (MPD), and autoimmune conditions.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Mutations associated with a loss of function in JAK3 lead to a SCID phenotype in an autosomal recessive fashion as noted above (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> but many activating mutations have also been described in JAK1, JAK2, and JAK3 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B) consistent with autoinhibitory conformations.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Importantly, the dysregulation of JAK2 in a number of myeloproliferative neoplasms is the direct consequence of a V617F activating mutation in the JH2 domain which led to the original targeting of JAK2 in myelofibrosis.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Analogously, activating mutations in JAK3 are observed in adult T-cell leukemia or lymphoma, as well as in T-cell ALL and NK-cell or T-cell lymphoma.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic of JAK3 structure and site specific inactivating mutations leading to a SCID phenotype or activating mutations leading to hematological malignancies. (A) Many mutations have been identified in JAK3 that lead to a SCID phenotype in humans. This phenotype results from the disruption of normal signaling of the Î³<sub>c</sub>-dependent cytokines that are important for T cell function, development, and homeostasis. Mutations have been identified in all of the structural domains of the kinase. Therefore, abrogation of normal catalytic activity can result from abnormalities in structural, regulatory, or catalytic function. (B) Gain of function mutations have also been identified in JAK3. These mutations are associated with lymphoproliferative disorders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The sequence homology within the ATP binding site of the JAKs is nearly identical making the discovery of selective, ATP competitive inhibitors within the JAK family difficult (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Until 2005 there were no published crystal structures of the JAKs adding to this challenge.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Today there are published high resolution structures of all four JAK family members.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> However, even guided by structure, developing selective JAK structureâactivity relationships (SARs) has been challenging owing to the similarity of these enzymes. In published crystal structures of the JAKs, âcompound <b>6</b>â (CMP6)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and the Pfizer inhibitor tofacitinib (<b>1</b>) have featured prominently. Both compounds interact similarly across the JAKs, binding deep in the ATP binding site. Both compounds make key hydrogen bond interactions with the hinge region and are capable, in most cases, of interacting directly with the glycine rich loop (P-loop). Additionally, in the case of tofacitinib, the piperidine methyl group binds in a lipophilic pocket in the C-terminal lobe at the base of the active site, making van der Waals interactions with key residues (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The high degree of shape complementarity that these structural features provide helps explain the exquisite kinome selectivity observed for <b>1</b>. However, with only four subtle amino acid differences across the JAK family in the region where <b>1</b> binds, it once again underscores the challenge of gaining selectivity within the JAKs.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Homology in JAK family ATP binding site. The JAKs exhibit a high degree of homology in the ATP binding site. This sequence alignment illustrates in color and in three dimensions, where amino acid differences occur across the JAK family.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of tofacitinib (purple) with JAK3 showing overlay with ATP (green). This overlay illustrates the ATP competitive behavior of tofacitinib (<b>1</b>). The pyrrolopyrimidine heterocycle of <b>1</b> binds to the hinge region of the kinase where the purine of ATP binds. The piperidine headgroup scaffold of <b>1</b> positions the cyanoacetamide group toward the glycine-rich loop (P-loop) and the ring methyl into a lipophilic pocket toward the C-terminal lobe at the base of the active site. This binding mode and arrangement of structural features of the inhibitor are believed to impart the high degree of kinome selectivity observed for the JAK family.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent reports have shown that although the differences in the ATP binding sites of the JAKs are subtle, when guided by structure and targeting specific amino acid interactions, higher levels of selectivity within the family are achievable (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Genentechâs imidazopyrrolopyridine chemical series is an example of this (<b>2</b>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> By targeting of a specific hydrogen bond interaction with Glu966 in JAK1, which is an Asp in JAK2, an improvement in selectivity for JAK1 relative to JAK2 (>35 fold) was observed. Additionally, <b>2</b> exhibits improved physicochemical properties for oral dosing compared to previously reported analogues within this chemotype.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Similarly, researchers at Roche have specifically targeted Cys 909 of JAK3 with lipophilic functionality (<b>3</b>), demonstrating improved selectivity relative to the other JAKs (â¼20-fold relative to JAK2), which have a Ser at the equivalent position.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Also, a 2011 report from Novartis describes their JAK inhibitor (<b>4</b>) being selective for JAK3, taking advantage of specific hydrophobic interactions as well as a key, through water, backbone hydrogen bond with Asp967 (<b>4</b> exhibits â¼12-fold selectivity for JAK3 over JAK2 and even greater selectivity relative to the other JAKs).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> It is important to point out that these selectivity improvements are all evaluated with isolated enzyme catalytic domains and at <i>K</i><sub>m</sub> concentrations of ATP. IC<sub>50</sub> values and therefore selectivity often change when determinations are conducted at more physiologically relevant levels of ATP. This latter point will be discussed in more detail in the next section.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitors exhibiting enhanced selectivity within the JAK family. By targeting of specific amino acid residues and aided by single crystal X-ray structures, it is possible to achieve some degree of enhanced selectivity within the JAK family. Compound <b>2</b> from Genentech achieves enhanced JAK1 selectivity by specifically targeting an interaction with E966 (JAK1). Rocheâs inhibitor (<b>3</b>) exhibits enhanced selectivity for JAK3 through a targeted, lipophilic interaction with C909 of JAK3. Novartisâ JAK3 inhibitor (<b>4</b>) derives its selectivity through specific lipophilic interactions and a key through water hydrogen bond with the backbone of JAK3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">JAK Inhibitors for Inflammatory Diseases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There are currently several JAK inhibitors in development for inflammatory indications (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The following sections provide additional details around the discovery and development of these entities. The authors have made an advised decision not to summarize clinical data for compounds other than tofacitinib nor to try to make any direct comparisons of clinical outcomes for these entities, since head-to-head studies have not yet been conducted. However, we have profiled many of them in our standard enzyme and whole blood assays for comparative purposes. The enzyme IC<sub>50</sub> values reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> were obtained with the purified JH1 domains of the four respective JAKs using caliper nanofluidics technology. The assays were performed at 1 mM ATP instead of <i>K</i><sub>m</sub> for ATP to better mimic the ATP physiological concentration, resulting in a more relevant comparison of inhibitory properties between them. As expected, the observed IC<sub>50</sub> values for these ATP competitive inhibitors were higher than that reported at the <i>K</i><sub>m</sub> values, and the shifts were greatest for JAK3 which has the lowest <i>K</i><sub>m</sub> for ATP.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Experimental and approved JAK inhibitors. Compounds <b>1</b> and <b>5</b> are the only JAK inhibitors, to date, to have received regulatory approvals. The other inhibitors are in various stages of clinical development across several inflammatory indications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A comparison of in vitro cellular inhibitory properties for these compounds was performed in primary cells in human whole blood (HWB) assays by fluorescence-activated cell sorting (FACS) as described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The phosphorylation state of various STAT proteins was measured as a proximal readout of JAK activity. The data reported with the set of cytokines shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> were chosen to assess as much as possible the cellular selectivity against the four JAK isoforms.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. JAK Kinase and Whole-Cell Assays: Comparison of Enzymatic and Whole-Cell Activity for Experimental and Approved JAK Inhibitors for Inflammatory Indications</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">enzyme assay IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="6" align="center">human whole blood (HWB) IC<sub>50</sub> (nM)<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">JAK1</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center">TYK2</th><th class="colsep0 rowsep0" align="center">IL-15<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> P-stat5</th><th class="colsep0 rowsep0" align="center">IL-6<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> P-stat1</th><th class="colsep0 rowsep0" align="center">IL-12<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> P-stat4</th><th class="colsep0 rowsep0" align="center">IFNÎ±<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> P-stat3</th><th class="colsep0 rowsep0" align="center">IL-23<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> P-stat3</th><th class="colsep0 rowsep0" align="center">CD34+â<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a> cells EPO<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a> P-stat5</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">15.1</td><td class="colsep0 rowsep0" align="left">77.4</td><td class="colsep0 rowsep0" align="left">55.0</td><td class="colsep0 rowsep0" align="left">489</td><td class="colsep0 rowsep0" align="left">55.8</td><td class="colsep0 rowsep0" align="left">75.4</td><td class="colsep0 rowsep0" align="left">409</td><td class="colsep0 rowsep0" align="left">35.0</td><td class="colsep0 rowsep0" align="left">229</td><td class="colsep0 rowsep0" align="left">302</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">8.8</td><td class="colsep0 rowsep0" align="left">487.0</td><td class="colsep0 rowsep0" align="left">30.1</td><td class="colsep0 rowsep0" align="left">1850</td><td class="colsep0 rowsep0" align="left">298</td><td class="colsep0 rowsep0" align="left">1090</td><td class="colsep0 rowsep0" align="left">194</td><td class="colsep0 rowsep0" align="left">818</td><td class="colsep0 rowsep0" align="left">677</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">6.6</td><td class="colsep0 rowsep0" align="left">787.0</td><td class="colsep0 rowsep0" align="left">61.0</td><td class="colsep0 rowsep0" align="left">259</td><td class="colsep0 rowsep0" align="left">21.1</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">28.7</td><td class="colsep0 rowsep0" align="left">81.9</td><td class="colsep0 rowsep0" align="left">87.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">112</td><td class="colsep0 rowsep0" align="left">619</td><td class="colsep0 rowsep0" align="left">74.4</td><td class="colsep0 rowsep0" align="left">>10K</td><td class="colsep0 rowsep0" align="left">932</td><td class="colsep0 rowsep0" align="left">1870</td><td class="colsep0 rowsep0" align="left">16400</td><td class="colsep0 rowsep0" align="left">1290</td><td class="colsep0 rowsep0" align="left">11200</td><td class="colsep0 rowsep0" align="left">>20K</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">363</td><td class="colsep0 rowsep0" align="left">2400</td><td class="colsep0 rowsep0" align="left">>10K</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">2140</td><td class="colsep0 rowsep0" align="left">918</td><td class="colsep0 rowsep0" align="left">13362</td><td class="colsep0 rowsep0" align="left">1500</td><td class="colsep0 rowsep0" align="left">10123</td><td class="colsep0 rowsep0" align="left">13200</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Run in the presence of 1 mM ATP.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Signals through JAK1/JAK3.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Signals though JAK1/JAK2 or TYK2.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Signals through JAK2/TYK2.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Signals through JAK1/TYK2.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Signals through JAK2/JAK2.</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">CD34+ cells spiked into human whole blood (HWB). Data reported for tofacitinib (<b>1</b>), ruxolitinib (<b>5</b>), baricitinib (<b>6</b>), decernotinib (<b>7</b>), and filgotinib (<b>8</b>).</p></div></div></div><div class="NLM_p">Although we will not directly compare efficacy and safety, several general themes are worth noting from the results of Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. The relative potency within this series of compounds varies greatly, suggesting that significantly different concentrations will be necessary for clinical activity. Potent inhibition of JAK1 is sufficient for inhibition of JAK1/JAK3 dependent IL-15 signaling. When assessed in kinase assays using 1 mM ATP, none of the compounds are JAK3 selective and all inhibit both JAK1/JAK3 dependent IL-15 signaling and JAK1/TYK2 dependent interferon Î± signaling. At higher concentrations, several of the compounds will be expected to inhibit JAK2 dependent EPO signaling, which is consistent with a decrease in hemoglobin levels at higher doses of tofacitinib in phase 2 rheumatoid arthritis (RA) studies. Lastly, several of the compounds are expected to inhibit IL-6 signaling which is consistent with lipid elevations seen for several JAK inhibitors and the anti-IL-6 receptor antibody tocilizumab.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Tofacitinib (<b>1</b>)</h3><div class="NLM_p">The first compound to enter development for the treatment of inflammatory indications was tofacitinib from Pfizer, which recently received its first regulatory approval for the treatment of moderate to severe RA. Tofacitinib was approved by the U.S. Food and Drug Administration on November 6, 2012, under the trade name Xeljanz.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Tofacitinib is also being developed by Pfizer for other inflammatory indications, including psoriasis (oral formulation, phase 3; topical formulation, phase 2), psoriatic arthritis (phase 3), ankylosing spondylitis (phase 2), ulcerative colitis (phase 3), and Crohnâs disease (phase 2).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">The medicinal chemistry program at Pfizer that culminated in the discovery of tofacitinib began with a high throughput screen, which resulted in the identification of a series of inhibitors represented by <b>9</b> that possessed a pyrrolo[2,3-<i>d</i>]pyrimidine pharmacophoric subunit (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Early efforts explored SAR around the pyrrolopyrimidine ring, which was assumed to be the hinge-binding element of the molecule. Attempts to either replace this heterocycle or make additional substitutions around the ring generally led to reduced potency. Substitutions at C-5 were tolerated in terms of JAK3 kinase potency; however, these modifications often resulted in suboptimal metabolic stability as indicated by human liver microsome incubations and/or diminished cell potency. As a consequence of this initial survey, efforts focused on optimization of the amino headgroup in order to achieve program objectives.</div><div class="NLM_p">The first major advance in the evolution of the amino headgroup came as a result of an empirical observation associating structure with improved potency in the IL-2 T-cell blast cellular proliferation assay being used at the time. These data suggested an advantage for compounds processing an <i>N</i>-methylcycloalkyl headgroup motif as illustrated by <b>10</b>. This improvement in cellular potency was likely associated with a concomitant increase in JAK1 potency observed, which was the first indication that combining inhibition of multiple JAK enzymes could present an advantage, at least in certain contexts.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Evolution of compound structures from HTS lead (<b>9</b>) to tofacitinib (<b>1</b>). Progression of the Pfizer JAK inhibitor from HTS lead to clinical candidate (<b>1</b>) is shown. This schematic of seminal compounds represents an approximately 3-year medicinal chemistry effort wherein greater than 1000 synthetic analogues in this pyrrolopyrimidine series were prepared and evaluated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With no JAK crystal structures available at the time to guide subsequent work, efforts to expand SAR around this <i>N</i>-methylcycloalkyl motif were facilitated by new (at the time) high-speed analoging (HSA) technology. The library of compounds produced provided several SAR insights, key of which was the potency advantage associated with a small alkyl substituent at the 2â²-position, the cyclohexyl group (<b>11</b>). A methyl group at this position would later also be recognized as contributing to the enhanced kinome selectivity observed with more advanced analogues including tofacitinib. Questions of optimal stereochemistry associated with the complex mixture of isomers produced with <b>11</b> were addressed by incorporating natural products as synthetic building blocks. Specifically, the natural terpenoids, âcarvonesâ, possessed the desired substitution around the cyclohexyl ring and were commercially available in both stereochemical antipodes. Analogues prepared from the carvones led to the conclusion that the optimal relative and absolute stereochemistry around the cyclohexane ring was the all-cis configuration derived from (<i>S</i>)-carvone (<b>12</b>). Subsequent analogues prepared from <b>13</b> using the isopropenyl group as a synthetic handle taught that a large pocket or perhaps solvent exposed site was accessible from this vector. However, the need to decrease stereochemical complexity and improve the druglike properties of new analogues being prepared inspired a move to the corresponding piperidine scaffold <b>14</b>. The piperidine also facilitated synthetic access to this active site pocket, which is now known to project toward the glycine rich loop (P-loop) of the kinases. Many analogues were prepared from the piperidine scaffold in an effort to optimize potency, selectivity, and druglike properties. In doing so, a deliberate effort was made to improve upon these attributes while avoiding addition of unnecessary lipophilicity or molecular weight. Eventually, it was the cyanoacetamide side chain of tofacitinib that imparted the best combination of these attributes. In all, greater than 1000 synthetic analogues of the original lead molecule (<b>9</b>) were prepared and profiled over an approximately 3-year period. The citrate salt of tofacitinib was nominated into development in 2000.</div><div class="NLM_p">Original reports of JAK kinase inhibition for tofacitinib using a solid-phase ELISA-based assay system suggested that this compound was primarily a JAK3 inhibitor, exhibiting approximately 20-fold selectivity over JAK2 and 100-fold selectivity over JAK1.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In more contemporary caliper assays, tofacitinib exhibits nanomolar potency against the JAK enzymes, although somewhat less potent against TYK2 (IC<sub>50</sub> of 3.2, 4.1, 1.6, and 34.0 nM, respectively, for JAK1, JAK2, JAK3, and TYK2).<a onclick="showRef(event, 'ref17 ref43'); return false;" href="javascript:void(0);" class="ref ref17 ref43">(17, 43)</a> These data, however, were collected at <i>K</i><sub>m</sub> concentrations of ATP. As discussed above, when run at 1 mM ATP, these data shift, suggesting that tofacitinib more potently inhibits JAK1 relative to the other JAKs (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In cellular assays, specificity values derived from original tissue culture assays are in good agreement with phospho-STAT reporter assays used more universally today. In these assays tofacitinib preferentially inhibits cytokines that signal via JAK1 and/or JAK3 with functional selectivity over receptors that signal via JAK2 homodimeric pairs like GM-CSF and EPO. In a comparison of IL-15 which signals via JAK1/3 pairs to GM-CSF and EPO, the fold selectivity is 24.7 and 5.4, respectively, based on IC<sub>50</sub> values of 55.8 nM for IL-15, 1377 nM for GM-CSF, and 302 nM for EPO. Although the reason for the difference in IC<sub>50</sub> values between EPO and GM-CSF is not understood, it is noteworthy that the receptor signaling mechanisms for EPO and GM-CSF are different. For example, EPO signals through homodimers,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> whereas GM-CSF signals through dimerization of two hexamers.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Hence, reduction in hemoglobin was observed at higher doses with tofacitinib and other JAK inhibitors. It is more relevant to monitor EPO rather than GM-CSF. While a greater degree of selectivity relative to JAK2 was originally desired because of the role of JAK2 in red blood cell homeostasis, the functional selectivity of tofacitinib in humans has proven to be manageable at the clinical doses tested. Since changes in hemoglobin were monitorable in phase 2 studies, the phase 3 doses were chosen to maximize the probability of achieving efficacy while minimizing the likelihood of hemoglobin reduction of >2 g/dL. The challenge of identifying highly selective, ATP competitive inhibitors within the JAK family stems from the high degree of homology in the active sites across the JAK family. However, outside of the JAKs, exploitable differences do exist. Tofacitinib is highly selective for the JAK family across the human kinome. Results of a broad kinase selectivity assessment have now been corroborated by studies from external groups.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> As alluded to in a previous section, there are a number of key proteinâligand interactions that are believed to contribute to the kinome selectivity observed for tofacitinib. Importantly, this high degree of selectivity across the human kinome may be essential in minimizing unwanted off-target pharmacology.</div><div class="NLM_p">In preclinical studies, tofacitinib demonstrated efficacy in both mouse and rat models of arthritis exhibiting dose dependent improvements in end points.<a onclick="showRef(event, 'ref39 ref47'); return false;" href="javascript:void(0);" class="ref ref39 ref47">(39, 47)</a> Tofacitinib was shown to be efficacious in the collagen induced arthritis (CIA) model. Inflammatory biomarkers including cytokines, chemokines, and acute phase proteins (IL-6, SAA, IP-10, G-CSF, and KC) are increased in mice with CIA relative to naive mice. Treatment with efficacious doses of tofacitinib resulted in the rapid reduction of these mediators within 4 h. The expression of many STAT1 responsive genes indicative of inflammation was also rapidly suppressed in the tissue of inflamed paws. With continuing treatment, significant improvements in arthritis scores were observed within 48 h and inflammatory cell infiltrates, including T cells and macrophages, were reduced by 7 days of treatment.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">Analogously, tofacitinib was tested in the rat adjuvant induced arthritis (AIA) model.<a onclick="showRef(event, 'ref17 ref43'); return false;" href="javascript:void(0);" class="ref ref17 ref43">(17, 43)</a> Treatment during development of disease (days 14â21 after immunization) results in a dose dependent decrease in paw swelling. Inflammatory cytokines IL-6 and IL-17 are elevated in AIA disease animals, and tofacitinib normalizes the levels of these mediators. Neutrophil levels are also elevated with AIA as in active RA and tofacitinib normalized neutrophil levels. A thorough dose response analysis demonstrated that this was secondary to inhibition of proinflammatory cytokines and not due to inhibition of JAK2 dependent hematopoietic factors which require higher concentrations of tofacitinib to inhibit.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In additional studies, AIA rats were treated after disease had developed. Elevated plasma IL-6 and IL-17 levels decreased rapidly, and gene expression of cytokines and chemokines decreased in the tissue. Importantly, osteoclast mediated bone resorption, which is common in the AIA model, was reduced with tofacitinib treatment and tofacitinib was shown to decrease the level of receptor activator of nuclear factor ÎºB ligand (RANKL), resulting in a reduction in osteoclasts and the associated bone resorption.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49, 50)</a></div><div class="NLM_p">Encouraged by these results, where tofacitinib normalized inflammatory mediators associated with disease and reversed bone resorption, tofacitinib entered the clinic in 2001. The development program consisted of 22 phase 1 studies, 8 phase 2 studies, 6 phase 3 studies, and 2 ongoing, open-label, long-term extension (LTE) studies. The phase 3 study designs are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Safety and tolerability were assessed in a demographically diverse RA patient population. As of April 2013 the RA phase 2, phase 3, and LTE studies included approximately 5700 patients across all treatment groups with approximately 13â000 patient-years of tofacitinib exposure at 5 and 10 mg dosed twice daily (b.i.d.). The development program demonstrated that tofacitinib consistently improved the signs and symptoms of RA, physical functioning, and other patient-reported outcomes including health related quality of life, along with inhibition of structural damage across multiple lines of therapy. Safety findings observed in the overall tofacitinib RA program include serious and other important infections, including tuberculosis and herpes zoster; malignancies, including lymphoma; gastrointestinal perforations; decreased neutrophil and lymphocyte counts; liver enzyme elevations; and lipid elevations.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Phase 3 RA Study Design for Tofacitinib (<b>1</b>)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">oral start<br /></br>A3921069</th><th class="colsep0 rowsep0" align="center">oral standard<br /></br>A3921064</th><th class="colsep0 rowsep0" align="center">oral scan<br /></br>A3921044</th><th class="colsep0 rowsep0" align="center">oral sync<br /></br>A3921046</th><th class="colsep0 rowsep0" align="center">oral solo<br /></br>A3921045</th><th class="colsep0 rowsep0" align="center">oral step<br /></br>A3921032</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">population</td><td class="colsep0 rowsep0" align="left">MTX naive</td><td class="colsep0 rowsep0" align="left">MTX IR</td><td class="colsep0 rowsep0" align="left">MTX IR</td><td class="colsep0 rowsep0" align="left">DMARD IR</td><td class="colsep0 rowsep0" align="left">DMARD IR</td><td class="colsep0 rowsep0" align="left">TNFi IR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">background treatment</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">MTX</td><td class="colsep0 rowsep0" align="left">MTX</td><td class="colsep0 rowsep0" align="left">nonbiologic DMARD(s)</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">MTX</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">study duration</td><td class="colsep0 rowsep0" align="left">2Â years</td><td class="colsep0 rowsep0" align="left">1Â year</td><td class="colsep0 rowsep0" align="left">2Â years</td><td class="colsep0 rowsep0" align="left">1Â year</td><td class="colsep0 rowsep0" align="left">6Â months</td><td class="colsep0 rowsep0" align="left">6Â months</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of patients</td><td class="colsep0 rowsep0" align="left">958</td><td class="colsep0 rowsep0" align="left">717</td><td class="colsep0 rowsep0" align="left">797</td><td class="colsep0 rowsep0" align="left">792</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">399</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">DMARD = disease-modifying antirheumatic drug; IR = inadequate responder; MTX= methotrexate; TNFi = tumor necrosis factor inhibitor.</p></div></div></div><div class="NLM_p">For the treatment of psoriasis, tofacitinib was first administered in patients during a phase 1 multidose study (A3921003).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In this study patients experienced a 50% improvement in modified PASI scores over 14 days of dosing at 30 mg b.i.d. While this study was not statistically powered for efficacy, this was, however, the first indication of biological activity for tofacitinib and prompted further investigation in psoriatic patients. In a phase 2b proof of concept study (A3921047), tofacitinib was investigated in patients with moderate-to-severe psoriasis.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This was a placebo-controlled, double blinded study investigating three dose groups of tofacitinib: 2, 5, and 15 mg b.i.d. The end points of the study were a 75% improvement in psoriasis area severity index (PASI) score (PASI75) and a global physicians assessment (PGA). In this study a significantly higher proportion of patients treated with tofacitinib achieved PASI75 and a PGA of âclearâ or âalmost clearâ compared with placebo during 12 weeks of treatment. A dose response was seen for both the PASI75 and PGA end points, with the magnitude of response increasing over time. Tofacitinib at 2, 5, and 15 mg b.i.d. was generally well-tolerated in this patient population. AEs in this study were qualitatively similar to those reported for the RA trials. Data for this study support a role for JAK1/JAK3 inhibition in the pathophysiology of psoriasis and suggest that tofacitinib has the potential to be a new first-in-class therapeutic option for patients with moderate-to-severe chronic plaque psoriasis.</div><div class="NLM_p">For ulcerative colitis (UC), tofacitinib was evaluated in a phase 2, double-blinded, placebo controlled study in patients with moderately to severely active UC.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Patients were administered tofacitinib at doses of 0.5, 3, 10, or 15 mg or placebo twice daily for 8 weeks. The primary end point was a clinical response at 8 weeks based on the Mayo scoring system. Clinical responses occurred in 32%, 48%, 61%, and 78% of patients at 0.5, 3, 10, and 15 mg of tofacitinib, respectively, compared to 42% for patients receiving placebo. Clinical remission occurred in 13%, 33%, 48%, and 41% of patients, respectively, in these dose groups compared with 10% in the placebo group. These data support the conclusion that patients with moderately to severely active UC receiving tofacitinib were more likely to have a clinical response or remission than those receiving placebo. Tofacitinib has now entered phase 3 studies for the treatment of UC.</div><div class="NLM_p last">For the treatment of Crohnâs disease (CD), in a phase 2 double-blinded study, patients with moderate to severe Crohnâs disease were randomized to 1, 5, or 15 mg of tofacitinib or placebo twice daily for 4 weeks. The primary end point was the percentage of patients with a Crohnâs disease activity index (CDAI) reduction of >70 points (response 70) at four weeks. The secondary end points included remission rate (SDAI < 150) and a response 100. In this study response 70 rates were 36.1, 57.6, and 45.7 for the 1, 5, and 15 mg dose groups, respectively, compared to 47.1 for placebo. Tofacitinib, 15 mg b.i.d., resulted in reductions from baseline in C-reactive protein and fecal calprotectin. The conclusion of this study was that although generally well tolerated, tofacitinib had no significant treatment effect within 4 weeks on clinical end points as measured by CDAI in patients with active CD. C-reactive protein and fecal calprotectin reductions observed with tofacitinib 15 mg b.i.d. suggest biological activity. Phase 2b studies are underway to further evaluate these findings.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Ruxolitinib (<b>5</b>) and Baricitinib (<b>6</b>)</h3><div class="NLM_p">Incyte has two compounds that have been studied in human RA trials.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Ruxolitinib (<b>5</b>), which was co-developed with Novartis, was evaluated in phase 2 studies of RA. In addition, this entity is approved for the treatment of myelofibrosis under the trade name Jakafi.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Baricitinib (<b>6</b>), which is being co-developed with Eli Lilly, is currently in recruitment for phase 3 clinical trials for RA and is pursuing a once-a-day (q.d.) therapeutic option.</div><div class="NLM_p">The medicinal chemistry discovery stories for ruxolitinib and baricitinib have not been described in the literature to date. However, like tofacitinib, these two chemical entities also take advantage of a pyrrolopyrimidine hinge binding heterocycle as a pharmacophoric subunit and may make other similar active site interactions with the JAKs.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> As indicated in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, unlike tofacitinib, ruxolitinib and baricitinib exhibit specificity for JAK1 and JAK2 over JAK3 in kinase assays. These data are consistent with previous reports from Incyte for these two compounds. However, since JAK1 is involved in receptor pairing with all the other JAKs, including JAK3, and therefore regulates signaling of the same cytokine subset as JAK3, the potential advantage of this specificity at the kinase level is not obvious and the effect of subtle changes in potency will only be evident if at all clinically.</div><div class="NLM_p">Dysregulation of JAK-STAT signaling is a characteristic of certain myeloproliferative neoplasms believed to be caused at least in part by the JAK2 (V617F) mutation, which is observed in approximately 70% of patients. Inhibition of JAK2 has therefore become a viable treatment strategy for this patient population. As a consequence, ruxolitinib has been developed for myeloproliferative neoplasms and represents a promising new therapy for myelofibrosis (MF). Although the activating JAK V617F mutation provides compelling rationale for JAK2 inhibition in myelofibrosis, the population of cells expressing the V167F allele does not decrease with ruxolitinib treatment and it has been suggested that some of the palliative effects of ruxolitinib may be due to the modulation of JAK1 dependent cytokines. Moreover anemia and thrombocytopenia, which are part of the side effects of MF, are more common with ruxolitinib treatment.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Consistent with this finding, Incyte has reported the testing of a JAK1 inhibitor INCB-039110 (structure not disclosed) in MF.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">Both ruxolitinib and baricitinib have shown efficacy in rodent models of arthritis.<a onclick="showRef(event, 'ref61 cit56a'); return false;" href="javascript:void(0);" class="ref ref61 cit56a">(61, 56a)</a> Both compounds have demonstrated the ability to inhibit the signaling and function of pathogenic cytokines such as IL-6 and IL-23 in relevant cells. Once a day dosing of baricitinib improves histological and radiological signs of disease in the rat AIA model, suggesting that fractional inhibition of JAK1 and JAK2 is sufficient to observe significant efficacy in these models. Baricitinib has completed phase 2 studies for RA and is currently in recruitment for phase 3. Details of phase 1 and 2 studies have been disclosed in papers and abstracts.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Decernotinib (<b>7</b>)</h3><div class="NLM_p">Vertex is developing a JAK inhibitor for the treatment of RA and is currently in phase 2 clinical development.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Vertex recently filed a patent for adelatinib (WO2013/006634), which has recently been renamed decernotinib, a JAK inhibitor that we infer is VX-509 based on published USAN information.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> However, we will refer to data reported by Vertex as data for this compound. Decernotinib (<b>7</b>) is a pyrrolopyridine-based inhibitor and is a potent inhibitor of JAK3 (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In cellular assays, Vertex has reported that their inhibitor demonstrated potent inhibition of endogenous JAK1/JAK3 pathways with IC<sub>50</sub> values ranging from 50 to 170 nM. It also exhibits very good kinome selectivity. Enzymatic selectivity over the other JAK family members was less than 10-fold; however, in cellular selectivity assays Vertex reported a selectivity window of approximately 25- to 150-fold, depending on the assay comparators (ACR 2011 poster 1136). At <i>K</i><sub>m</sub> concentrations of ATP in biochemical assays the IC<sub>50</sub> for decernotinib was 13.2 nM for JAK1, 24 nM for JAK2, and 1.2 nM for JAK3, which is consistent with the <i>K</i><sub>i</sub> values described by Vertex with 11, 13, and 2.5 nM for JAK1, JAK2, and JAK3, respectively (ACR 2011 poster 1136). At 1 mM ATP in biochemical assays, decernotinib (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) shows similar activity against JAK3 (IC<sub>50</sub> = 74.4 nM) and JAK1 (IC<sub>50</sub> = 112 nM). This similar activity against JAK1 and JAK3 is consistent with the HWB data with IC<sub>50</sub> values against IL-15 (IC<sub>50</sub> = 932 nM), IL-6 (P-STAT1 IC<sub>50</sub> = 1870 nM), and IFNÎ± (IC<sub>50</sub> = 1290 nM) also being comparable. The data that we obtained with decernotinib are overall consistent with the published data from Vertex (ACR 2011 poster 1136).</div><div class="NLM_p last">In preclinical models Vertex reported activity in animal models of aberrant immune/inflammatory function. When dosed orally in a rat model of rheumatoid arthritis (CIA), their compound showed a dose-dependent reduction in ankle swelling and paw weight and improved histological scores in affected paws, with the effects/potency exceeding the reference standard etanercept (Enbrel). In the mouse oxazolone delayed type hypersensitivity (DTH) model, it displayed dose-dependent effects in alleviating the T-cell mediated skin inflammatory response, which was comparable to the reference standard prednisolone. Decernotinib has completed a phase 2a POC study in patients with RA, and results (efficacy and AEs) have been disclosed in papers and abstracts. A larger, longer-duration phase 2b study that will evaluate this entity in combination with methotrexate is ongoing. This study is expected to be 6 months in duration and will evaluate both q.d. and b.i.d. dosing.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Filgotinib (<b>8</b>)</h3><div class="NLM_p">More recently, Galapagos has entered development with JAK inhibitors;<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Galapagos now has two compounds in development. Filgotinib, also known as GLPG0634 (<b>8</b>), recently completed a phase 2a proof of concept study in RA, and a new entity GSK2586184 (structure not disclosed) is being advanced to phase 2 trials for lupus erythematosus and chronic plaque psoriasis.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> This small molecule inhibitor of the JAK enzymes (<b>8</b>) has only recently been disclosed.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69, 70)</a> Some details of the discovery of filgotinib have been described as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Lead identification en route to filgotinib involved screening of an approximately 10â000 compound, kinase focused collection resulting in compound <b>15</b>. Docking in a JAK2 crystal structure suggested that a ring nitrogen and the hydrogen associated with the adjacent exocyclic amine are involved in binding to the hinge region of the kinase in a donorâacceptor motif. This places the conserved cyclopropyl group in a lipophilic pocket. Lead optimization was conducted through separate manipulation of the two triazolopyridine substituents. These efforts revealed that replacement of the cyclopropylamide moiety was not tolerated, while substitution on the phenyl group, particularly at the para position, was open to a wide range of substitutions. Compounds prepared were driven toward greater JAK1 selectivity and toward improved ADME parameters of solubility and plasma protein binding, eventually leading to filgotinib.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Progression of Galapagos lead to filgotinib (<b>8</b>). Two sites of the original lead molecule <b>15</b> were optimized leading to <b>8</b>. The conserved triazolopyridine cyclopropanecarboxamide moiety is reported to be a key hinge-binding pharmacophoric feature for the series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A key feature of the filgotinib enzymatic profile is greater selectivity for JAK1 over the other JAKs compared to other experimental JAK inhibitors in the clinic (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In preclinical studies, filgotinib selectively inhibited JAK1-related pathways, exhibiting approximately 30-fold selectivity for JAK1 over JAK2 in human whole blood (IL-6/pSTAT1 over GM-CSF/pSTAT5).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In biochemical assays shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, filgotinib showed a bias toward JAK1 inhibition. The HWB data in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> are also consistent with a bias toward the inhibition of JAK1 dependent cytokine signaling (IL-15, IL-6, IFNÎ±) when compared to JAK2 dependent cytokine signaling (IL-12, IL-23, EPO). These data are also consistent with previously reported HWB data for this compound in terms of selectivity and potency.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The potency observed for filgotinib suggested that higher exposure would be required for clinical efficacy; however, Galapagos has recently reported that filgotinib is metabolized to a JAK1 selective inhibitor that is 10- to 20-fold less potent in human whole blood but has a compensating increase in exposure to drive prolonged inhibition.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74, 75)</a> To date, Galapagos reports a unique safety profile for an inhibitor that modulates Il-6 signaling, with no consistent increase in LDL cholesterol.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> AC430 (Structure Not Disclosed)</h3><div class="NLM_p">Ambit has also been developing a JAK inhibitor with a different JAK isoform selectivity profile. This compound has been shown to inhibit JAK2 in binding assays and TEL-JAK (fusion of TEL dimerization domain with JAK JH1 domain) in cellular assays.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> It also exhibits potent inhibition of pSTAT5 in an ex vivo assay stimulated by TPO, consistent with JAK2 inhibitory activity.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">In preclinical studies Ambitâs compound demonstrated dose dependent improvement in ankle thickness at or above 5 mg b.i.d. in the rat CIA model. Maximum efficacy was observed at 20 and 60 mg/kg q.d. or b.i.d. correlating with histology.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> It also demonstrated efficacy in the murine myelin oligodendrocyte (MOG) induced experimental autoimmune encephalomyelitis (EAE) model for MS exhibiting dose proportional reversal of disease progression in the 20 and 60 mg/kg b.i.d. dose groups, as well as efficacy in the murine DTH model.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p last">In a phase 1 multidose study this entity was evaluated over 14 days where it was generally well tolerated with predicted dose-dependent PK. Despite alleging to be a specific JAK2 inhibitor, there were no signs of cytopenias in this study. At the same time ex vivo PD biomarkers exhibited both dose- and time-dependent inhibition of relevant cytokine signaling.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> ASP015K (Structure Not Disclosed)</h3><div class="NLM_p">Astellas has entered into an agreement with Janssen Biotech, Inc. to develop their JAK inhibitor for RA following a promising phase 2a outcome in a 6-week study in patients with psoriasis.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p last">Beyond the new chemical entities (NCEs) described above that have completed clinical studies, there are still others that are listed at clinicaltrials.gov that have entered development recently or that are in the recruitment stage for phase 1 studies. These include Rigelâs compound R348 that is being positioned for dry-eye disease<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and Cell Therapeuticâs macrocyclic JAK2 inhibitor SB1578, which is being studied for the treatment of RA.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> There are also many more compounds in preclinical stages of discovery. The majority of these have been captured in recent patent reviews.<a onclick="showRef(event, 'ref67 ref81'); return false;" href="javascript:void(0);" class="ref ref67 ref81">(67, 81)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions and Future Directions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The approval of tofacitinib represents a milestone as the first kinase inhibitor used for the treatment of RA. Tofacitinib has demonstrated a high degree of selectivity across the kinome, and thus, the effects observed in the clinical studies inform us about the utility of JAK inhibition in the clinic.</div><div class="NLM_p">JAK inhibition represents a change in approach toward autoimmune diseases. Monoclonal antibodies targeting complete inhibition of one to two pathogenic cytokines have shown efficacy in RA for TNF and IL-6 and in psoriasis for IL-23/12 p40 and IL-17. JAK inhibition represents an alternative approach in that inhibitors are dosed to partially inhibit or modulate the signaling of JAK-dependent pathways at clinical doses. At the 5 mg b.i.d. dose of tofacitinib, the plasma concentration of inhibitor exceeds the IC<sub>50</sub>, as measured in whole blood assays, for the JAK1/3 dependent Î³-common chain cytokines and JAK1/TYK2 dependent type I interferons and a portion of IL-6 signaling for a portion of each dosing period. Many of these JAK dependent cytokines were previously postulated to play a role in RA,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> but to date, the relative contribution toward efficacy of each cytokine pathway modulated by tofacitinib remains to be fully understood.</div><div class="NLM_p">As suggested in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and noted in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, the current inhibitors in development for autoimmune disease have varying levels of selectivity within the JAK family, and as a consequence, the level of relative cytokine inhibition will vary. For example, baricitinib with greater inhibition of JAK2 and TYK2 than tofacitinib is roughly equipotent vs IFNÎ± signaling but more potent vs TYK2/JAK2 dependent IL-12 signaling and modestly less potent vs IL-15.</div><div class="NLM_p">In theory, it may be possible to design JAK inhibitors with distinct selectivity profiles within the JAK family to deliver differentiated results. Although no highly selective inhibitors have been reported yet, current clinical candidates may inform us about the benefits and liabilities of distinct profiles. For example, a JAK1 selective inhibitor as reported by Galapagos could inhibit the Î³-common dependent cytokines, the type I and type II interferons and IL-6 without inhibiting JAK2 dependent EPO and TPO signaling or JAK2/TYK2 dependent IL-12 and IL-23 signaling. Conceivably these inhibitors could modulate the immune response without having negative effects on EPO signaling. Alternatively, the JAK1/JAK2 inhibitor baricitinib may derive some of its efficacy from direct inhibition of JAK2/TYK2 dependent IL-12/23 signaling but may be limited in its upper dose by JAK2 dependent inhibition. However, because of a broader panel of cytokine inhibition, baricitinib may achieve efficacy without needing to dose to the point of significant EPO inhibition.</div><div class="NLM_p">Clinical trials testing biologics are revealing that the cytokines driving autoimmune disease will differ with disease, and therefore, a different mix of JAK selectivity may be optimal for each disease. Recent data have shown that whereas an anti-IL-17 therapy is highly effective in psoriasis and promising in ankylosing spondylitis, anti-IL-17 therapy was not highly effective in RA and surprisingly poor in inflammatory bowel disease (IBD).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Thus, it is reasonable to postulate that a JAK inhibitor with a TYK2 bias that would preferentially inhibit the IL-23 and TH17 differentiation and maintenance may have a better benefit risk profile in psoriasis. Tofacitinb has demonstrated efficacy in a full phase 2 psoriasis program with even more robust activity at higher doses. Whether this represents deeper inhibition of a broad panel of cytokines or inhibition of IL-23 is not clear. If a more biased TYK2 inhibitor can be identified and developed, we can test this hypothesis.</div><div class="NLM_p">Tofacitinib has also reported efficacy in ulcerative colitis and inconclusive results in a small Crohnâs study. IL-27 and IL-10, which signal via JAK1 and TYK2, are postulated to be anti-inflammatory, particularly in IBD. Therefore, if the positive activity seen for tofacitinib is largely via modulation of the Î³-common chain cytokines, a JAK3 selective inhibitor that spares anti-inflammatory cytokines may provide greater efficacy with a more focused inhibitory profile.</div><div class="NLM_p last">Finally, much of our understanding of the combinations of JAKs associated with each cytokine pathway comes from mouse or human deficiencies representing complete loss of catalytic activity or, in some cases, loss of proteins. In each case a limited number of cell types and stimuli have been tested, and then receptor pairing has been surmised. In the case of IL-6 signaling, the role of TYK2 has not been consistent across mice and humans with TYK2 playing a more important role in humans. Another indication of our partial understanding is that beyond JAK3 deficiency, which is a phenocopy of the Î³-common chain deficiency, only TYK2 deficiencies have been observed in humans, and the consequences were not predictable from existing receptor, cytokine, or STAT deficiencies. Moreover, the consequence of selective partial inhibition cannot be assessed by studying inborn errors of immune deficiency. Therefore, with the advent of selective inhibitors we will begin to be able to more clearly delineate the importance of each JAK in signaling pathways, the target occupancy required for each kinase to see either beneficial or negative effects, and with careful analysis we will be able to determine the consequences of partial inhibition at steady state.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm401490p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73158" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73158" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Flanagan</span> - <span class="hlFld-Affiliation affiliation">Center
for Chemistry Innovation and Excellence, Pfizer, Inc., Eastern
Point Road, Groton, Connecticut 06340, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#056864776e2b602b6369646b6462646b4575636c7f60772b666a68"><span class="__cf_email__" data-cfemail="92fff3e0f9bcf7bcf4fef3fcf3f5f3fcd2e2f4fbe8f7e0bcf1fdff">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James D. Clark</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Immunosciences, 200 CambridgePark, Cambridge, Massachusetts 02140, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Telliez</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Immunosciences, 200 CambridgePark, Cambridge, Massachusetts 02140, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Authors are Pfizer Employees and have stock/shares in Pfizer, Inc.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">James D. Clark</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=BIO-d1061e1327-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>James D. Clark</b> received his B.A. in Chemistry from the University of Utah in 1982 and his Ph.D. in Organic Chemistry from Harvard University, MA, in 1988, studying mechanistic enzymology under the guidance of Jeremy R. Knowles. Following his Ph.D., he joined Genetics Institute/Wyeth where he led the cPLA2Î± inhibitor program. He is currently the Head of the Cytokine Signaling Group within Pfizer Immunosciences where one of the key areas of interest is the development of second generation JAK inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Mark E. Flanagan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=BIO-d1061e1332-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mark E. Flanagan</b> is a graduate of New York University. He received his Ph.D. in Organic Chemistry from Colorado State University, working with Professor Robert M. Williams. He then went on to study as an NIH Postdoctoral Fellow for Professor Peter G. Schultz at the University of California, Berkeley. In 1997 he joined the Immunology Group at Pfizer where he worked for 4 years as a medicinal chemist during Pfizerâs early years investigating the Janus kinases as therapeutic targets. In 2001 he transferred to the Antibacterials Group where he worked for several years before moving to his current position where he is an Associate Research Fellow in the Experimental Design Chemistry Group for Pfizer Worldwide Medicinal Chemistry.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Jean-Baptiste Telliez</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=BIO-d1061e1337-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jean-Baptiste Telliez</b> received his B.A. in Biochemistry from the University of Lille I, France, in 1988 and his Ph.D. in Molecular Biology from University of Lille I in 1993, studying the transcriptional regulation of the oncogene Ha-ras. Following his Ph.D., he joined the laboratory of Larry Feig at Tufts University, MA, studying the role of GRF in Ras signaling. He then joined Genetics Institute/Wyeth working in the TNF signaling field prior to leading an MK2 inhibitor program. He is currently an Associate Research Fellow leading a second generation JAK inhibitor program.</p></figure></div><div class="ack" id="ACK-d1061e1342-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge Drs. Birgitta Benda, Mark Bunnage, Jennifer Hodge, Suvit Thaisrivongs, Anthony Wood, and Samuel Zwillich for many helpful conversations and for their critical review of this manuscript. We also thank Dr. Maria-Dolores Vazquez-Abad for illustrations in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. This study was funded by Pfizer, Inc.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i18" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i18"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i19" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i19"> Abbreviations Used</h2><tr><td class="NLM_term">AE</td><td class="NLM_def"><p class="first last">adverse event</p></td></tr><tr><td class="NLM_term">AIA</td><td class="NLM_def"><p class="first last">adjuvant induced arthritis</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">antigen presenting cell</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice daily dosing</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">Crohnâs disease</p></td></tr><tr><td class="NLM_term">CDAI</td><td class="NLM_def"><p class="first last">Crohnâs disease activity index</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collogen induced arthritis</p></td></tr><tr><td class="NLM_term">CMP6</td><td class="NLM_def"><p class="first last">compound <b>6</b></p></td></tr><tr><td class="NLM_term">DMARD</td><td class="NLM_def"><p class="first last">disease modifying antirheumatic drug</p></td></tr><tr><td class="NLM_term">DTH</td><td class="NLM_def"><p class="first last">delayed type hypersensitivity reaction</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">autoimmune encephalomyelitis</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">G-CSF</td><td class="NLM_def"><p class="first last">granulocyte colony stimulating factor</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">HSA</td><td class="NLM_def"><p class="first last">high-speed analoging</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IP-10</td><td class="NLM_def"><p class="first last">interferon Î³-induced protein 10</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">KC</td><td class="NLM_def"><p class="first last">keratinocyte chemoattractant</p></td></tr><tr><td class="NLM_term">LTE</td><td class="NLM_def"><p class="first last">long-term extension study</p></td></tr><tr><td class="NLM_term">MPD</td><td class="NLM_def"><p class="first last">myeloproliferative disorder</p></td></tr><tr><td class="NLM_term">MTX</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">PASI</td><td class="NLM_def"><p class="first last">psoriasis area severity index</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PGA</td><td class="NLM_def"><p class="first last">physician global assessment</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">proof of concept</p></td></tr><tr><td class="NLM_term">q.d.</td><td class="NLM_def"><p class="first last">once daily dosing</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RANKL</td><td class="NLM_def"><p class="first last">receptor activator of nuclear factor ÎºB ligand</p></td></tr><tr><td class="NLM_term">SAA</td><td class="NLM_def"><p class="first last">serum amyloid A</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">TPO</td><td class="NLM_def"><p class="first last">thrombopoietin</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">ulcerative colitis</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 84 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leonard, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">JAKS and STATS: biological implications</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1146%2Fannurev.immunol.16.1.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=9597132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK1cXislygurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=293-322&author=W.+J.+Leonardauthor=J.+J.+O%E2%80%99Shea&title=JAKS+and+STATS%3A+biological+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">JAKS and STATS: Biological implications</span></div><div class="casAuthors">Leonard, Warren J.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-322</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 185 refs.  Cytokines and interferons are mols. that play central roles in the regulation of a wide array of cellular functions in the lympho-hematopoietic system.  These factors stimulate proliferation, differentiation, and survival signals, as well as specialized functions in host resistance to pathogens.  Although cytokines are known to activate multiple signaling pathways that together mediate these important functions, one of these pathways, the Jak-STAT pathway, is the focus of this chapter.  This pathway is triggered by both cytokines and interferons, and it very rapidly allows the transduction of an extracellular signal into the nucleus.  The pathway uses a novel mechanism in which cytosolic latent transcription factors, known as signal transducers and activators of transcription (STATs), are tyrosine phosphorylated by Janus family tyrosine kinases (Jaks), allowing STAT protein dimerization and nuclear translocation.  STATs then can modulate the expression of target genes.  The basic biol. of this system, including the range of known Jaks and STATs, is discussed, as are the defects in animals and human lacking some of these signaling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkrO-nJd5D_LVg90H21EOLACvtfcHk0lhg70s2JNg4LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislygurs%253D&md5=ac5eeeb0159c2c8769e2cb28720cdf98</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.16.1.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.16.1.293%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAKS%2520and%2520STATS%253A%2520biological%2520implications%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1998%26volume%3D16%26spage%3D293%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lhg70s2JNg4LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1002%2Fjlb.60.4.441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs%2C+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0ljxAK_oMRNi3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1002%2Fjlb.60.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.60.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%252C%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plenge, R.</span><span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">550</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">â</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0ljxAK_oMRNi3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0ljxAK_oMRNi3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J.</span><span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span> <span class="citation_source-journal">Open Rheumatol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0ljxXnPBjrlLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutra, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span> </span><span class="NLM_article-title">Genomic sequence, organization, and chromosomal localization of human JAK3</span> <span class="citation_source-journal">Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">â</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=57-61&author=M.+C.+Riedyauthor=A.+S.+Dutraauthor=T.+B.+Blakeauthor=W.+Modiauthor=B.+K.+Lalauthor=J.+Davisauthor=A.+Bosseauthor=J.+J.+O%E2%80%99Sheaauthor=J.+A.+Johnston&title=Genomic+sequence%2C+organization%2C+and+chromosomal+localization+of+human+JAK3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DDutra%26aufirst%3DA.%2BS.%26aulast%3DBlake%26aufirst%3DT.%2BB.%26aulast%3DModi%26aufirst%3DW.%26aulast%3DLal%26aufirst%3DB.%2BK.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DBosse%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26atitle%3DGenomic%2520sequence%252C%2520organization%252C%2520and%2520chromosomal%2520localization%2520of%2520human%2520JAK3%26jtitle%3DGenomics%26date%3D1996%26volume%3D37%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Firmbach-Kraft, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shows, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla-Favera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolewski, J. J.</span><span> </span><span class="NLM_article-title">tyk2, prototype of a novel class of non-receptor tyrosine kinase genes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">â</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=tyk2%2C+prototype+of+a+novel+class+of+non-receptor+tyrosine+kinase+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0ljxXnPBjrlLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3Dtyk2%252C%2520prototype%2520of%2520a%2520novel%2520class%2520of%2520non-receptor%2520tyrosine%2520kinase%2520genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">â</span> <span class="NLM_lpage">6737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0ljxXnPBjrlLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mavers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruderman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, H.</span><span> </span><span class="NLM_article-title">Intracellular signal pathways: potential for therapies</span> <span class="citation_source-journal">Curr. Rheumatol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1007%2Fs11926-009-0054-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19772834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=378-385&author=M.+Maversauthor=E.+M.+Rudermanauthor=H.+Perlman&title=Intracellular+signal+pathways%3A+potential+for+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal pathways: potential for therapies</span></div><div class="casAuthors">Mavers, Melissa; Ruderman, Eric M.; Perlman, Harris</div><div class="citationInfo"><span class="NLM_cas:title">Current Rheumatology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">CRRUCI</span>;
        ISSN:<span class="NLM_cas:issn">1523-3774</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drawbacks to current therapies for rheumatoid arthritis and the high cost of many of these drugs have lead to the investigation of novel approaches for treatment of this disease.  One such tactic is the targeting of proteins involved in intracellular signal transduction.  Inhibitors of p38 kinase have largely failed in clin. trials, due to both lack of efficacy and adverse events.  The degree of adverse events may reflect off-target effects or, conversely, may be a mechanism-related event subsequent to successful inhibition of p38.  Drugs targeting Janus kinases or spleen tyrosine kinase have shown greater success in clin. trials.  A thorough anal. of specificity, as well as publication of both pos. and neg. results, must be the goal of continuing trials of these and other inhibitors of signal transduction mols.  The success of many clin. trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBrleay_ctfrVg90H21EOLACvtfcHk0ljxXnPBjrlLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE&md5=f3a18d64ac9620db5e43ca55df40c83b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11926-009-0054-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11926-009-0054-9%26sid%3Dliteratum%253Aachs%26aulast%3DMavers%26aufirst%3DM.%26aulast%3DRuderman%26aufirst%3DE.%2BM.%26aulast%3DPerlman%26aufirst%3DH.%26atitle%3DIntracellular%2520signal%2520pathways%253A%2520potential%2520for%2520therapies%26jtitle%3DCurr.%2520Rheumatol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D378%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinobu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lighvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visconti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by type I and II cytokine receptors: ten years after</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2FS0952-7915%2800%2900228-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=363-373&author=M.+Gadinaauthor=D.+Hiltonauthor=J.+A.+Johnstonauthor=A.+Morinobuauthor=A.+Lighvaniauthor=Y.-J.+Zhouauthor=R.+Viscontiauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+type+I+and+II+cytokine+receptors%3A+ten+years+after"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by type I and II cytokine receptors: ten years after</span></div><div class="casAuthors">Gadina, Massimo; Hilton, Douglas; Johnston, James A.; Morinobu, Akio; Lighvani, Arash; Zhou, Yong-Jie; Visconti, Roberta; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Discovered during the past ten years, Janus kinases and signal transducers and activators of transcription have emerged as crit. elements in cytokine signaling and immunoregulation.  Recently, knockout mice for all the members of these families have been generated, with remarkably specific outcomes.  Equally exciting is the discovery of a new class of inhibitors, the suppressor of cytokine signaling family.  The phenotypes of mice deficient in these mols. are also striking, underscoring the importance of neg. regulation in cytokine signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG4srLWQWES7Vg90H21EOLACvtfcHk0lg8ORn1FjeQGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D&md5=ee2b4d8b8aebd180e22f1e80c688f717</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900228-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900228-4%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DHilton%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DMorinobu%26aufirst%3DA.%26aulast%3DLighvani%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DVisconti%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520type%2520I%2520and%2520II%2520cytokine%2520receptors%253A%2520ten%2520years%2520after%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2001%26volume%3D13%26spage%3D363%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lg8ORn1FjeQGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Levesque, M. C.</span><span> </span><span class="NLM_article-title">Biologic rheumatoid arthritis therapies: Do we need more comparative effectiveness data?</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">70</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=65-70&author=M.+C.+Levesque&title=Biologic+rheumatoid+arthritis+therapies%3A+Do+we+need+more+comparative+effectiveness+data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevesque%26aufirst%3DM.%2BC.%26atitle%3DBiologic%2520rheumatoid%2520arthritis%2520therapies%253A%2520Do%2520we%2520need%2520more%2520comparative%2520effectiveness%2520data%253F%26jtitle%3DBioDrugs%26date%3D2012%26volume%3D26%26spage%3D65%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">Cytokines in the pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri2094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17525752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-442&author=I.+B.+McInnesauthor=G.+Schett&title=Cytokines+in+the+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in the pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Iain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-442</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines regulate a broad range of inflammatory processes that are implicated in the pathogenesis of rheumatoid arthritis.  In rheumatoid joints, it is well known that an imbalance between pro- and anti-inflammatory cytokine activities favors the induction of autoimmunity, chronic inflammation and thereby joint damage.  However, it remains less clear how cytokines are organized within a hierarchical regulatory network, and therefore which cytokines may be the best targets for clin. intervention a priori.  Here, we discuss the crucial effector function of cytokines in the immunol. processes that are central to the pathogenesis of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0RdTFn7jhXLVg90H21EOLACvtfcHk0lg8ORn1FjeQGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D&md5=139510ac7d6607fbd46c6d32f781dfc6</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnri2094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2094%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DCytokines%2520in%2520the%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodszky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ersek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulacsi, L.</span><span> </span><span class="NLM_article-title">Adherence to biologic DMARD therapies in rheumatoid arthritis</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">â</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F14712598.2010.510508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFWrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1367-1378&author=T.+Konczauthor=M.+Pentekauthor=V.+Brodszkyauthor=K.+Ersekauthor=E.+Orlewskaauthor=L.+Gulacsi&title=Adherence+to+biologic+DMARD+therapies+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Adherence to biologic DMARD therapies in rheumatoid arthritis</span></div><div class="casAuthors">Koncz, Tamas; Pentek, Marta; Brodszky, Valentin; Ersek, Katalin; Orlewska, Ewa; Gulacsi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1367-1378</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The efficacy of the biol. disease-modifying antirheumatic drugs (DMARDs) shown in clin. trials may be jeopardized due to prevalent poor patient adherence.  Areas covered in this review: Patient adherence including compliance and persistence with biol. DMARDs in rheumatoid arthritis.  What the reader will gain: This is a comprehensive review of the literature.  The various definitions and methodologies of measurement used in adherence research are reviewed and data are presented by sepg. compliance and persistence.  Differences in compliance rates were mainly based on numerical trends.  There was evidence for and against greater persistence with infliximab vs. adalimumab and etanercept.  There was a trend in favor of greater compliance and lower persistence with TNF-Î± inhibitor monotherapy vs. in combination therapy with methotrexate.  Take home message: The evidence suggests that adherence to biol. DMARDs is suboptimal.  When further research is applied in the field, agreed definitions and methodol. need to be used to allow for cross-study comparisons.  In addn., adherence should be assessed in conjunction with clin. outcomes and not on its own so that it can be better understood what levels of adherence provide the required clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIzufe0IGkLVg90H21EOLACvtfcHk0ljc0iWSiU7qRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFWrur4%253D&md5=575566f4bf349db9675c926696f2bcfc</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14712598.2010.510508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2010.510508%26sid%3Dliteratum%253Aachs%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DPentek%26aufirst%3DM.%26aulast%3DBrodszky%26aufirst%3DV.%26aulast%3DErsek%26aufirst%3DK.%26aulast%3DOrlewska%26aufirst%3DE.%26aulast%3DGulacsi%26aufirst%3DL.%26atitle%3DAdherence%2520to%2520biologic%2520DMARD%2520therapies%2520in%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D1367%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Harrold, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, J. D.</span><span> </span><span class="NLM_article-title">The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2013-203936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1136%2Fannrheumdis-2013-203936" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=L.+R.+Harroldauthor=G.+W.+Reedauthor=J.+M.+Kremerauthor=J.+R.+Curtisauthor=D.+H.+Solomonauthor=M.+C.+Hochbergauthor=J.+D.+Greenberg&title=The+comparative+effectiveness+of+abatacept+versus+anti-tumour+necrosis+factor+switching+for+rheumatoid+arthritis+patients+previously+treated+with+an+anti-tumour+necrosis+factor&doi=10.1136%2Fannrheumdis-2013-203936"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2013-203936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2013-203936%26sid%3Dliteratum%253Aachs%26aulast%3DHarrold%26aufirst%3DL.%2BR.%26aulast%3DReed%26aufirst%3DG.%2BW.%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSolomon%26aufirst%3DD.%2BH.%26aulast%3DHochberg%26aufirst%3DM.%2BC.%26aulast%3DGreenberg%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520comparative%2520effectiveness%2520of%2520abatacept%2520versus%2520anti-tumour%2520necrosis%2520factor%2520switching%2520for%2520rheumatoid%2520arthritis%2520patients%2520previously%2520treated%2520with%2520an%2520anti-tumour%2520necrosis%2520factor%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26doi%3D10.1136%2Fannrheumdis-2013-203936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span> </span><span class="NLM_article-title">Novel small-molecular therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2FBOR.0b013e32835190ef" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22357358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=335-341&author=R.+Fleischmann&title=Novel+small-molecular+therapeutics+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small-molecular therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the introduction of biol. therapies into the treatment paradigm of rheumatoid arthritis (RA), there has been hope that oral small mol. immune modulators would be developed that would have a risk : benefit profile at least similar to biol. therapies, be more convenient for the patient and, hopefully, be less expensive.  This article reviews the progress made in the development of these compds. over the past year.  Recent findings: Addnl. information has become available in the past year on five oral compds. including kinase inhibitors (tofacitinib, fostamatinib, VX-509), an S1P lyase inhibitor (LX 3305) and a chemokine receptor-1 antagonist (CCX354-C).  Efficacy has been shown in phase III with tofacitinib and in phase II with fostamatinib and VX-509; safety was the primary endpoint of the trials of CCX354-C and LX3305.  Regarding side effects, liver test elevation and neutropenia occurred with tofacitinib, VX-509 and fostamatinib; lipid elevation with tofacitinib and VX-509; creatinine elevation and anemia with tofacitinib, and hypertension and diarrhea with fostamatinib.  Summary: Compds. that inhibit tyrosine kinase pathways involved in cellular signalling have been shown to be effective in the treatment of RA with a reasonable risk : benefit ratio.  It is too early to tell about inhibitors of other pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALXnYT2mHjLVg90H21EOLACvtfcHk0ljc0iWSiU7qRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D&md5=46627d79c7fe388c3a9d0fe05d83b040</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e32835190ef&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e32835190ef%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26atitle%3DNovel%2520small-molecular%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2012%26volume%3D24%26spage%3D335%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Vijayakrishnan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataramanan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulati, P.</span><span> </span><span class="NLM_article-title">Treating inflammation with the Janus kinase inhibitor CP-690,550</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=25-34&author=L.+Vijayakrishnanauthor=R.+Venkataramananauthor=P.+Gulati&title=Treating+inflammation+with+the+Janus+kinase+inhibitor+CP-690%2C550"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVijayakrishnan%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DR.%26aulast%3DGulati%26aufirst%3DP.%26atitle%3DTreating%2520inflammation%2520with%2520the%2520Janus%2520kinase%2520inhibitor%2520CP-690%252C550%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D25%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2013</span><span class="NLM_x">) </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&issue=2013&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.-J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2ebe3yWBjXJx7rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26issue%3D2013%26spage%3D495%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des, E. S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science (Washington, DC, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=S.-P.+Changauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=E.+S.+G.+Desauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.-S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.-J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lgDVetaJ_uIrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%26aufirst%3DE.%2BS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.-S.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x"> (</span><span class="NLM_issue">5237</span><span class="NLM_x">) </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&issue=5237&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5237%26spage%3D797%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Casanova, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Inborn errors of human JAKs and STATs</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=515-528&author=J.-L.+Casanovaauthor=S.+M.+Hollandauthor=L.+D.+Notarangelo&title=Inborn+errors+of+human+JAKs+and+STATs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DInborn%2520errors%2520of%2520human%2520JAKs%2520and%2520STATs%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2ebsHYx03-Oqkrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&issue=3&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+Jaks+in+cytokine-induced+biologic+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520Jaks%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">397</span><span class="NLM_x">â</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&issue=3&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D397%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&issue=3&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+van+Deursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinobu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lighvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visconti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by type I and II cytokine receptors: ten years after</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2FS0952-7915%2800%2900228-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=363-373&issue=3&author=M.+Gadinaauthor=D.+Hiltonauthor=J.+A.+Johnstonauthor=A.+Morinobuauthor=A.+Lighvaniauthor=Y.+J.+Zhouauthor=R.+Viscontiauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+type+I+and+II+cytokine+receptors%3A+ten+years+after"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by type I and II cytokine receptors: ten years after</span></div><div class="casAuthors">Gadina, Massimo; Hilton, Douglas; Johnston, James A.; Morinobu, Akio; Lighvani, Arash; Zhou, Yong-Jie; Visconti, Roberta; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Discovered during the past ten years, Janus kinases and signal transducers and activators of transcription have emerged as crit. elements in cytokine signaling and immunoregulation.  Recently, knockout mice for all the members of these families have been generated, with remarkably specific outcomes.  Equally exciting is the discovery of a new class of inhibitors, the suppressor of cytokine signaling family.  The phenotypes of mice deficient in these mols. are also striking, underscoring the importance of neg. regulation in cytokine signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG4srLWQWES7Vg90H21EOLACvtfcHk0lhCCeLglirn4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D&md5=ee2b4d8b8aebd180e22f1e80c688f717</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900228-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900228-4%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DHilton%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DMorinobu%26aufirst%3DA.%26aulast%3DLighvani%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DVisconti%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520type%2520I%2520and%2520II%2520cytokine%2520receptors%253A%2520ten%2520years%2520after%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2001%26volume%3D13%26issue%3D3%26spage%3D363%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kilic, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacimustafaoglu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisson-Dupuis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreins, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome</span> <span class="citation_source-journal">J. Pediatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1055</span><span class="NLM_x">â</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jpeds.2012.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC38vlvFOjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2012&pages=1055-1057&issue=6&author=S.+S.+Kilicauthor=M.+Hacimustafaogluauthor=S.+Boisson-Dupuisauthor=A.+Y.+Kreinsauthor=A.+V.+Grantauthor=L.+Abelauthor=J.+L.+Casanova&title=A+patient+with+tyrosine+kinase+2+deficiency+without+hyper-IgE+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome</span></div><div class="casAuthors">Kilic Sara S; Hacimustafaoglu Mustafa; Boisson-Dupuis Stephanie; Kreins Alexandra Y; Grant Audrey V; Abel Laurent; Casanova Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pediatrics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1055-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe a Turkish patient with tyrosine kinase 2 deficiency who suffered from disseminated Bacille Calmette-Guerin infection, neurobrucellosis, and cutaneous herpes zoster infection.  Tyrosine kinase 2 deficiency should be considered in patients susceptible to herpes viruses and intramacrophage pathogens even in the absence of atopy, high serum IgE, and staphylococcal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQojBYLpTn-mbBItaL1WaVAfW6udTcc2eYF3bcEovtwG7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vlvFOjug%253D%253D&md5=90788c5590881e202705da37184ecb09</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.jpeds.2012.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpeds.2012.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DHacimustafaoglu%26aufirst%3DM.%26aulast%3DBoisson-Dupuis%26aufirst%3DS.%26aulast%3DKreins%26aufirst%3DA.%2BY.%26aulast%3DGrant%26aufirst%3DA.%2BV.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DA%2520patient%2520with%2520tyrosine%2520kinase%25202%2520deficiency%2520without%2520hyper-IgE%2520syndrome%26jtitle%3DJ.%2520Pediatr.%26date%3D2012%26volume%3D160%26issue%3D6%26spage%3D1055%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yachie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renner, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belohradsky, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">745</span><span class="NLM_x">â</span> <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&issue=5&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26issue%3D5%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Casanova, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Inborn errors of human JAKs and STATs</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=515-528&issue=4&author=J.+L.+Casanovaauthor=S.+M.+Hollandauthor=L.+D.+Notarangelo&title=Inborn+errors+of+human+JAKs+and+STATs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DInborn%2520errors%2520of%2520human%2520JAKs%2520and%2520STATs%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26issue%3D4%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">JAK2, a third member of the JAK family of protein tyrosine kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2013</span><span class="NLM_x">) </span> <span class="NLM_fpage">1347</span><span class="NLM_x">â</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1992&pages=1347-1353&issue=2013&author=A.+G.+Harpurauthor=A.+C.+Andresauthor=A.+Ziemieckiauthor=R.+R.+Astonauthor=A.+F.+Wilks&title=JAK2%2C+a+third+member+of+the+JAK+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26aulast%3DZiemiecki%26aufirst%3DA.%26aulast%3DAston%26aufirst%3DR.%2BR.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DJAK2%252C%2520a%2520third%2520member%2520of%2520the%2520JAK%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DOncogene%26date%3D1992%26volume%3D7%26issue%3D2013%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaluoma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">Regulation of the Jak2 tyrosine kinase by its pseudokinase domain</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3387</span><span class="NLM_x">â</span> <span class="NLM_lpage">3395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1128%2FMCB.20.10.3387-3395.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=10779328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFyhtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=3387-3395&author=P.+Saharinenauthor=K.+Takaluomaauthor=O.+Silvennoinen&title=Regulation+of+the+Jak2+tyrosine+kinase+by+its+pseudokinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Jak2 tyrosine kinase by its pseudokinase domain</span></div><div class="casAuthors">Saharinen, Pipsa; Takaluoma, Kati; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3387-3395</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Activation of Jak tyrosine kinases through hematopoietic cytokine receptors occurs as a consequence of ligand-induced aggregation of receptor-assocd. Jaks and their subsequent autophosphorylation.  Jak kinases consist of a C-terminal tyrosine kinase domain, a pseudokinase domain of unknown function, and Jak homol. (JH) domains 3 to 7, implicated in receptor-Jak interaction.  We analyzed the functional roles of the different protein domains in activation of Jak2.  Deletion anal. of Jak2 showed that the pseudokinase domain but not JH domains 3 to 7 neg. regulated the catalytic activity of Jak2 as well Jak2-mediated activation of Stat5.  Phosphorylation of Stat5 by wild-type Jak2 was dependent on the SH2 domain of Stat5; however, this requirement was lost upon deletion of the pseudokinase domain of Jak2.  Investigation of the mechanisms of the pseudokinase domain-mediated inhibition of Jak2 suggested that this regulation did not involve protein tyrosine phosphatases.  Instead, anal. of interactions between the tyrosine kinase domain and Jak2 suggested that the pseudokinase domain interacted with the kinase domain.  Furthermore, co-expression of the pseudokinase domain inhibited the activity of the single tyrosine kinase domain.  Finally, deletion of the pseudokinase domain of Jak2 deregulated signal transduction through the gamma interferon receptor by significantly increasing ligand-independent activation of Stat transcription factors.  These results indicate that the pseudokinase domain neg. regulates the activity of Jak2, probably through an interaction with the kinase domain, and this regulation is required to keep Jak2 inactive in the absence of ligand stimulation.  Furthermore, the pseudokinase domain may have a role in regulation of Jak2-substrate interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiXFK81wIJ7Vg90H21EOLACvtfcHk0liTen0ogAqoXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFyhtrw%253D&md5=17ac4581ee9c36e03e95f0f88405339c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.10.3387-3395.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.10.3387-3395.2000%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DTakaluoma%26aufirst%3DK.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DRegulation%2520of%2520the%2520Jak2%2520tyrosine%2520kinase%2520by%2520its%2520pseudokinase%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D3387%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">47954</span><span class="NLM_x">â</span> <span class="NLM_lpage">47963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=47954-47963&author=P.+Saharinenauthor=O.+Silvennoinen&title=The+pseudokinase+domain+is+required+for+suppression+of+basal+activity+of+Jak2+and+Jak3+tyrosine+kinases+and+for+cytokine-inducible+activation+of+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520pseudokinase%2520domain%2520is%2520required%2520for%2520suppression%2520of%2520basal%2520activity%2520of%2520Jak2%2520and%2520Jak3%2520tyrosine%2520kinases%2520and%2520for%2520cytokine-inducible%2520activation%2520of%2520signal%2520transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D47954%26epage%3D47963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ungureanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekkala, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niranjan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubert, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoda, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">971</span><span class="NLM_x">â</span> <span class="NLM_lpage">976</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnsmb.2099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWmur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=971-976&issue=9&author=D.+Ungureanuauthor=J.+Wuauthor=T.+Pekkalaauthor=Y.+Niranjanauthor=C.+Youngauthor=O.+N.+Jensenauthor=C.+F.+Xuauthor=T.+A.+Neubertauthor=R.+C.+Skodaauthor=S.+R.+Hubbardauthor=O.+Silvennoinen&title=The+pseudokinase+domain+of+JAK2+is+a+dual-specificity+protein+kinase+that+negatively+regulates+cytokine+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling</span></div><div class="casAuthors">Ungureanu, Daniela; Wu, Jinhua; Pekkala, Tuija; Niranjan, Yashavanthi; Young, Clifford; Jensen, Ole N.; Xu, Chong-Feng; Neubert, Thomas A.; Skoda, Radek C.; Hubbard, Stevan R.; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human JAK2 tyrosine kinase mediates signaling through numerous cytokine receptors.  The JAK2 JH2 domain functions as a neg. regulator and is presumed to be a catalytically inactive pseudokinase, but the mechanism(s) for its inhibition of JAK2 remains unknown.  Mutations in JH2 lead to increased JAK2 activity, contributing to myeloproliferative neoplasms (MPNs).  Here we show that JH2 is a dual-specificity protein kinase that phosphorylates two neg. regulatory sites in JAK2: Ser523 and Tyr570.  Inactivation of JH2 catalytic activity increased JAK2 basal activity and downstream signaling.  Notably, different MPN mutations abrogated JH2 activity in cells, and in MPN (V617F) patient cells phosphorylation of Tyr570 was reduced, suggesting that loss of JH2 activity contributes to the pathogenesis of MPNs.  These results identify the catalytic activity of JH2 as a previously unrecognized mechanism to control basal activity and signaling of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGxnYmkTj5rVg90H21EOLACvtfcHk0liTen0ogAqoXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWmur7J&md5=381c93988ea9d0a720fe759ec7d09e27</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2099%26sid%3Dliteratum%253Aachs%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DPekkala%26aufirst%3DT.%26aulast%3DNiranjan%26aufirst%3DY.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DO.%2BN.%26aulast%3DXu%26aufirst%3DC.%2BF.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520pseudokinase%2520domain%2520of%2520JAK2%2520is%2520a%2520dual-specificity%2520protein%2520kinase%2520that%2520negatively%2520regulates%2520cytokine%2520signaling%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D18%26issue%3D9%26spage%3D971%26epage%3D976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Radtke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerissen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermanns, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyczek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz-VandeLeur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haan, C.</span><span> </span><span class="NLM_article-title">The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">25760</span><span class="NLM_x">â</span> <span class="NLM_lpage">25768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=25760-25768&author=S.+Radtkeauthor=S.+Haanauthor=A.+Joerissenauthor=H.+M.+Hermannsauthor=S.+Diefenbachauthor=T.+Smyczekauthor=H.+Schmitz-VandeLeurauthor=P.+C.+Heinrichauthor=I.+Behrmannauthor=C.+Haan&title=The+Jak1+SH2+domain+does+not+fulfill+a+classical+SH2+function+in+Jak%2FSTAT+signaling+but+plays+a+structural+role+for+receptor+interaction+and+up-regulation+of+receptor+surface+expression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRadtke%26aufirst%3DS.%26aulast%3DHaan%26aufirst%3DS.%26aulast%3DJoerissen%26aufirst%3DA.%26aulast%3DHermanns%26aufirst%3DH.%2BM.%26aulast%3DDiefenbach%26aufirst%3DS.%26aulast%3DSmyczek%26aufirst%3DT.%26aulast%3DSchmitz-VandeLeur%26aufirst%3DH.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DHaan%26aufirst%3DC.%26atitle%3DThe%2520Jak1%2520SH2%2520domain%2520does%2520not%2520fulfill%2520a%2520classical%2520SH2%2520function%2520in%2520Jak%252FSTAT%2520signaling%2520but%2520plays%2520a%2520structural%2520role%2520for%2520receptor%2520interaction%2520and%2520up-regulation%2520of%2520receptor%2520surface%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D25760%26epage%3D25768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Girault, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labesse, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mornon, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callebaut, I.</span><span> </span><span class="NLM_article-title">Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction</span> <span class="citation_source-journal">Mol. Med. (N. Y.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFyisrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=751-769&author=J.-A.+Giraultauthor=G.+Labesseauthor=J.-P.+Mornonauthor=I.+Callebaut&title=Janus+kinases+and+focal+adhesion+kinases+play+in+the+4.1+band%3A+a+superfamily+of+band+4.1+domains+important+for+cell+structure+and+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction</span></div><div class="casAuthors">Girault, Jean-Antoine; Labesse, Gilles; Mornon, Jean-Paul; Callebaut, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (New York)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">751-769</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag New York Inc.</span>)
        </div><div class="casAbstract">A review, with 137 refs.  The band 4.1 domain was first identified in the red blood cell protein band 4.1, and subsequently in ezrin, radixin, and moesin (ERM proteins) and other proteins, including tumor suppressor merlin/schwannomin, talin, unconventional myosins VIIa and X, and protein tyrosine phosphatases.  Recently, the presence of a structurally related domain has been demonstrated in the N-terminal region of two groups of tyrosine kinases: the focal adhesion kinases (FAK) and the Janus kinases (JAK).  Addnl. proteins contg. the 4.1/JEF (JAK, ERM, FAK) domain include plant kinesin-like calmodulin-binding proteins (KCBP) and a no. of uncharacterized open reading frames identified by systematic DNA sequencing.  Phylogenetic anal. of amino acid sequences suggests that band 4.1/JEF domains can be grouped in several families that have probably diverged early during evolution.  Hydrophobic cluster anal. indicates that the band 4.1/JEF domains might consist of a duplicated module of â¼140 residues and a central hinge region.  A conserved property of the domain is its capacity to bind to the membrane-proximal region of the C-terminal cytoplasmic tail of proteins with a single transmembrane segment.  Many proteins with band 4.1/JEF domains undergo regulated intra- or intermol. homotypic interactions.  Addnl. properties common to band 4.1/JEF domains of several proteins are binding of phosphoinositides and regulation by GTPases of the Rho family.  Many proteins with band 4.1/JEF domains are assocd. with the actin-based cytoskeleton and are enriched at points of contact with other cells or the extracellular matrix, from which they can exert control over cell growth.  Thus, proteins with band 4.1/JEF domain are at the crossroads between cytoskeletal organization and signal transduction in multicellular organisms.  Their importance is underlined by the variety of diseases that can result from their mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD2L3dA2cE77Vg90H21EOLACvtfcHk0lgQh8msRbLZeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFyisrw%253D&md5=97f78937667dd2bd09631828a9465e77</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGirault%26aufirst%3DJ.-A.%26aulast%3DLabesse%26aufirst%3DG.%26aulast%3DMornon%26aufirst%3DJ.-P.%26aulast%3DCallebaut%26aufirst%3DI.%26atitle%3DJanus%2520kinases%2520and%2520focal%2520adhesion%2520kinases%2520play%2520in%2520the%25204.1%2520band%253A%2520a%2520superfamily%2520of%2520band%25204.1%2520domains%2520important%2520for%2520cell%2520structure%2520and%2520signal%2520transduction%26jtitle%3DMol.%2520Med.%2520%2528N.%2520Y.%2529%26date%3D1998%26volume%3D4%26spage%3D751%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Sheaauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common Î³-chain (Î³c), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the Î³c-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100âCys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lgQh8msRbLZeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%2520%2528London%2529%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yachie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renner, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belohradsky, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">â</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0lhXtu8rsQsTfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Deon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaletta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, I.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivashkiv, L. B.</span><span> </span><span class="NLM_article-title">Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">5395</span><span class="NLM_x">â</span> <span class="NLM_lpage">5403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=5395-5403&author=D.+Deonauthor=S.+Ahmedauthor=K.+Taiauthor=N.+Scalettaauthor=C.+Herreroauthor=I.-H.+Leeauthor=A.+Krauseauthor=L.+B.+Ivashkiv&title=Cross-talk+between+IL-1+and+IL-6+signaling+pathways+in+rheumatoid+arthritis+synovial+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeon%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DK.%26aulast%3DScaletta%26aufirst%3DN.%26aulast%3DHerrero%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DI.-H.%26aulast%3DKrause%26aufirst%3DA.%26aulast%3DIvashkiv%26aufirst%3DL.%2BB.%26atitle%3DCross-talk%2520between%2520IL-1%2520and%2520IL-6%2520signaling%2520pathways%2520in%2520rheumatoid%2520arthritis%2520synovial%2520fibroblasts%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D5395%26epage%3D5403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniv, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falck-Pedersen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivashkiv, L. B.</span><span> </span><span class="NLM_article-title">Sensitization of IFN-Î³ Jak-STAT signaling during macrophage activation</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">â</span> <span class="NLM_lpage">866</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27d&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fni828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27d&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ags7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=859-866&author=X.+Huauthor=C.+Herreroauthor=W.-P.+Liauthor=T.+T.+Antonivauthor=E.+Falck-Pedersenauthor=A.+E.+Kochauthor=J.+M.+Woodsauthor=G.+K.+Hainesauthor=L.+B.+Ivashkiv&title=Sensitization+of+IFN-%CE%B3+Jak-STAT+signaling+during+macrophage+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27dR"><div class="casContent"><span class="casTitleNuber">27d</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitization of IFN-Î³ Jak-STAT signaling during macrophage activation</span></div><div class="casAuthors">Hu, Xiaoyu; Herrero, Carmen; Li, Wai-Ping; Antoniv, Taras T.; Falck-Pedersen, Erik; Koch, Alisa E.; Woods, James M.; Haines, G. Kenneth; Ivashkiv, Lionel B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A general paradigm in signal transduction is ligand-induced feedback inhibition and the desensitization of signaling.  We found that subthreshold concns. of interferon-Î³ (IFN-Î³), which did not activate macrophages, increased their sensitivity to subsequent IFN-Î³ stimulation; this resulted in increased signal transducer and activator of transcription 1 (STAT1) activation and increased IFN-Î³-dependent gene activation.  Sensitization of IFN-Î³ signaling was mediated by the induction of STAT1 expression by low doses of IFN-Î³ that did not effectively induce feedback inhibition.  IFN-Î³ signaling was sensitized in vivo after IFN-Î³ injection, and STAT1 expression was increased after injection of lipopolysaccharide and in rheumatoid arthritis synovial cells.  These results identify a mechanism that sensitizes macrophages to low concns. of IFN-Î³ and regulates IFN-Î³ responses in acute and chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq15kv8A5SFdLVg90H21EOLACvtfcHk0lhXtu8rsQsTfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ags7w%253D&md5=3672158efb50a86750b8cb95faa0035f</span></div><a href="/servlet/linkout?suffix=cit27d&amp;dbid=16384&amp;doi=10.1038%2Fni828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni828%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DHerrero%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DW.-P.%26aulast%3DAntoniv%26aufirst%3DT.%2BT.%26aulast%3DFalck-Pedersen%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DWoods%26aufirst%3DJ.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DIvashkiv%26aufirst%3DL.%2BB.%26atitle%3DSensitization%2520of%2520IFN-%25CE%25B3%2520Jak-STAT%2520signaling%2520during%2520macrophage%2520activation%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D859%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor Î³ chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell (Cambridge, MA, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=8462096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK3sXktVOjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+%CE%B3+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-2 receptor Î³ chain mutation results in X-linked severe combined immunodeficiency in humans</span></div><div class="casAuthors">Noguchi, Masayuki; Yi, Huafang; Rosenblatt, Howard M.; Filipovich, Alexandra H.; Adelstein, Stephen; Modi, William S.; McBride, O. Wesley; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-57</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The interleukin-2 receptor Î³ chain (IL-2RÎ³) is a component of high and intermediate affinity IL-2 receptors that is required to achieve full ligand binding affinity and internalization.  The IL-2RÎ³ gene was localized to human chromosome Xq13.  Genetic linkage anal. indicates that the IL-2RÎ³ gene and the locus for X-linked severe combined immunodeficiency (XSCID) appear to be at the same position.  Moreover, each of 3 unrelated patients with XSCID has a different mutation in his IL-2RÎ³ gene resulting in a different premature stop codon and predicted C-terminal truncation.  These data establish that XSCID is assocd. with mutations of the IL-2RÎ³ gene product.  Since XSCID is characterized by absent or markedly reduced nos. of T cells, these findings imply that IL-2RÎ³ plays a vital role in thymic maturation of T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN9VGDNlllq7Vg90H21EOLACvtfcHk0lhXtu8rsQsTfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVOjtro%253D&md5=5a13ffadf49bf72141237dfc376136dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520%25CE%25B3%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%2520%2528Cambridge%252C%2520MA%252C%2520U.%2520S.%2529%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">JAK-mutant myeloproliferative neoplasms</span> <span class="citation_source-journal">Curr. Top. Microbiol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2012&pages=119-133&author=R.+L.+Levine&title=JAK-mutant+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK-mutant%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2012%26volume%3D355%26spage%3D119%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atlas, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifford, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhard, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reaman, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunger, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willman, C. L.</span><span> </span><span class="NLM_article-title">JAK mutations in high-risk childhood acute lymphoblastic leukemia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">9414</span><span class="NLM_x">â</span> <span class="NLM_lpage">9418</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=9414-9418&author=C.+G.+Mullighanauthor=J.+Zhangauthor=R.+C.+Harveyauthor=J.+R.+Collins-Underwoodauthor=B.+A.+Schulmanauthor=L.+A.+Phillipsauthor=S.+K.+Tasianauthor=M.+L.+Lohauthor=X.+Suauthor=W.+Liuauthor=M.+Devidasauthor=S.+R.+Atlasauthor=I.+M.+Chenauthor=R.+J.+Cliffordauthor=D.+S.+Gerhardauthor=W.+L.+Carrollauthor=G.+H.+Reamanauthor=M.+Smithauthor=J.+R.+Downingauthor=S.+P.+Hungerauthor=C.+L.+Willman&title=JAK+mutations+in+high-risk+childhood+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DCollins-Underwood%26aufirst%3DJ.%2BR.%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26aulast%3DPhillips%26aufirst%3DL.%2BA.%26aulast%3DTasian%26aufirst%3DS.%2BK.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DAtlas%26aufirst%3DS.%2BR.%26aulast%3DChen%26aufirst%3DI.%2BM.%26aulast%3DClifford%26aufirst%3DR.%2BJ.%26aulast%3DGerhard%26aufirst%3DD.%2BS.%26aulast%3DCarroll%26aufirst%3DW.%2BL.%26aulast%3DReaman%26aufirst%3DG.%2BH.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26atitle%3DJAK%2520mutations%2520in%2520high-risk%2520childhood%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D9414%26epage%3D9418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Basquiera, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salquero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moiraghi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturich, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berretta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonafe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barral, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. J.</span><span> </span><span class="NLM_article-title">Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders</span> <span class="citation_source-journal">Hematology (Leeds, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">â</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlais7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=323-330&author=A.+L.+Basquieraauthor=N.+W.+Soriaauthor=R.+Ryserauthor=M.+Salqueroauthor=B.+Moiraghiauthor=F.+Sackmannauthor=A.+G.+Sturichauthor=A.+Borelloauthor=A.+Berrettaauthor=M.+Bonafeauthor=J.+M.+Barralauthor=E.+D.+Palazzoauthor=J.+J.+Garcia&title=Clinical+significance+of+V617F+mutation+of+the+JAK2+gene+in+patients+with+chronic+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders</span></div><div class="casAuthors">Basquiera, Ana L.; Soria, Nestor W.; Ryser, Ricardo; Salquero, Miriam; Moiraghi, Beatriz; Sackmann, Federico; Sturich, Ana G.; Borello, Adriana; Berretta, Adriana; Bonafe, Miriam; Barral, Jose Moreno; Palazzo, Emilio D.; Garcia, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Hematology (Leeds, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-330</span>CODEN:
                <span class="NLM_cas:coden">HMATFL</span>;
        ISSN:<span class="NLM_cas:issn">1024-5332</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">The objective was to det. the prevalence of JAK2 V617F mutation and its clin. correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).  Detection of JAK2 V617F mutation by allele specific-PCR.  One hundred and three patients with CMD were included in the study.  JAK2 V617F distribution was PV 40/45 (89%), ET 30/43 (69%), and IMF 7/15 (47%).  In PV and ET patients only, 18 had thrombosis at diagnosis and 12 during follow-up (these were microvascular: 11, venous: 7 and arterial: 12); of these 28/70 (40%) were JAK2pos vs. 2/18 (11%) JAK2neg; P=0.02.  In a median of 4 years, two patients with PV JAK2pos evolved to myelofibrosis and one patient with PV presented in leukemic transformation (JAK2pos before and after transformation); six patients died: four patients with IMF and two patients with PV.  We found an assocn. between JAK2 V617F and thrombotic events in patients with PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIveoppCLDNrVg90H21EOLACvtfcHk0lggWbKcnbudqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlais7c%253D&md5=1ca0927fe5648903988bc8a3ebe7ed36</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasquiera%26aufirst%3DA.%2BL.%26aulast%3DSoria%26aufirst%3DN.%2BW.%26aulast%3DRyser%26aufirst%3DR.%26aulast%3DSalquero%26aufirst%3DM.%26aulast%3DMoiraghi%26aufirst%3DB.%26aulast%3DSackmann%26aufirst%3DF.%26aulast%3DSturich%26aufirst%3DA.%2BG.%26aulast%3DBorello%26aufirst%3DA.%26aulast%3DBerretta%26aufirst%3DA.%26aulast%3DBonafe%26aufirst%3DM.%26aulast%3DBarral%26aufirst%3DJ.%2BM.%26aulast%3DPalazzo%26aufirst%3DE.%2BD.%26aulast%3DGarcia%26aufirst%3DJ.%2BJ.%26atitle%3DClinical%2520significance%2520of%2520V617F%2520mutation%2520of%2520the%2520JAK2%2520gene%2520in%2520patients%2520with%2520chronic%2520myeloproliferative%2520disorders%26jtitle%3DHematology%2520%2528Leeds%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D14%26spage%3D323%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Elliott, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleveland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, U. P.</span><span> </span><span class="NLM_article-title">FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">3911</span><span class="NLM_x">â</span> <span class="NLM_lpage">3921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=3911-3921&issue=14&author=N.+E.+Elliottauthor=S.+M.+Clevelandauthor=V.+Grannauthor=J.+Janikauthor=T.+A.+Waldmannauthor=U.+P.+Dave&title=FERM+domain+mutations+induce+gain+of+function+in+JAK3+in+adult+T-cell+leukemia%2Flymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DN.%2BE.%26aulast%3DCleveland%26aufirst%3DS.%2BM.%26aulast%3DGrann%26aufirst%3DV.%26aulast%3DJanik%26aufirst%3DJ.%26aulast%3DWaldmann%26aufirst%3DT.%2BA.%26aulast%3DDave%26aufirst%3DU.%2BP.%26atitle%3DFERM%2520domain%2520mutations%2520induce%2520gain%2520of%2520function%2520in%2520JAK3%2520in%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26issue%3D14%26spage%3D3911%26epage%3D3921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koo, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoh, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutcutache, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasegaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teh, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S. T.</span><span> </span><span class="NLM_article-title">Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span><span class="NLM_x">â</span> <span class="NLM_lpage">597</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=591-597&issue=7&author=G.+C.+Kooauthor=S.+Y.+Tanauthor=T.+Tangauthor=S.+L.+Poonauthor=G.+E.+Allenauthor=L.+Tanauthor=S.+C.+Chongauthor=W.+S.+Ongauthor=K.+Tayauthor=M.+Taoauthor=R.+Quekauthor=S.+Loongauthor=K.+W.+Yeohauthor=S.+P.+Yapauthor=K.+A.+Leeauthor=L.+C.+Limauthor=D.+Tanauthor=C.+Gohauthor=I.+Cutcutacheauthor=W.+Yuauthor=C.+C.+Ngauthor=V.+Rajasegaranauthor=H.+L.+Hengauthor=A.+Ganauthor=C.+K.+Ongauthor=S.+Rozenauthor=P.+Tanauthor=B.+T.+Tehauthor=S.+T.+Lim&title=Janus+kinase+3-activating+mutations+identified+in+natural+killer%2FT-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoo%26aufirst%3DG.%2BC.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DS.%2BL.%26aulast%3DAllen%26aufirst%3DG.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DChong%26aufirst%3DS.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BS.%26aulast%3DTay%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DQuek%26aufirst%3DR.%26aulast%3DLoong%26aufirst%3DS.%26aulast%3DYeoh%26aufirst%3DK.%2BW.%26aulast%3DYap%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BA.%26aulast%3DLim%26aufirst%3DL.%2BC.%26aulast%3DTan%26aufirst%3DD.%26aulast%3DGoh%26aufirst%3DC.%26aulast%3DCutcutache%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DC.%2BC.%26aulast%3DRajasegaran%26aufirst%3DV.%26aulast%3DHeng%26aufirst%3DH.%2BL.%26aulast%3DGan%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DC.%2BK.%26aulast%3DRozen%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DTeh%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DS.%2BT.%26atitle%3DJanus%2520kinase%25203-activating%2520mutations%2520identified%2520in%2520natural%2520killer%252FT-cell%2520lymphoma%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D7%26spage%3D591%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmfeldt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heatley, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne-Turner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pounds, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulyanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becksfort, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huether, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriwacki, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoldrick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobba, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coustan-Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shurtleff, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondi, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimano, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermiston, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doulatov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunger, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunsmore, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obenauer, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pui, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span> </span><span class="NLM_article-title">The genetic basis of early T-cell precursor acute lymphoblastic leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">481</span><span class="NLM_x"> (</span><span class="NLM_issue">7380</span><span class="NLM_x">) </span> <span class="NLM_fpage">157</span><span class="NLM_x">â</span> <span class="NLM_lpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=157-163&issue=7380&author=J.+Zhangauthor=L.+Dingauthor=L.+Holmfeldtauthor=G.+Wuauthor=S.+L.+Heatleyauthor=D.+Payne-Turnerauthor=J.+Eastonauthor=X.+Chenauthor=J.+Wangauthor=M.+Ruschauthor=C.+Luauthor=S.+C.+Chenauthor=L.+Weiauthor=J.+R.+Collins-Underwoodauthor=J.+Maauthor=K.+G.+Robertsauthor=S.+B.+Poundsauthor=A.+Ulyanovauthor=J.+Becksfortauthor=P.+Guptaauthor=R.+Huetherauthor=R.+W.+Kriwackiauthor=M.+Parkerauthor=D.+J.+McGoldrickauthor=D.+Zhaoauthor=D.+Alfordauthor=S.+Espyauthor=K.+C.+Bobbaauthor=G.+Songauthor=D.+Peiauthor=C.+Chengauthor=S.+Robertsauthor=M.+I.+Barbatoauthor=D.+Campanaauthor=E.+Coustan-Smithauthor=S.+A.+Shurtleffauthor=S.+C.+Raimondiauthor=M.+Kleppeauthor=J.+Coolsauthor=K.+A.+Shimanoauthor=M.+L.+Hermistonauthor=S.+Doulatovauthor=K.+Eppertauthor=E.+Laurentiauthor=F.+Nottaauthor=J.+E.+Dickauthor=G.+Bassoauthor=S.+P.+Hungerauthor=M.+L.+Lohauthor=M.+Devidasauthor=B.+Woodauthor=S.+Winterauthor=K.+P.+Dunsmoreauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=X.+Hongauthor=C.+C.+Harrisauthor=D.+J.+Doolingauthor=K.+Ochoaauthor=K.+J.+Johnsonauthor=J.+C.+Obenauerauthor=W.+E.+Evansauthor=C.+H.+Puiauthor=C.+W.+Naeveauthor=T.+J.+Leyauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=J.+R.+Downingauthor=C.+G.+Mullighan&title=The+genetic+basis+of+early+T-cell+precursor+acute+lymphoblastic+leukaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DHolmfeldt%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHeatley%26aufirst%3DS.%2BL.%26aulast%3DPayne-Turner%26aufirst%3DD.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DCollins-Underwood%26aufirst%3DJ.%2BR.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DPounds%26aufirst%3DS.%2BB.%26aulast%3DUlyanov%26aufirst%3DA.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%2BW.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DMcGoldrick%26aufirst%3DD.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DAlford%26aufirst%3DD.%26aulast%3DEspy%26aufirst%3DS.%26aulast%3DBobba%26aufirst%3DK.%2BC.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DBarbato%26aufirst%3DM.%2BI.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DShurtleff%26aufirst%3DS.%2BA.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DKleppe%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DShimano%26aufirst%3DK.%2BA.%26aulast%3DHermiston%26aufirst%3DM.%2BL.%26aulast%3DDoulatov%26aufirst%3DS.%26aulast%3DEppert%26aufirst%3DK.%26aulast%3DLaurenti%26aufirst%3DE.%26aulast%3DNotta%26aufirst%3DF.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DWinter%26aufirst%3DS.%26aulast%3DDunsmore%26aufirst%3DK.%2BP.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DObenauer%26aufirst%3DJ.%2BC.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DPui%26aufirst%3DC.%2BH.%26aulast%3DNaeve%26aufirst%3DC.%2BW.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DThe%2520genetic%2520basis%2520of%2520early%2520T-cell%2520precursor%2520acute%2520lymphoblastic%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D481%26issue%3D7380%26spage%3D157%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">â</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+Jak3+kinase+domain+in+complex+with+a+staurosporine+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, Î³c.  Patients unable to signal via Î³c present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0lgNvHaKXXzeIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Jak3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lj-cFYXD6ht7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lj-cFYXD6ht7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Thompson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubbon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankshun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">â</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1219-1223&author=J.+E.+Thompsonauthor=R.+M.+Cubbonauthor=R.+T.+Cummingsauthor=L.+S.+Wickerauthor=R.+Frankshunauthor=B.+R.+Cunninghamauthor=P.+M.+Cameronauthor=P.+T.+Meinkeauthor=N.+Livertonauthor=Y.+Wengauthor=J.+A.+DeMartino&title=Photochemical+preparation+of+a+pyridone+containing+tetracycle%3A+a+JAK+protein+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26aulast%3DCubbon%26aufirst%3DR.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DFrankshun%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DPhotochemical%2520preparation%2520of%2520a%2520pyridone%2520containing%2520tetracycle%253A%2520a%2520JAK%2520protein%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1219%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">â</span> <span class="NLM_lpage">5921</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=K.+P.+Birauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0lghLB5G9H1T4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6176</span><span class="NLM_x">â</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=K.+P.+Birauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavailable+JAK1+inhibitors+with+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Mendonca, Rohan; Balazs, Mercedesz; Barrett, Kathy; Bergeron, Philippe; Blair, Wade S.; Chang, Christine; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Hamman, Chris; Hanan, Emily J.; Harstad, Eric; Hewitt, Peter R.; Hurley, Christopher A.; Jin, Tian; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Kulagowski, Janusz J.; Labadie, Sharada; Liao, Jiangpeng; Liimatta, Marya; Lin, Zhonghua; Lupardus, Patrick J.; Maxey, Robert J.; Murray, Jeremy M.; Pulk, Rebecca; Rodriguez, Madeleine; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Xiao, Ling; Xiao, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6176-6193</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the discovery of the C-2 Me substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.  The C-2 Me substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compd. 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochem. and cell-based assays, resp.).  Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated.  Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20).  Details of the biol. characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclin. in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogQqQMRvwKbVg90H21EOLACvtfcHk0ljLtWtgAP8__w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D&md5=8c57a4cb02fc245ed12f6f4efdb82318</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=K.+P.+Birauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+A.+vanauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%26aufirst%3DA.%2BA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lynch, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaime-Figueroa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tivitmahaisoon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span> </span><span class="NLM_article-title">Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2793</span><span class="NLM_x">â</span> <span class="NLM_lpage">2800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2793-2800&author=S.+M.+Lynchauthor=J.+DeVicenteauthor=J.+C.+Hermannauthor=S.+Jaime-Figueroaauthor=S.+Jinauthor=A.+Kuglstatterauthor=H.+Liauthor=A.+Loveyauthor=J.+Menkeauthor=L.+Niuauthor=V.+Patelauthor=D.+Royauthor=M.+Sothauthor=S.+Steinerauthor=P.+Tivitmahaisoonauthor=M.+D.+Vuauthor=C.+Yee&title=Strategic+use+of+conformational+bias+and+structure+based+design+to+identify+potent+JAK3+inhibitors+with+improved+selectivity+against+the+JAK+family+and+the+kinome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DDeVicente%26aufirst%3DJ.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DTivitmahaisoon%26aufirst%3DP.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DYee%26aufirst%3DC.%26atitle%3DStrategic%2520use%2520of%2520conformational%2520bias%2520and%2520structure%2520based%2520design%2520to%2520identify%2520potent%2520JAK3%2520inhibitors%2520with%2520improved%2520selectivity%2520against%2520the%2520JAK%2520family%2520and%2520the%2520kinome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2793%26epage%3D2800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Identification of a potent janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.-G.+Zerwes&title=Identification+of+a+potent+janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DIdentification%2520of%2520a%2520potent%2520janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lin, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimble, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewet, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaev, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidl, K. J.</span><span> </span><span class="NLM_article-title">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2283</span><span class="NLM_x">â</span> <span class="NLM_lpage">2293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1002%2Fart.27536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20506481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2283-2293&issue=8&author=T.+H.+Linauthor=M.+Hegenauthor=E.+Quadrosauthor=C.+L.+Nickerson-Nutterauthor=K.+C.+Appellauthor=A.+G.+Coleauthor=Y.+Shaoauthor=S.+Tamauthor=M.+Ohlmeyerauthor=B.+Wangauthor=D.+G.+Goodwinauthor=E.+F.+Kimbleauthor=J.+Quinteroauthor=M.+Gaoauthor=P.+Symanowiczauthor=C.+Wrocklageauthor=J.+Lussierauthor=S.+H.+Schellingauthor=A.+G.+Hewetauthor=D.+Xuanauthor=R.+Krykbaevauthor=J.+Togiasauthor=X.+Xuauthor=R.+Harrisonauthor=T.+Mansourauthor=M.+Collinsauthor=J.+D.+Clarkauthor=M.+L.+Webbauthor=K.+J.+Seidl&title=Selective+functional+inhibition+of+JAK-3+is+sufficient+for+efficacy+in+collagen-induced+arthritis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span></div><div class="casAuthors">Lin, Tsung H.; Hegen, Martin; Quadros, Elizabeth; Nickerson-Nutter, Cheryl L.; Appell, Kenneth C.; Cole, Andrew G.; Shao, Yuefei; Tam, Steve; Ohlmeyer, Michael; Wang, Bojing; Goodwin, Debra G.; Kimble, Earl F.; Quintero, Jorge; Gao, Min; Symanowicz, Peter; Wrocklage, Christopher; Lussier, Jennifer; Schelling, Scott H.; Hewet, Amha G.; Xuan, Dejun; Krykbaev, Rustem; Togias, Jenny; Xu, Xin; Harrison, Richard; Mansour, Tarek; Collins, Mary; Clark, James D.; Webb, Maria L.; Seidi, Katherine J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2283-2293</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. All Î³-chain cytokines signal through JAK-3 and JAK-1 acting in tandem.  We undertook this study to det. whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathol. without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.  Methods. JAK-3 kinase selective compds. were characterized by kinase assay and JAK-3-dependent (interleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF]) cell-based assays measuring proliferation or STAT phosphorylation.  In vivo, off-target signaling was measured by IL-22- and erythropoietin (EPO)-mediated models, while on-target signaling was measured by IL-2-mediated signaling.  Efficacy of JAK-3 inhibitors was detd. using delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA) models in mice.  Results. In vitro, WYE-151650 potently suppressed IL-2-induced STAT-5 phosphorylation and cell proliferation, while exhibiting 10-29-fold less activity against JAK-3-independent IL-6- or GM-CSF-induced STAT phosphorylation.  Ex vivo, WYE-151650 suppressed IL-2-induced STAT phosphorylation, but not IL-6-induced STAT phosphorylation, as measured in whole blood.  In vivo, WYE-151650 inhibited JAK-3-mediated IL-2-induced interferon-Î³ prodn. and decreased the natural killer cell population in mice, while not affecting IL-22-induced serum amyloid A prodn. or EPO-induced reticulocytosis.  WYE-151650 was efficacious in mouse DTH and CIA models.  Conclusion. In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity.  These data question the need to broadly inhibit JAK-1-, JAK-2-, or Tyk-2-dependent cytokine pathways for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcss6tt3iw7Vg90H21EOLACvtfcHk0lgIISZn_z-Enw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP&md5=7fd4f4dae47df1d1a33d3fc0edf5e13d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fart.27536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27536%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DD.%2BG.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DQuintero%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DSchelling%26aufirst%3DS.%2BH.%26aulast%3DHewet%26aufirst%3DA.%2BG.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTogias%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DSeidl%26aufirst%3DK.%2BJ.%26atitle%3DSelective%2520functional%2520inhibition%2520of%2520JAK-3%2520is%2520sufficient%2520for%2520efficacy%2520in%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3D8%26spage%3D2283%26epage%3D2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span>Anonymous. <span> </span><span class="NLM_article-title">News in brief</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous.+News+in+brief.+Nat.+Rev.+Drug+Discovery+2012%2C+11%2C+895."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DNews%2520in%2520brief%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span>Anonymous. <span> </span><span class="NLM_article-title">Tofacitinib (Xeljanz) for rheumatoid arthritis</span>.  <span class="citation_source-journal">Med. Lett. Drugs Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">3</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ms1CktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous.+Tofacitinib+%28Xeljanz%29+for+rheumatoid+arthritis.+Med.+Lett.+Drugs+Ther.+2013%2C+55%2C+1%E2%80%933."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib (Xeljanz) for rheumatoid arthritis</span></div><div class="casAuthors">Anonymous</div><div class="citationInfo"><span class="NLM_cas:title">The Medical letter on drugs and therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1407</span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUeOlD8ZOZmfxQvRxYU81tfW6udTcc2eZrSy6p0QmIbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ms1CktQ%253D%253D&md5=fef14b09b1940144c92fa778eee4dd60</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DTofacitinib%2520%2528Xeljanz%2529%2520for%2520rheumatoid%2520arthritis%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2013%26volume%3D55%26spage%3D1%26epage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescovitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">â</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-6143.2008.02307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1711-1718&author=G.+E.+vanauthor=W.+Weimarauthor=R.+Gastonauthor=D.+Brennanauthor=R.+Mendezauthor=J.+Pirschauthor=S.+Swanauthor=M.+D.+Pescovitzauthor=G.+Niauthor=C.+Wangauthor=S.+Krishnaswamiauthor=V.+Chowauthor=G.+Chan&title=Phase+1+dose-escalation+study+of+CP-690+550+in+stable+renal+allograft+recipients%3A+preliminary+findings+of+safety%2C+tolerability%2C+effects+on+lymphocyte+subsets+and+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span></div><div class="casAuthors">van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Pirsch, J.; Swan, S.; Pescovitz, M. D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1711-1718</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">CP-690 550 inhibits Janus kinase 3 with nanomolar potency.  In this dose-escalation study, we assessed the safety, tolerability, effects on lymphocyte subsets, and pharmacokinetics of CP-690 550 when coadministered with mycophenolate mofetil in stable renal allograft recipients for 28 days.  Twenty-eight patients were enrolled.  Six patients received CP-690 550 5 mg twice daily (BID), 6 patients received 15 mg BID, 10 patients received 30 mg BID, and 6 patients received placebo.  The most frequent adverse events were infections and gastrointestinal (abdominal pain, diarrhea, dyspepsia, and vomiting).  CP-690 550 15 mg BID and 30 mg BID were assocd. with a mean decrease in Hb from baseline of 11% and a mean decrease in abs. natural killer cell counts of 50%.  CP-690 550 30 mg BID was also assocd. with a mean increase in abs. CD19+ B-lymphocytes of 130%.  There were no changes in the no. of neutrophils, total lymphocytes, platelets, or CD4+ or CD8+ T cells; clin. chem.; vital signs; or electrocardiograms from the pretreatment baseline.  Administration of CP-690 550 without a concomitant calcineurin inhibitor resulted in CP-690 550 exposures consistent with previous studies in nontransplant subjects.  Addnl. dose-ranging studies are warranted to evaluate the safety and efficacy of CP-690 550 in renal transplant recipients over longer treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo69SNdm7tfMrVg90H21EOLACvtfcHk0lgIISZn_z-Enw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ&md5=14582e231681d5cb704f11d1cdfd54d5</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2008.02307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2008.02307.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%26aufirst%3DG.%2BE.%26aulast%3DWeimar%26aufirst%3DW.%26aulast%3DGaston%26aufirst%3DR.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DR.%26aulast%3DPirsch%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DPescovitz%26aufirst%3DM.%2BD.%26aulast%3DNi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DPhase%25201%2520dose-escalation%2520study%2520of%2520CP-690%2520550%2520in%2520stable%2520renal%2520allograft%2520recipients%253A%2520preliminary%2520findings%2520of%2520safety%252C%2520tolerability%252C%2520effects%2520on%2520lymphocyte%2520subsets%2520and%2520pharmacokinetics%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2008%26volume%3D8%26spage%3D1711%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Busque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klintmalm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulgaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromberg, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariharan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slakey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1936</span><span class="NLM_x">â</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-6143.2009.02720.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19660021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1936-1945&author=S.+Busqueauthor=J.+Leventhalauthor=D.+C.+Brennanauthor=S.+Steinbergauthor=G.+Klintmalmauthor=T.+Shahauthor=S.+Mulgaonkarauthor=J.+S.+Brombergauthor=F.+Vincentiauthor=S.+Hariharanauthor=D.+Slakeyauthor=V.+R.+Peddiauthor=R.+A.+Fisherauthor=N.+Lawendyauthor=C.+Wangauthor=G.+Chan&title=Calcineurin-inhibitor-free+immunosuppression+based+on+the+JAK+inhibitor+CP-690%2C550%3A+a+pilot+study+in+de+novo+kidney+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in De novo kidney allograft recipients</span></div><div class="casAuthors">Busque, S.; Leventhal, J.; Brennan, D. C.; Steinberg, S.; Klintmalm, G.; Shah, T.; Mulgaonkar, S.; Bromberg, J. S.; Vincenti, F.; Hariharan, S.; Slakey, D.; Peddi, V. R.; Fisher, R. A.; Lawendy, N.; Wang, C.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients.  Patients received an IL-2 receptor antagonist, concomitant mycophenolate mofetil (MMF) and corticosteroids.  CP-690,550 doses were reduced after 6 mo.  Due to a high incidence of BK virus nephropathy (BKN) in CP30, MMF was discontinued in this group.  The 6-mo biopsy-proven acute rejection rates were 1 of 20, 4 of 20 and 1 of 21 for CP15, CP30 and tacrolimus groups, resp.  BKN developed in 4 of 20 patients in CP30 group.  The 6-mo rates of cytomegalovirus disease were 2 of 20, 4 of 20 and none of 21 for CP15, CP30 and tacrolimus groups, resp.  Estd. glomerular filtration rate was >70 mL/min at 6 and 12 mo (all groups).  NK cells were reduced by <77% in CP-690,550-treated patients.  In the CP-690,550 arms, there were modest lipid elevations and a trend toward more frequent anemia and neutropenia during the first 6 mo.  These data suggest that coadministration of CP-690,550 30 mg BID with MMF is assocd. with overimmunosuppression.  At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection.  Further dose-ranging evaluation of CP-690,550 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptskDnsVhSnrVg90H21EOLACvtfcHk0lg_vieA92nrLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP&md5=c63d35ad46e6041c3b63886aa75e424d</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02720.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02720.x%26sid%3Dliteratum%253Aachs%26aulast%3DBusque%26aufirst%3DS.%26aulast%3DLeventhal%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DD.%2BC.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DKlintmalm%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DT.%26aulast%3DMulgaonkar%26aufirst%3DS.%26aulast%3DBromberg%26aufirst%3DJ.%2BS.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DSlakey%26aufirst%3DD.%26aulast%3DPeddi%26aufirst%3DV.%2BR.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DCalcineurin-inhibitor-free%2520immunosuppression%2520based%2520on%2520the%2520JAK%2520inhibitor%2520CP-690%252C550%253A%2520a%2520pilot%2520study%2520in%2520de%2520novo%2520kidney%2520allograft%2520recipients%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D1936%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lg_vieA92nrLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsup, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward-Tharp, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">4234</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=4234-4243&author=K.+Ghoreschiauthor=M.+I.+Jessonauthor=X.+Liauthor=J.+L.+Leeauthor=S.+Ghoshauthor=J.+W.+Alsupauthor=J.+D.+Warnerauthor=M.+Tanakaauthor=S.+M.+Steward-Tharpauthor=M.+Gadinaauthor=C.+J.+Thomasauthor=J.+C.+Minnerlyauthor=C.+E.+Storerauthor=T.+P.+LaBrancheauthor=Z.+A.+Radiauthor=M.+E.+Dowtyauthor=R.+D.+Headauthor=D.+M.+Meyerauthor=N.+Kishoreauthor=J.+J.+O%E2%80%99Shea&title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAlsup%26aufirst%3DJ.%2BW.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSteward-Tharp%26aufirst%3DS.%2BM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DRadi%26aufirst%3DZ.%2BA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHead%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DModulation%2520of%2520innate%2520and%2520adaptive%2520immune%2520responses%2520by%2520tofacitinib%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D4234%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Watowich, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmore, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, H. F.</span><span> </span><span class="NLM_article-title">Homodimerization and constitutive activation of the erythropoietin receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2140</span><span class="NLM_x">â</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=2140-2144&issue=6&author=S.+S.+Watowichauthor=A.+Yoshimuraauthor=G.+D.+Longmoreauthor=D.+J.+Hiltonauthor=Y.+Yoshimuraauthor=H.+F.+Lodish&title=Homodimerization+and+constitutive+activation+of+the+erythropoietin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatowich%26aufirst%3DS.%2BS.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DLongmore%26aufirst%3DG.%2BD.%26aulast%3DHilton%26aufirst%3DD.%2BJ.%26aulast%3DYoshimura%26aufirst%3DY.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DHomodimerization%2520and%2520constitutive%2520activation%2520of%2520the%2520erythropoietin%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1992%26volume%3D89%26issue%3D6%26spage%3D2140%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Perugini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojkoski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercus, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbs, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonda, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAndrea, R. J.</span><span> </span><span class="NLM_article-title">Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">3346</span><span class="NLM_x">â</span> <span class="NLM_lpage">3353</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3346-3353&issue=16&author=M.+Peruginiauthor=A.+L.+Brownauthor=D.+G.+Salernoauthor=G.+W.+Bookerauthor=C.+Stojkoskiauthor=T.+R.+Hercusauthor=A.+F.+Lopezauthor=M.+L.+Hibbsauthor=T.+J.+Gondaauthor=R.+J.+D%E2%80%99Andrea&title=Alternative+modes+of+GM-CSF+receptor+activation+revealed+using+activated+mutants+of+the+common+beta-subunit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerugini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BL.%26aulast%3DSalerno%26aufirst%3DD.%2BG.%26aulast%3DBooker%26aufirst%3DG.%2BW.%26aulast%3DStojkoski%26aufirst%3DC.%26aulast%3DHercus%26aufirst%3DT.%2BR.%26aulast%3DLopez%26aufirst%3DA.%2BF.%26aulast%3DHibbs%26aufirst%3DM.%2BL.%26aulast%3DGonda%26aufirst%3DT.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DAlternative%2520modes%2520of%2520GM-CSF%2520receptor%2520activation%2520revealed%2520using%2520activated%2520mutants%2520of%2520the%2520common%2520beta-subunit%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26issue%3D16%26spage%3D3346%26epage%3D3353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhHZJqbPbeuLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audoly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">R14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R14&issue=1&author=A.+J.+Miliciauthor=E.+M.+Kudlaczauthor=L.+Audolyauthor=S.+Zwillichauthor=P.+Changelian&title=Cartilage+preservation+by+inhibition+of+Janus+kinase+3+in+two+rodent+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DAudoly%26aufirst%3DL.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DCartilage%2520preservation%2520by%2520inhibition%2520of%2520Janus%2520kinase%25203%2520in%2520two%2520rodent%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2008%26volume%3D10%26issue%3D1%26spage%3DR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsup, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward-Tharp, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">4234</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=4234-4243&issue=7&author=K.+Ghoreschiauthor=M.+I.+Jessonauthor=X.+Liauthor=J.+L.+Leeauthor=S.+Ghoshauthor=J.+W.+Alsupauthor=J.+D.+Warnerauthor=M.+Tanakaauthor=S.+M.+Steward-Tharpauthor=M.+Gadinaauthor=C.+J.+Thomasauthor=J.+C.+Minnerlyauthor=C.+E.+Storerauthor=T.+P.+LaBrancheauthor=Z.+A.+Radiauthor=M.+E.+Dowtyauthor=R.+D.+Headauthor=D.+M.+Meyerauthor=N.+Kishoreauthor=J.+J.+O%E2%80%99Shea&title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAlsup%26aufirst%3DJ.%2BW.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSteward-Tharp%26aufirst%3DS.%2BM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DRadi%26aufirst%3DZ.%2BA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHead%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DModulation%2520of%2520innate%2520and%2520adaptive%2520immune%2520responses%2520by%2520tofacitinib%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26issue%3D7%26spage%3D4234%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eaC2iWWIbDsNrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman-Brecks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Happa, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barve, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, P. M.</span><span> </span><span class="NLM_article-title">Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1388</span><span class="NLM_x">â</span> <span class="NLM_lpage">1396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.2353%2Fajpath.2010.100195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjosVOnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2010&pages=1388-1396&issue=3&author=T.+P.+LaBrancheauthor=C.+L.+Hickman-Brecksauthor=D.+M.+Meyerauthor=C.+E.+Storerauthor=M.+I.+Jessonauthor=K.+M.+Shevlinauthor=F.+A.+Happaauthor=R.+A.+Barveauthor=D.+J.+Weissauthor=J.+C.+Minnerlyauthor=J.+L.+Raczauthor=P.+M.+Allen&title=Characterization+of+the+KRN+cell+transfer+model+of+rheumatoid+arthritis+%28KRN-CTM%29%2C+a+chronic+yet+synchronized+version+of+the+K%2FBxN+mouse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse</span></div><div class="casAuthors">LaBranche Timothy P; Hickman-Brecks Cynthia L; Meyer Debra M; Storer Chad E; Jesson Michael I; Shevlin Kimberly M; Happa Fernando A; Barve Ruteja A; Weiss David J; Minnerly John C; Racz Jennifer L; Allen Paul M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1388-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this study, a chronic yet synchronized version of the K/BxN mouse, the KRN-cell transfer model (KRN-CTM), was developed and extensively characterized.  The transfer of purified splenic KRN T cells into T cell-deficient B6.TCR.Calpha(-/-)H-2(b/g7) mice induced anti-glucose 6-phosphate isomerase antibody-dependent chronic arthritis in 100% of the mice with uniform onset of disease 7 days after T cell transfer.  Cellular infiltrations were assessed by whole-ankle transcript microarray, cytokine and chemokine levels, and microscopic and immunohistochemical analyses 7 through 42 days after T cell transfer.  Transcripts identified an influx of monocytes/macrophages and neutrophils into the ankles and identified temporal progression of cartilage damage and bone resorption.  In both serum and ankle tissue there was a significant elevation in interleukin-6, whereas macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1 were only elevated in tissue.  Microscopic and immunohistochemical analyses revealed a time course for edema, synovial hypertrophy and hyperplasia, infiltration of F4/80-positive monocytes/macrophages and myeloperoxidase-positive neutrophils, destruction of articular cartilage, pannus invasion, bone resorption, extra-articular fibroplasia, and joint ankylosis.  The KRN cell transfer model replicates many features of chronic rheumatoid arthritis in humans in a synchronized manner and lends itself to manipulation of adoptively transferred T cells and characterizing specific genes and T cell subsets responsible for rheumatoid arthritis pathogenesis and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvU92OJyfajexsqfvU0ziafW6udTcc2eaC2iWWIbDsNrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjosVOnsQ%253D%253D&md5=1944e48359e786c8ec0fd5f084ef522c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.100195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.100195%26sid%3Dliteratum%253Aachs%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DHickman-Brecks%26aufirst%3DC.%2BL.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DShevlin%26aufirst%3DK.%2BM.%26aulast%3DHappa%26aufirst%3DF.%2BA.%26aulast%3DBarve%26aufirst%3DR.%2BA.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DRacz%26aufirst%3DJ.%2BL.%26aulast%3DAllen%26aufirst%3DP.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520KRN%2520cell%2520transfer%2520model%2520of%2520rheumatoid%2520arthritis%2520%2528KRN-CTM%2529%252C%2520a%2520chronic%2520yet%2520synchronized%2520version%2520of%2520the%2520K%252FBxN%2520mouse%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D177%26issue%3D3%26spage%3D1388%26epage%3D1396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span> </span><span class="NLM_article-title">Novel small-molecular therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2FBOR.0b013e32835190ef" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22357358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=335-341&author=R.+Fleischmann&title=Novel+small-molecular+therapeutics+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small-molecular therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the introduction of biol. therapies into the treatment paradigm of rheumatoid arthritis (RA), there has been hope that oral small mol. immune modulators would be developed that would have a risk : benefit profile at least similar to biol. therapies, be more convenient for the patient and, hopefully, be less expensive.  This article reviews the progress made in the development of these compds. over the past year.  Recent findings: Addnl. information has become available in the past year on five oral compds. including kinase inhibitors (tofacitinib, fostamatinib, VX-509), an S1P lyase inhibitor (LX 3305) and a chemokine receptor-1 antagonist (CCX354-C).  Efficacy has been shown in phase III with tofacitinib and in phase II with fostamatinib and VX-509; safety was the primary endpoint of the trials of CCX354-C and LX3305.  Regarding side effects, liver test elevation and neutropenia occurred with tofacitinib, VX-509 and fostamatinib; lipid elevation with tofacitinib and VX-509; creatinine elevation and anemia with tofacitinib, and hypertension and diarrhea with fostamatinib.  Summary: Compds. that inhibit tyrosine kinase pathways involved in cellular signalling have been shown to be effective in the treatment of RA with a reasonable risk : benefit ratio.  It is too early to tell about inhibitors of other pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALXnYT2mHjLVg90H21EOLACvtfcHk0liUFCObBlBTHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D&md5=46627d79c7fe388c3a9d0fe05d83b040</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e32835190ef&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e32835190ef%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26atitle%3DNovel%2520small-molecular%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2012%26volume%3D24%26spage%3D335%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span>Xeljanz USPI.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Xeljanz+USPI."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Boy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V. F.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clucas, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">2299</span><span class="NLM_x">â</span> <span class="NLM_lpage">2302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2009&pages=2299-2302&author=M.+G.+Boyauthor=C.+Wangauthor=B.+E.+Wilkinsonauthor=V.+F.-S.+Chowauthor=A.+T.+Clucasauthor=J.+G.+Kruegerauthor=A.+S.+Gawecoauthor=S.+H.+Zwillichauthor=P.+S.+Changelianauthor=G.+Chan&title=Double-blind%2C+placebo-controlled%2C+dose-escalation+study+to+evaluate+the+pharmacologic+effect+of+CP-690%2C550+in+patients+with+psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoy%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DChow%26aufirst%3DV.%2BF.-S.%26aulast%3DClucas%26aufirst%3DA.%2BT.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DDouble-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520pharmacologic%2520effect%2520of%2520CP-690%252C550%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2009%26volume%3D129%26spage%3D2299%26epage%3D2302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strober, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harness, J. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1365-2133.2012.11168.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GrsL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=668-677&author=K.+A.+Pappauthor=A.+Menterauthor=B.+Stroberauthor=R.+G.+Langleyauthor=M.+Buonannoauthor=R.+Wolkauthor=P.+Guptaauthor=S.+Krishnaswamiauthor=H.+Tanauthor=J.+A.+Harness&title=Efficacy+and+safety+of+tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+the+treatment+of+psoriasis%3A+a+phase+2b+randomized+placebo-controlled+dose-ranging+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study</span></div><div class="casAuthors">Papp, K. A.; Menter, A.; Strober, B.; Langley, R. G.; Buonanno, M.; Wolk, R.; Gupta, P.; Krishnaswami, S.; Tan, H.; Harness, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">668-677</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis.  This Phase 2b, 12-wk, dose-ranging study (A3921047, NCT00678210) aimed to characterize the exposure-response, efficacy and safety of tofacitinib vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  One hundred and ninety-seven patients were randomized.  The primary endpoint was the proportion of patients achieving a â¥ 75% redn. in the Psoriasis Area and Severity Index (PASI 75) score at week 12.  At week 12, PASI 75 response rates were significantly higher for all tofacitinib twice-daily groups: 25Â·0% (2 mg; P < 0Â·001), 40Â·8% (5 mg; P < 0Â·0001) and 66Â·7% (15 mg; P < 0Â·0001), compared with placebo (2Â·0%).  Significant increases in the proportion of PASI 75 responses were seen by week 4 and were maintained at week 12.  Exposure-response over the 0-15 mg tofacitinib twice-daily dose range was successfully characterized.  PASI 50, PASI 90 and Physician's Global Assessment response rates were also higher for tofacitinib vs. placebo.  The most frequently reported adverse events (AEs) were infections and infestations: 22Â·4% (2 mg twice daily), 20Â·4% (5 mg twice daily), 36Â·7% (15 mg twice daily) and 32Â·0% (placebo).  Discontinuations due to AEs were 6Â·0%, 2Â·0%, 4Â·1% and 6Â·1% of patients in the placebo, and 2, 5 and 15 mg twice-daily tofacitinib groups, resp.  Dose-dependent increases from baseline in mean serum high-d. lipoprotein, low-d. lipoprotein and total cholesterol, and decreases in Hb and neutrophils were obsd.  Short-term treatment with oral tofacitinib results in significant clin. improvement in patients with moderate-to-severe plaque psoriasis and is generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmKDEpf3aYmrVg90H21EOLACvtfcHk0liIHqgSyKoUyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GrsL3L&md5=ca139728efe1e709442630b8da243ab2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2012.11168.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2012.11168.x%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DHarness%26aufirst%3DJ.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520tofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520psoriasis%253A%2520a%2520phase%25202b%2520randomized%2520placebo-controlled%2520dose-ranging%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2012%26volume%3D167%26spage%3D668%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">â</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+active+ulcerative+colitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score â¤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0liIHqgSyKoUyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520active%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D616%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0liIHqgSyKoUyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. N.</span><span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span> <span class="citation_source-journal">Ther. Adv. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+N.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+Janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+An+update+for+clinicians"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0lhubztI3d58Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BN.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520An%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit56c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span> </span><span class="NLM_article-title">Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2397</span><span class="NLM_x">â</span> <span class="NLM_lpage">2407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F14656566.2012.732998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=2397-2407&author=K.+Vaddiauthor=N.+J.+Sarlisauthor=V.+Gupta&title=Ruxolitinib%2C+an+oral+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56cR"><div class="casContent"><span class="casTitleNuber">56c</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Vaddi, Kris; Sarlis, Nicholas J.; Gupta, Vikas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2397-2407</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) is a debilitating hematol. malignancy characterized by progressive splenomegaly, burdensome symptoms, cytopenias and shortened survival.  Chronic alterations in Janus-assocd. kinase-signal transducer and activator of transcription (JAK-STAT) signaling have been identified in the pathogenesis of MF, making this pathway a target for drug development.  Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration.  This review describes the characteristics of MF, the current therapeutic options and need for effective therapies, the contribution of aberrant JAK-STAT signaling to various disease-specific manifestations and the pharmacodynamics, pharmacokinetics, efficacy and tolerability of ruxolitinib.  Articles describing MF disease burden and results of ruxolitinib pre-clin. and clin. trials were identified and summarized.  Conventional MF treatments alleviate some MF symptoms but have limited efficacy, do not modify the natural history of the disease and are not approved for MF.  The JAK1 and JAK2 inhibitor ruxolitinib has shown promising results in pre-clin. and clin. trials.  In Phase III trials, ruxolitinib was shown to reduce splenomegaly and improve MF-related symptoms.  Recent evidence also suggests that ruxolitinib may improve survival.  The most common adverse events were anemia and thrombocytopenia, which were managed with dose adjustments (or red blood cell transfusions for anemia).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaW-We0y2vrVg90H21EOLACvtfcHk0lhubztI3d58Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtrrL&md5=460b020ad17c3828f8948ba9c24131cc</span></div><a href="/servlet/linkout?suffix=cit56c&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.732998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.732998%26sid%3Dliteratum%253Aachs%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DSarlis%26aufirst%3DN.%2BJ.%26aulast%3DGupta%26aufirst%3DV.%26atitle%3DRuxolitinib%252C%2520an%2520oral%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D2397%26epage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Deisseroth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3212</span><span class="NLM_x">â</span> <span class="NLM_lpage">3217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+approval%3A+ruxolitinib+for+the+treatment+of+patients+with+intermediate+and+high-risk+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of â¥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a â¥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a â¥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a â¥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0lhubztI3d58Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520approval%253A%2520ruxolitinib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520intermediate%2520and%2520high-risk%2520myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3212%26epage%3D3217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Friedman, P. A.; Fridman, J. S.; Luchi, M. E.; Williams, W. V.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidine derivatives as Janus kinase inhibitors for treatment of dry eye and other eye related diseases</span>. WO2010039939A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=P.+A.+Friedman&author=J.+S.+Fridman&author=M.+E.+Luchi&author=W.+V.+Williams&title=Preparation+of+pyrrolopyrimidine+derivatives+as+Janus+kinase+inhibitors+for+treatment+of+dry+eye+and+other+eye+related+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DP.%2BA.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidine%2520derivatives%2520as%2520Janus%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520dry%2520eye%2520and%2520other%2520eye%2520related%2520diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit58b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rodgers, J. D.; Shepard, S.; Li, Y.-L.; Zhou, J.; Liu, P.; Meloni, D.; Xia, M.</span><span> </span><span class="NLM_article-title">Preparation of azetidine and cyclobutane derivatives as JAK inhibitors</span>. WO2009114512A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+D.+Rodgers&author=S.+Shepard&author=Y.-L.+Li&author=J.+Zhou&author=P.+Liu&author=D.+Meloni&author=M.+Xia&title=Preparation+of+azetidine+and+cyclobutane+derivatives+as+JAK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520azetidine%2520and%2520cyclobutane%2520derivatives%2520as%2520JAK%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit58c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rodgers, J. D.; Shepard, S.; Maduskuie, T. P.; Wang, H.; Falahatpisheh, N.; Rafalski, M.; Arvanitis, A. G.; Storace, L.; Jalluri, R. K.; Fridman, J. S.; Vaddi, K.</span><span> </span><span class="NLM_article-title">Preparation of heteroaryl substituted pyrrolo[2,3-<i>b</i>]pyridines and pyrrolo[2,3-<i>b</i>]pyrimidines as Janus kinase inhibitors</span>. US20070135461A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+D.+Rodgers&author=S.+Shepard&author=T.+P.+Maduskuie&author=H.+Wang&author=N.+Falahatpisheh&author=M.+Rafalski&author=A.+G.+Arvanitis&author=L.+Storace&author=R.+K.+Jalluri&author=J.+S.+Fridman&author=K.+Vaddi&title=Preparation+of+heteroaryl+substituted+pyrrolo%5B2%2C3-b%5Dpyridines+and+pyrrolo%5B2%2C3-b%5Dpyrimidines+as+Janus+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520heteroaryl%2520substituted%2520pyrrolo%255B2%252C3-b%255Dpyridines%2520and%2520pyrrolo%255B2%252C3-b%255Dpyrimidines%2520as%2520Janus%2520kinase%2520inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">844</span><span class="NLM_x">â</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMe1115119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=844-846&issue=9&author=A.+Tefferi&title=Challenges+facing+JAK+inhibitor+therapy+for+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">844-846</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnem-u-DDG1rVg90H21EOLACvtfcHk0lhFTLYU32th1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qu78%253D&md5=5623bc5a33b70efe6c54301078454ba5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1115119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1115119%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DChallenges%2520facing%2520JAK%2520inhibitor%2520therapy%2520for%2520myeloproliferative%2520neoplasms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D9%26spage%3D844%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span>ClinicalTrials.gov identifier: NCT01633372.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+identifier%3A+NCT01633372."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Fridman, J.; Scherle, P.; Collins, R.; Li, Y.; Shepard, S.; Sparks, R.; Arvanitis, A.; Shi, G.; Combs, A.; Rodgers, J.; Neilan, C.; Contel, N.; Haley, P.; Yeleswaram, S.; Newton, R.; Friedman, S.; Vaddi, K.</span><span> </span><span class="NLM_article-title">Efficacy and Tolerability of Novel JAK Inhibitors in Animal Models of Rheumatoid Arthritis</span>. Presented at the 2007 Annual Scientific Meeting of the American College of Rheumatology,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Abstract 1771.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Fridman&author=P.+Scherle&author=R.+Collins&author=Y.+Li&author=S.+Shepard&author=R.+Sparks&author=A.+Arvanitis&author=G.+Shi&author=A.+Combs&author=J.+Rodgers&author=C.+Neilan&author=N.+Contel&author=P.+Haley&author=S.+Yeleswaram&author=R.+Newton&author=S.+Friedman&author=K.+Vaddi&title=Efficacy+and+Tolerability+of+Novel+JAK+Inhibitors+in+Animal+Models+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520Tolerability%2520of%2520Novel%2520JAK%2520Inhibitors%2520in%2520Animal%2520Models%2520of%2520Rheumatoid%2520Arthritis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span> </span><span class="NLM_article-title">24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1049</span><span class="NLM_x">â</span> <span class="NLM_lpage">S1050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S1049-S1050&author=M.+C.+Genoveseauthor=E.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=P.-Y.+Berclazauthor=C.+H.+Leeauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=W.+Macias&title=24-week+results+of+a+blinded+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease+modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DBerclaz%26aufirst%3DP.-Y.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DMacias%26aufirst%3DW.%26atitle%3D24-week%2520results%2520of%2520a%2520blinded%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease%2520modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS1049%26epage%3DS1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roddriguez, J. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, C. L.</span><span> </span><span class="NLM_article-title">12-and 24-week patient reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/jJanus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S214</span><span class="NLM_x">â</span> <span class="NLM_lpage">S220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S214-S220&author=J.+S.+Smolenauthor=D.+E.+Schlichtingauthor=K.+L.+Sterlingauthor=E.+Keystoneauthor=P.+Taylorauthor=M.+C.+Genoveseauthor=L.+Johnsonauthor=J.+C.+R.+Roddriguezauthor=C.+H.+Leeauthor=C.+L.+Gaich&title=12-and+24-week+patient+reported+outcomes+from+a+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FjJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSterling%26aufirst%3DK.%2BL.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DRoddriguez%26aufirst%3DJ.%2BC.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DGaich%26aufirst%3DC.%2BL.%26atitle%3D12-and%252024-week%2520patient%2520reported%2520outcomes%2520from%2520a%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FjJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS214%26epage%3DS220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span> </span><span class="NLM_article-title">Decernotinib: Statement on a Nonproprietary Name Adopted by the USAN Council</span>; July 31,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>USAN (ZZ-20) = decernotinib.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Decernotinib%3A+Statement+on+a+Nonproprietary+Name+Adopted+by+the+USAN+Council%3B+July+31%2C+2013%3B+USAN+%28ZZ-20%29+%3D+decernotinib."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DDecernotinib%253A%2520Statement%2520on%2520a%2520Nonproprietary%2520Name%2520Adopted%2520by%2520the%2520USAN%2520Council%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Thakkar, M.; Koul, S.; Bhuniya, D.; Singh, U.</span><span> </span><span class="NLM_article-title">Preparation of substituted heterobicyclic compounds, compositions and medicinal applications thereof</span>. WO2013157021A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Thakkar&author=S.+Koul&author=D.+Bhuniya&author=U.+Singh&title=Preparation+of+substituted+heterobicyclic+compounds%2C+compositions+and+medicinal+applications+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThakkar%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520substituted%2520heterobicyclic%2520compounds%252C%2520compositions%2520and%2520medicinal%2520applications%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Farmer, L.; Martinez-Botella, G.; Pierce, A.; Salituro, F.; Wang, J.; Wannamker, M.; Wang, T.</span><span> </span><span class="NLM_article-title">Azaindoles useful as inhibitors of Janus kinases and their preparation and use in the treatment of diseases</span>. WO2007084557A2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Farmer&author=G.+Martinez-Botella&author=A.+Pierce&author=F.+Salituro&author=J.+Wang&author=M.+Wannamker&author=T.+Wang&title=Azaindoles+useful+as+inhibitors+of+Janus+kinases+and+their+preparation+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DL.%26atitle%3DAzaindoles%2520useful%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">â</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+Tyk2+inhibitor+patents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0lhV0PIxOT7GSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520Tyk2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J. M.; Hodges, A. J.; Vater, H. D.</span><span> </span><span class="NLM_article-title">Preparation of pyrazolopyridines as JAK inhibitors useful in the treatment of degenerative and inflammatory diseases</span>. WO2012146659A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+M.+Menet&author=A.+J.+Hodges&author=H.+D.+Vater&title=Preparation+of+pyrazolopyridines+as+JAK+inhibitors+useful+in+the+treatment+of+degenerative+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520pyrazolopyridines%2520as%2520JAK%2520inhibitors%2520useful%2520in%2520the%2520treatment%2520of%2520degenerative%2520and%2520inflammatory%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C. J. M.; Hodges, A. J.; Vater, H. D.</span><span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine derivatives for use as JAK kinase inhibitors</span>. WO2012146657A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+M.+Menet&author=A.+J.+Hodges&author=H.+D.+Vater&title=Preparation+of+pyrazolopyridine+derivatives+for+use+as+JAK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520derivatives%2520for%2520use%2520as%2520JAK%2520kinase%2520inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span>Clinicaltrialsregister.eu, EudraCT no.: 2012-003635-31.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinicaltrialsregister.eu%2C+EudraCT+no.%3A+2012-003635-31."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span> <span class="citation_source-book">WHO Drug Information</span>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">26</span>, No. <span class="NLM_issue">4</span>, p  <span class="NLM_fpage">419</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO+Drug+Information%3B+World+Health+Organization%3A+Geneva%2C+Switzerland%2C+2012%3B+Vol.+26%2C+No.+4%2C+p+419."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWHO%2520Drug%2520Information%26pub%3DWorld%2520Health%2520Organization%26date%3D2012%26volume%3D26%26issue%3D4%26spage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J. M.; Smits, K. K.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-(triazolopyridinyl)carboxamides as JAK kinase inhibitors and useful in treatment of diseases</span>. WO2010149769A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+J.+M.+Menet&author=K.+K.+Smits&title=Preparation+of+N-%28triazolopyridinyl%29carboxamides+as+JAK+kinase+inhibitors+and+useful+in+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520N-%2528triazolopyridinyl%2529carboxamides%2520as%2520JAK%2520kinase%2520inhibitors%2520and%2520useful%2520in%2520treatment%2520of%2520diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit71b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C. J. M.; Van, R. L. J. C.; Fletcher, S. R.; Blanc, J.; Jouannigot, N.; Hodges, A. J.; Smits, K. K.</span><span> </span><span class="NLM_article-title">Novel triazolopyridine compounds as JAK kinase inhibitors useful for the treatment of degenerative and inflammatory diseases and their preparation</span>. WO2010010190A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+J.+M.+Menet&author=R.+L.+J.+C.+Van&author=S.+R.+Fletcher&author=J.+Blanc&author=N.+Jouannigot&author=A.+J.+Hodges&author=K.+K.+Smits&title=Novel+triazolopyridine+compounds+as+JAK+kinase+inhibitors+useful+for+the+treatment+of+degenerative+and+inflammatory+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DNovel%2520triazolopyridine%2520compounds%2520as%2520JAK%2520kinase%2520inhibitors%2520useful%2520for%2520the%2520treatment%2520of%2520degenerative%2520and%2520inflammatory%2520diseases%2520and%2520their%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Van, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, d. A. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeghinste, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanât Klooster, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">3568</span><span class="NLM_x">â</span> <span class="NLM_lpage">3577</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&issue=7&author=R.+L.+Vanauthor=R.+Galienauthor=d.+A.+E.+M.+vanauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van%E2%80%99t+Kloosterauthor=J.+H.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%26aufirst%3DR.%2BL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%26aufirst%3Dd.%2BA.%2BE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26issue%3D7%26spage%3D3568%26epage%3D3577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Namour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyle, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoutte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klooster, G.</span><span> </span><span class="NLM_article-title">Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S573&author=F.+Namourauthor=R.+Galienauthor=L.+Gheyleauthor=F.+Vanhoutteauthor=B.+Vayssiereauthor=A.+Van+der+Aaauthor=B.+Smetsauthor=G.+Klooster&title=Once+daily+high+dose+regimens+of+GLPG0634+in+healthy+volunteers+are+safe+and+provide+continuous+inhibition+of+JAK1+but+not+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DGheyle%26aufirst%3DL.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DKlooster%26aufirst%3DG.%26atitle%3DOnce%2520daily%2520high%2520dose%2520regimens%2520of%2520GLPG0634%2520in%2520healthy%2520volunteers%2520are%2520safe%2520and%2520provide%2520continuous%2520inhibition%2520of%2520JAK1%2520but%2520not%2520JAK2%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Galien, R.; VayssiÃ¨re, B.; Vos, S.; Auberval, M.; Vandeghinste, N.; Dupont, S.; ClÃ©ment-Lacroix, P.; Delerive, P.; Vanhoutte, F.; Brys, R.; Van der Aa, A.; Van Rompaey, L.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Analysis of the JAK1 Selectivity of GLPG0634 and Its Main Metabolite in Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients</span>. Presented at the Annual Meeting of ACR/ARHP, San Diego, CA, Oct 26â30,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 478.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Galien&author=B.+Vayssi%C3%A8re&author=S.+Vos&author=M.+Auberval&author=N.+Vandeghinste&author=S.+Dupont&author=P.+Cl%C3%A9ment-Lacroix&author=P.+Delerive&author=F.+Vanhoutte&author=R.+Brys&author=A.+Van+der+Aa&author=L.+Van+Rompaey&author=G.+van%E2%80%99t+Klooster&title=Analysis+of+the+JAK1+Selectivity+of+GLPG0634+and+Its+Main+Metabolite+in+Different+Species%2C+Healthy+Volunteers+and+Rheumatoid+Arthritis+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGalien%26aufirst%3DR.%26atitle%3DAnalysis%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520GLPG0634%2520and%2520Its%2520Main%2520Metabolite%2520in%2520Different%2520Species%252C%2520Healthy%2520Volunteers%2520and%2520Rheumatoid%2520Arthritis%2520Patients%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Namour, F.; Galien, R.; Vanhoutte, F. P.; Wigerinck, P.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, Is Supported by Its Active Metabolite</span>. Presented at EULAR 2013, Madrid, Spain, June 12â15,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract THU0236.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Namour&author=R.+Galien&author=F.+P.+Vanhoutte&author=P.+Wigerinck&author=G.+van%E2%80%99t+Klooster&title=Once-Daily+Dosing+of+GLPG0634%2C+a+Selective+JAK1+Inhibitor%2C+Is+Supported+by+Its+Active+Metabolite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26atitle%3DOnce-Daily%2520Dosing%2520of%2520GLPG0634%252C%2520a%2520Selective%2520JAK1%2520Inhibitor%252C%2520Is%2520Supported%2520by%2520Its%2520Active%2520Metabolite%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Tasset, C.; Harrison, P.; Van der Aa, A.; Meuleners, L.; Vanhoutte, F.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity in Patients with Moderate to Severe Rheumatoid Arthritis; Results of a 4-Week Dose Ranging Study</span>. Presented at the Annual Meeting of ACR/ARHP, San Diego, CA, Oct 26â30,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 2381.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Tasset&author=P.+Harrison&author=A.+Van+der+Aa&author=L.+Meuleners&author=F.+Vanhoutte&author=G.+van%E2%80%99t+Klooster&title=The+JAK1-Selective+Inhibitor+GLPG0634+Is+Safe+and+Rapidly+Reduces+Disease+Activity+in+Patients+with+Moderate+to+Severe+Rheumatoid+Arthritis%3B+Results+of+a+4-Week+Dose+Ranging+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTasset%26aufirst%3DC.%26atitle%3DThe%2520JAK1-Selective%2520Inhibitor%2520GLPG0634%2520Is%2520Safe%2520and%2520Rapidly%2520Reduces%2520Disease%2520Activity%2520in%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Rheumatoid%2520Arthritis%253B%2520Results%2520of%2520a%25204-Week%2520Dose%2520Ranging%2520Study%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span> </span><span class="NLM_article-title">AC430, a potent JAK2 inhibitor, provides protection in multiple inflammatory and autoimmune disease models</span> <span class="citation_source-journal">Arthritis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=269&issue=Suppl.+10&author=B.+Belliauthor=D.+Brighamauthor=A.+Daoauthor=R.+Nepomucenoauthor=E.+Settiauthor=G..+Liuauthor=M.+Haddauthor=S.+Bhagwatauthor=W.+Wierengaauthor=M.+Holladayauthor=R.+C.+Armstrong&title=AC430%2C+a+potent+JAK2+inhibitor%2C+provides+protection+in+multiple+inflammatory+and+autoimmune+disease+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DDao%26aufirst%3DA.%26aulast%3DNepomuceno%26aufirst%3DR.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DG..%26aulast%3DHadd%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DWierenga%26aufirst%3DW.%26aulast%3DHolladay%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26atitle%3DAC430%252C%2520a%2520potent%2520JAK2%2520inhibitor%252C%2520provides%2520protection%2520in%2520multiple%2520inflammatory%2520and%2520autoimmune%2520disease%2520models%26jtitle%3DArthritis%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Kinase inhibition by low molecular weight products in the treatment of autoimmune diseases</span> <span class="citation_source-journal">Saishin Igaku</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">â</span> <span class="NLM_lpage">703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Slurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=692-703&author=Y.+Tanaka&title=Kinase+inhibition+by+low+molecular+weight+products+in+the+treatment+of+autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibition by low molecular weight products in the treatment of autoimmune diseases</span></div><div class="casAuthors">Tanaka, Yoshiya</div><div class="citationInfo"><span class="NLM_cas:title">Saishin Igaku</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3, Zokango</span>),
    <span class="NLM_cas:pages">692-703</span>CODEN:
                <span class="NLM_cas:coden">SAIGAK</span>;
        ISSN:<span class="NLM_cas:issn">0370-8241</span>.
    
            (<span class="NLM_cas:orgname">Saishin Igakusha</span>)
        </div><div class="casAbstract">A review on action mechanism of tofacitinib; a low mol. wt. and Jak3 competitive inhibitor, on autoimmune diseases such as rheumatoid arthritis with clin. efficacy and safety.  Novel Jak3 specific inhibitors, VX-509 or ASP015k, Syk (spleen tyrosine kinase) inhibitor, calcineurin inhibitors, and Jak-Stat signal inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsAMGRmpNsfrVg90H21EOLACvtfcHk0ljZMb_dIH5DBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Slurw%253D&md5=2b65a89fba260ef0efad5b1a0bae58ee</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DKinase%2520inhibition%2520by%2520low%2520molecular%2520weight%2520products%2520in%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DSaishin%2520Igaku%26date%3D2013%26volume%3D68%26spage%3D692%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braselmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullard, D. C.</span><span> </span><span class="NLM_article-title">JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">2183</span><span class="NLM_x">â</span> <span class="NLM_lpage">2192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=2183-2192&author=B.+Y.+Changauthor=F.+Zhaoauthor=X.+Heauthor=H.+Renauthor=S.+Braselmannauthor=V.+Taylorauthor=J.+Wicksauthor=D.+G.+Payanauthor=E.+B.+Grossbardauthor=P.+R.+Pineauthor=D.+C.+Bullard&title=JAK3+inhibition+significantly+attenuates+psoriasiform+skin+inflammation+in+CD18+mutant+PL%2FJ+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DWicks%26aufirst%3DJ.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DBullard%26aufirst%3DD.%2BC.%26atitle%3DJAK3%2520inhibition%2520significantly%2520attenuates%2520psoriasiform%2520skin%2520inflammation%2520in%2520CD18%2520mutant%2520PL%252FJ%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D2183%26epage%3D2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">4123</span><span class="NLM_x">â</span> <span class="NLM_lpage">4134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+novel+inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520novel%2520inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4123%26epage%3D4134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit80b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit80c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle (9<i>E</i>)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2623</span><span class="NLM_x">â</span> <span class="NLM_lpage">2640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201454n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2623-2640&author=A.+D.+Williamauthor=A.+C.+H.+Leeauthor=A.+Poulsenauthor=K.+C.+Gohauthor=B.+Madanauthor=S.+Hartauthor=E.+Tanauthor=H.+Wangauthor=H.+Nagarajauthor=D.+Chenauthor=C.+P.+Leeauthor=E.+T.+Sunauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+%289E%29-15-%282-%28pyrrolidin-1-yl%29ethoxy%29-7%2C12%2C25-trioxa-19%2C21%2C24-triaza-tetracyclo%5B18.3.1.1%282%2C5%29.1%2814%2C18%29%5Dhexacosa-1%2824%29%2C2%2C4%2C9%2C14%2826%29%2C15%2C17%2C20%2C22-nonaene+%28SB1578%29%2C+a+potent+inhibitor+of+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80c&amp;dbid=16384&amp;doi=10.1021%2Fjm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201454n%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%2520%25289E%2529-15-%25282-%2528pyrrolidin-1-yl%2529ethoxy%2529-7%252C12%252C25-trioxa-19%252C21%252C24-triaza-tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255Dhexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-nonaene%2520%2528SB1578%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2623%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">See, C. S.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010â2012</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F13543776.2013.765862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=449-501&issue=4&author=B.+W.+Dymockauthor=C.+S.+See&title=Inhibitors+of+JAK2+and+JAK3%3A+an+update+on+the+patent+literature+2010%E2%80%932012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span></div><div class="casAuthors">Dymock, Brian W.; See, Cheng Shang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-501</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally implicated in cell signaling processes important in cancer and immune-inflammatory diseases.  Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.  There are many new JAK family enzyme inhibitors in the clinic now with a range of selectivity profiles.  More selective JAK2 or JAK3 compds. are now coming through in considerable nos. and this review attempts to provide an update of the recent patent literature of those new compds.  An overview is given on the diversity of core structures employed for inhibitor design showing that the vast majority of compds. are based on classic ATP-competitive kinase inhibitor heterocycles.Areas covered: This review updates new patents claiming JAK2 and/or JAK3 inhibitors published from 2010 to 2012.  Pre-2010 patents have been extensively covered in previous reviews.  Comments on the context of each chem. series are given where applicable to orient the readers on the bewildering array of mol. designs now available.  This review does not cover JAK1 or TYK2 inhibitors but mention is made of these where they occur within series of JAK2/3 inhibitors.  Given the overlap between many pharmacophores, it was not possible to completely sep. inhibitors of JAK2 from JAK3, hence the material is organized by JAK2, JAK3 and JAK2/3 and within each section by alphabetical order of the patent assignee, some companies having published five or more patents, such as Ambit (10), Incyte (9), Galapagos (7), Almirall (6) and Biocryst (5).  A total of 98 patents are reviewed herein.Expert opinion: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.  Selectivity against the four individual JAK family enzymes, JAK1, 2, 3 and TYK2, is now a key goal since they each play subtly different roles in cytokine-induced cell signaling.  The future looks bright for patients as many new drugs are being developed and now combinations of JAK inhibitors with other targeted agents are being studied in the clinic.  These advances are expected to lead to further significant progress improving patient outcomes and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpx3w37MTHrVg90H21EOLACvtfcHk0liB3s4BtBXlQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D&md5=a958c185f6c6d500ce19c04eb5665247</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DSee%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520JAK2%2520and%2520JAK3%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202010%25E2%2580%25932012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D449%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">The pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2205</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMra1004965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22150039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=2205-2219&issue=23&author=I.+B.+McInnesauthor=G.+Schett&title=The+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">The pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Lain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2205-2219</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses key pathogenic advances in rheumatoid arthritis, genetics, environmental factors, immunol. processes, inflammation, and structural damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJslDVaG7MxbVg90H21EOLACvtfcHk0liB3s4BtBXlQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM&md5=31a79ccb05bca03f207b15f934b2d52d</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1004965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1004965%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DThe%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26issue%3D23%26spage%3D2205%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit82b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">Cytokines in the pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri2094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17525752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-442&issue=6&author=I.+B.+McInnesauthor=G.+Schett&title=Cytokines+in+the+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82bR"><div class="casContent"><span class="casTitleNuber">82b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in the pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Iain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-442</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines regulate a broad range of inflammatory processes that are implicated in the pathogenesis of rheumatoid arthritis.  In rheumatoid joints, it is well known that an imbalance between pro- and anti-inflammatory cytokine activities favors the induction of autoimmunity, chronic inflammation and thereby joint damage.  However, it remains less clear how cytokines are organized within a hierarchical regulatory network, and therefore which cytokines may be the best targets for clin. intervention a priori.  Here, we discuss the crucial effector function of cytokines in the immunol. processes that are central to the pathogenesis of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0RdTFn7jhXLVg90H21EOLACvtfcHk0liB3s4BtBXlQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D&md5=139510ac7d6607fbd46c6d32f781dfc6</span></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1038%2Fnri2094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2094%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DCytokines%2520in%2520the%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26issue%3D6%26spage%3D429%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Martin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towne, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kricorian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klekotka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudjonsson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, C. B.</span><span> </span><span class="NLM_article-title">The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=17-26&author=D.+A.+Martinauthor=J.+E.+Towneauthor=G.+Kricorianauthor=P.+Klekotkaauthor=J.+E.+Gudjonssonauthor=J.+G.+Kruegerauthor=C.+B.+Russell&title=The+emerging+role+of+IL-17+in+the+pathogenesis+of+psoriasis%3A+preclinical+and+clinical+findings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DTowne%26aufirst%3DJ.%2BE.%26aulast%3DKricorian%26aufirst%3DG.%26aulast%3DKlekotka%26aufirst%3DP.%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DRussell%26aufirst%3DC.%2BB.%26atitle%3DThe%2520emerging%2520role%2520of%2520IL-17%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%253A%2520preclinical%2520and%2520clinical%2520findings%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D17%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="note"><p class="first last">HWB cytokine induced STAT phosphorylation assays procedure: Compounds were prepared as 30 mM stocks in 100% DMSO and then diluted to 5 mM. A 10-point 2.5 dilution series was created in DMSO with a top concentration of 5 mM. Further dilution was done by adding 4 Î¼L of the above test article solutions into 96 Î¼L of PBS with a top concentration of 200 Î¼M. To a 96-well polypropylene plate (VWR 82007-292) 90 Î¼L of HWB was added per well, followed by addition of 5 Î¼L compound solutions prepared above to give a top concentration of 10 Î¼M. The plate was mixed and incubated for 45 min at 37 Â°C. To each well was added 5 Î¼L of IFNÎ± (Universal Type I IFN, R&D Systems catalog no. 11200-2; final concentration of 5000 U/mL) or IL-6 (R&D Systems, catalog no. 206-IL; final concentration of 100 ng/mL) or IL-15 (R&D Systems, catalog no. 247-IL; final concentration of 100 ng/mL) or IL-12 (R&D Systems, catalog no. 219-ILl final concentration of 100 ng/mL) or IL-23 (R&D Systems, catalog no. 1290-IL; final concentration of 100 ng/mL) or D-PBS (unstimulated control), mixed, and incubated for 15 min at 37 Â°C. The reaction was quenched by adding lyse/fix buffer [BD Phosflow 5Ã lyse/fix buffer (BD catalog no. 558049)] to all wells at 1000 Î¼L/well, and the samples were incubated for 20 min at 37 Â°C. After the samples were washed with FACS buffer [D-PBS (Invitrogen catalog no. 14190) containing 0.1% BSA and 0.1% sodium azide], 400 Î¼L of ice cold 90% methanol/water was added to each well and incubated on ice for 30 min. One more wash was done with cold FACS buffer, and all samples were finally resuspended in 250 Î¼L/well of the desired fluorochrome-labeled anti-phospho-STAT antibody (BD) at 1:125 dilution in FACS buffer. After overnight incubation at 4 Â°C all the samples were transferred into a 96-well polypropylene U-bottom plate (Falcon catalog no. 353077) and STATs phosphorylation were analyzed and quantified using a FACS Canto flow cytometer.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27a','cit27b','cit27c','cit27d'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31a','cit31b','cit31c'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40a','cit40b'],'ref41':['cit41a','cit41b'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56a','cit56b','cit56c'],'ref57':['cit57'],'ref58':['cit58a','cit58b','cit58c'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68a','cit68b'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71a','cit71b'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80a','cit80b','cit80c'],'ref81':['cit81'],'ref82':['cit82a','cit82b'],'ref83':['cit83'],'ref84':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 255 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Maria Galvez-Llompart, Riccardo Ocello, Laura Rullo, Serena Stamatakos, Irene Alessandrini, Riccardo Zanni, IÃ±aki TuÃ±Ã³n, Andrea Cavalli, Sanzio Candeletti, Matteo Masetti, Patrizia Romualdi, <span class="NLM_string-name hlFld-ContribAuthor">Maurizio Recanatini</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (6)
                                     , 3091-3108. <a href="https://doi.org/10.1021/acs.jcim.0c01468" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01468%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DTargeting%252Bthe%252BJAK%25252FSTAT%252BPathway%25253A%252BA%252BCombined%252BLigand-%252Band%252BTarget-Based%252BApproach%26aulast%3DGalvez-Llompart%26aufirst%3DMaria%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22122020%26date%3D17052021%26volume%3D61%26issue%3D6%26spage%3D3091%26epage%3D3108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu-meng Zhang, Jian Shen, Jun-ming Zhao, Jian Guan, Xin-rui Wei, Dong-yu Miao, Wei Li, Yi-cheng Xie, <span class="NLM_string-name hlFld-ContribAuthor">Yu-qing Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Cedrol from Ginger Ameliorates Rheumatoid Arthritis via Reducing Inflammation and Selectively Inhibiting JAK3 Phosphorylation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2021,</strong> <em>69 </em>
                                    (18)
                                     , 5332-5343. <a href="https://doi.org/10.1021/acs.jafc.1c00284" title="DOI URL">https://doi.org/10.1021/acs.jafc.1c00284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.1c00284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.1c00284%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DCedrol%252Bfrom%252BGinger%252BAmeliorates%252BRheumatoid%252BArthritis%252Bvia%252BReducing%252BInflammation%252Band%252BSelectively%252BInhibiting%252BJAK3%252BPhosphorylation%26aulast%3DZhang%26aufirst%3DYu-meng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D15012021%26date%3D19032021%26date%3D18032021%26date%3D28042021%26volume%3D69%26issue%3D18%26spage%3D5332%26epage%3D5343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Stephen W. Wright</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13561-13577. <a href="https://doi.org/10.1021/acs.jmedchem.0c00948" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BInhibitor%252B%252528PF-06826647%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03062020%26date%3D25082020%26date%3D05082020%26volume%3D63%26issue%3D22%26spage%3D13561%26epage%3D13577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qichao Bao, Liangying Zhang, Nan Wang, Brian Gabet, Weikang Yang, Xingyang Gao, Qidong You, <span class="NLM_string-name hlFld-ContribAuthor">Zhengyu Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2182-2189. <a href="https://doi.org/10.1021/acsmedchemlett.0c00323" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00323</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00323%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHydrogen%252BPeroxide%252BInducible%252BJAK3%252BCovalent%252BInhibitor%25253A%252BProdrug%252Bfor%252Bthe%252BTreatment%252Bof%252BRA%252Bwith%252BEnhanced%252BSafety%252BProfile%26aulast%3DBao%26aufirst%3DQichao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11062020%26date%3D01102020%26date%3D05102020%26volume%3D11%26issue%3D11%26spage%3D2182%26epage%3D2189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Satoru Noji, Yoshinori Hara, Tomoya Miura, Hiroshi Yamanaka, Katsuya Maeda, Akimi Hori, Hiroshi Yamamoto, Shingo Obika, Masafumi Inoue, Yasunori Hase, Takuya Orita, Satoki Doi, Tsuyoshi Adachi, Atsuo Tanimoto, Chika Oki, Yukari Kimoto, Yoshihiro Ogawa, Tamotsu Negoro, Hiromasa Hashimoto, <span class="NLM_string-name hlFld-ContribAuthor">Makoto Shiozaki</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7163-7185. <a href="https://doi.org/10.1021/acs.jmedchem.0c00450" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00450</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00450%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BJanus%252BKinase%252BInhibitor%252BBearing%252Ba%252BHighly%252BThree-Dimensional%252BSpiro%252BScaffold%25253A%252BJTE-052%252B%252528Delgocitinib%252529%252Bas%252Ba%252BNew%252BDermatological%252BAgent%252Bto%252BTreat%252BInflammatory%252BSkin%252BDisorders%26aulast%3DNoji%26aufirst%3DSatoru%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17032020%26date%3D29062020%26date%3D08062020%26volume%3D63%26issue%3D13%26spage%3D7163%26epage%3D7185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vijayabhaskar Veeravalli, <span class="NLM_string-name hlFld-ContribAuthor">Ranjeet P. Dash</span>. </span><span class="cited-content_cbyCitation_article-title">âTofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4â: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (2)
                                     , 281-282. <a href="https://doi.org/10.1021/acs.chemrestox.9b00455" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.9b00455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.9b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.9b00455%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3D%2525E2%252580%25259CTofacitinib%252BIs%252Ba%252BMechanism-Based%252BInactivator%252Bof%252BCytochrome%252BP450%252B3A4%2525E2%252580%25259D%25253A%252BRevisiting%252Bthe%252BSignificance%252Bof%252Bthe%252BEpoxide%252BIntermediate%252Band%252BGlutathione%252BTrapping%26aulast%3DVeeravalli%26aufirst%3DVijayabhaskar%26date%3D2020%26date%3D2019%26date%3D18122019%26date%3D13122019%26volume%3D33%26issue%3D2%26spage%3D281%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski, Shuqun Lin, Michael Mertzman, Steven Spergel, John S. Tokarski, Joann Strnad, Kathleen Gillooly, Kim W. McIntyre, Adriana Zupa-Fernandez, Lihong Cheng, Huadong Sun, Charu Chaudhry, Christine Huang, Celia DâArienzo, Elizabeth Heimrich, Xiaoxia Yang, Jodi K. Muckelbauer, ChiehYing Chang, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Nelly Aranibar, Manoj Chiney, James R. Burke, Louis Lombardo, Percy H. Carter, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8953-8972. <a href="https://doi.org/10.1021/acs.jmedchem.9b00443" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-Methyl%252BNicotinamide%252Band%252BN-Methyl%252BPyridazine-3-Carboxamide%252BPseudokinase%252BDomain%252BLigands%252Bas%252BHighly%252BSelective%252BAllosteric%252BInhibitors%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%26aulast%3DMoslin%26aufirst%3DRyan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D17072019%26volume%3D62%26issue%3D20%26spage%3D8953%26epage%3D8972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia DâArienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jordi Bach, Paul Eastwood, Jacob GonzÃ¡lez, Elena GÃ³mez, Juan Antonio Alonso, Silvia Fonquerna, Estrella Lozoya, Adela Orellana, MÃ³nica Maldonado, Elena Calaf, Joan AlbertÃ­, Juan PÃ©rez, Ana AndrÃ©s, Neus Prats, Cristina CarreÃ±o, Elena Calama, Jorge De Alba, Marta Calbet, Montserrat Miralpeix, <span class="NLM_string-name hlFld-ContribAuthor">Isabel Ramis</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 9045-9060. <a href="https://doi.org/10.1021/acs.jmedchem.9b00533" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B2-Imidazopyridine%252Band%252B2-Aminopyridone%252BPurinones%252Bas%252BPotent%252BPan-Janus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bfor%252Bthe%252BInhaled%252BTreatment%252Bof%252BRespiratory%252BDiseases%26aulast%3DBach%26aufirst%3DJordi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D14102019%26volume%3D62%26issue%3D20%26spage%3D9045%26epage%3D9060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexander Gontcharov, Javier Magano, Lacey Samp, Tim L. Houck, Peter R. Rose, Anil Rane, Jotham W. Coe, Steven W. Kortum, SeungWon Chung, Peter Jones, <span class="NLM_string-name hlFld-ContribAuthor">David Pattavina</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Scalable Synthesis for an Inhaled pan-JAK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1990-2000. <a href="https://doi.org/10.1021/acs.oprd.9b00253" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00253%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BScalable%252BSynthesis%252Bfor%252Ban%252BInhaled%252Bpan-JAK%252BInhibitor%26aulast%3DGontcharov%26aufirst%3DAlexander%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04062019%26date%3D06082019%26date%3D24072019%26volume%3D23%26issue%3D9%26spage%3D1990%26epage%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hua Xu, Michael I. Jesson, Uthpala I. Seneviratne, Tsung H. Lin, M. Nusrat Sharif, Liang Xue, Chuong Nguyen, Robert A. Everley, John I. Trujillo, Douglas S. Johnson, Gary R. Point, Atli Thorarensen, Iain Kilty, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Baptiste Telliez</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (6)
                                     , 1235-1242. <a href="https://doi.org/10.1021/acschembio.9b00188" title="DOI URL">https://doi.org/10.1021/acschembio.9b00188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00188%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DPF-06651600%25252C%252Ba%252BDual%252BJAK3%25252FTEC%252BFamily%252BKinase%252BInhibitor%26aulast%3DXu%26aufirst%3DHua%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08032019%26date%3D13052019%26date%3D22052019%26date%3D13052019%26volume%3D14%26issue%3D6%26spage%3D1235%26epage%3D1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liyang Shi, Zhenpeng Zhong, Xitao Li, Yiqing Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Zhengying Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 1054-1066. <a href="https://doi.org/10.1021/acs.jmedchem.8b01823" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ban%252BOrally%252BAvailable%252BJanus%252BKinase%252B3%252BSelective%252BCovalent%252BInhibitor%26aulast%3DShi%26aufirst%3DLiyang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D07012019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonio Llinas, Rafael Barbas, MercÃ¨ Font-Bardia, Amir Smailagic, <span class="NLM_string-name hlFld-ContribAuthor">Rafel Prohens</span>. </span><span class="cited-content_cbyCitation_article-title">Derisking Development by a Cocrystallization Screen of a Novel Selective Inhaled JAK-STAT inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Crystal Growth & Design</span><span> <strong>2019,</strong> <em>19 </em>
                                    (1)
                                     , 403-414. <a href="https://doi.org/10.1021/acs.cgd.8b01492" title="DOI URL">https://doi.org/10.1021/acs.cgd.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.cgd.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.cgd.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystal%2520Growth%2520%2526%2520Design%26atitle%3DDerisking%252BDevelopment%252Bby%252Ba%252BCocrystallization%252BScreen%252Bof%252Ba%252BNovel%252BSelective%252BInhaled%252BJAK-STAT%252Binhibitor%26aulast%3DLlinas%26aufirst%3DAntonio%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04102018%26date%3D31102018%26date%3D28112018%26date%3D15112018%26volume%3D19%26issue%3D1%26spage%3D403%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mohamed
S. A. Elsayed, Jeffery J. Nielsen, Sungtae Park, Jeongho Park, Qingyang Liu, Chang H. Kim, Yves Pommier, Keli Agama, Philip S. Low, <span class="NLM_string-name hlFld-ContribAuthor">Mark Cushman</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10440-10462. <a href="https://doi.org/10.1021/acs.jmedchem.8b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252BSequential%252BPalladium%252BCatalysis%252Bfor%252Bthe%252BDiscovery%252Bof%252BJanus%252BKinase%252BInhibitors%252Bin%252Bthe%252BBenzo%25255Bc%25255Dpyrrolo%25255B2%25252C3-h%25255D%25255B1%25252C6%25255Dnaphthyridin-5-one%252B%252528BPN%252529%252BSeries%26aulast%3DElsayed%26aufirst%3DMohamed%2BS.%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31032018%26date%3D21112018%26volume%3D61%26issue%3D23%26spage%3D10440%26epage%3D10462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Agustin Casimiro-Garcia, John I. Trujillo, Felix Vajdos, Brian Juba, Mary Ellen Banker, Ann Aulabaugh, Paul Balbo, Jonathan Bauman, Jill Chrencik, Jotham W. Coe, Robert Czerwinski, Martin Dowty, John D. Knafels, Soojin Kwon, Louis Leung, Sidney Liang, Ralph P. Robinson, Jean-Baptiste Telliez, Ray Unwalla, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Atli Thorarensen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10665-10699. <a href="https://doi.org/10.1021/acs.jmedchem.8b01308" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01308%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BCyanamide-Based%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BCovalent%252BInhibitors%26aulast%3DCasimiro-Garcia%26aufirst%3DAgustin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18082018%26date%3D30112018%26date%3D13112018%26volume%3D61%26issue%3D23%26spage%3D10665%26epage%3D10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew Fensome, Catherine M. Ambler, Eric Arnold, Mary Ellen Banker, Matthew F. Brown, Jill Chrencik, James D. Clark, Martin E. Dowty, Ivan V. Efremov, Andrew Flick, Brian S. Gerstenberger, Ariamala Gopalsamy, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, Jason Jussif, John D. Knafels, David C. Limburg, David Lin, Tsung H. Lin, Betsy S. Pierce, Eddine Saiah, Raman Sharma, Peter T. Symanowicz, Jean-Baptiste Telliez, John I. Trujillo, Felix F. Vajdos, Fabien Vincent, Zhao-Kui Wan, Li Xing, Xiaojing Yang, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Liying Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8597-8612. <a href="https://doi.org/10.1021/acs.jmedchem.8b00917" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BInhibition%252Bof%252BTYK2%252Band%252BJAK1%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252B%252528%252528S%252529-2%25252C2-Difluorocyclopropyl%252529%252528%2525281R%25252C5S%252529-3-%2525282-%252528%2525281-methyl-1H-pyrazol-4-yl%252529amino%252529pyrimidin-4-yl%252529-3%25252C8-diazabicyclo%25255B3.2.1%25255Doctan-8-yl%252529methanone%252B%252528PF-06700841%252529%26aulast%3DFensome%26aufirst%3DAndrew%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D08062018%26date%3D16082018%26volume%3D61%26issue%3D19%26spage%3D8597%26epage%3D8612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Diego
GonzÃ¡lez Cabrera, AndrÃ© Horatscheck, Colin R. Wilson, Greg Basarab, Charles J. Eyermann, <span class="NLM_string-name hlFld-ContribAuthor">Kelly Chibale</span>. </span><span class="cited-content_cbyCitation_article-title">Plasmodial Kinase Inhibitors: License to Cure?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (18)
                                     , 8061-8077. <a href="https://doi.org/10.1021/acs.jmedchem.8b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPlasmodial%252BKinase%252BInhibitors%25253A%252BLicense%252Bto%252BCure%25253F%26aulast%3DCabrera%26aufirst%3DDiego%2BGonz%25C3%25A1lez%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28022018%26date%3D04062018%26date%3D17052018%26volume%3D61%26issue%3D18%26spage%3D8061%26epage%3D8077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Forster, Apirat Chaikuad, Teodor Dimitrov, Eva DÃ¶ring, Julia Holstein, Benedict-Tilman Berger, Matthias Gehringer, Kamran Ghoreschi, Susanne MÃ¼ller, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Stefan A. Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Development, Optimization, and StructureâActivity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5350-5366. <a href="https://doi.org/10.1021/acs.jmedchem.8b00571" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00571%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%25252C%252BOptimization%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BCovalent-Reversible%252BJAK3%252BInhibitors%252BBased%252Bon%252Ba%252BTricyclic%252BImidazo%25255B5%25252C4-d%25255Dpyrrolo%25255B2%25252C3-b%25255Dpyridine%252BScaffold%26aulast%3DForster%26aufirst%3DMichael%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11042018%26date%3D13062018%26date%3D31052018%26volume%3D61%26issue%3D12%26spage%3D5350%26epage%3D5366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicia J.  Angelbello</span>, <span class="hlFld-ContribAuthor ">Jonathan L.  Chen</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Childs-Disney</span>, <span class="hlFld-ContribAuthor ">Peiyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi-Fu  Wang</span>, and <span class="hlFld-ContribAuthor ">Matthew D.  Disney</span>  . </span><span class="cited-content_cbyCitation_article-title">Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2018,</strong> <em>118 </em>
                                    (4)
                                     , 1599-1663. <a href="https://doi.org/10.1021/acs.chemrev.7b00504" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00504</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00504%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DUsing%252BGenome%252BSequence%252Bto%252BEnable%252Bthe%252BDesign%252Bof%252BMedicines%252Band%252BChemical%252BProbes%26aulast%3DAngelbello%26aufirst%3DAlicia%2BJ.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D19082017%26date%3D11012018%26date%3D28022018%26volume%3D118%26issue%3D4%26spage%3D1599%26epage%3D1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Vazquez</span>, <span class="hlFld-ContribAuthor ">Neelu  Kaila</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Strohbach</span>, <span class="hlFld-ContribAuthor ">John D.  Trzupek</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Mark J.  Mitton-Fry</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Johnson</span>, <span class="hlFld-ContribAuthor ">Ruth E.  TenBrink</span>, <span class="hlFld-ContribAuthor ">Eric P.  Arnold</span>, <span class="hlFld-ContribAuthor ">Arindrajit  Basak</span>, <span class="hlFld-ContribAuthor ">Steven E.  Heasley</span>, <span class="hlFld-ContribAuthor ">Soojin  Kwon</span>, <span class="hlFld-ContribAuthor ">Jonathan  Langille</span>, <span class="hlFld-ContribAuthor ">Mihir D.  Parikh</span>, <span class="hlFld-ContribAuthor ">Sarah H.  Griffin</span>, <span class="hlFld-ContribAuthor ">Jeffrey M.  Casavant</span>, <span class="hlFld-ContribAuthor ">Brian A.  Duclos</span>, <span class="hlFld-ContribAuthor ">Ashley E.  Fenwick</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Harris</span>, <span class="hlFld-ContribAuthor ">Seungil  Han</span>, <span class="hlFld-ContribAuthor ">Nicole  Caspers</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Peter T.  Symanowicz</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Ralph P.  Robinson</span>, and <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (3)
                                     , 1130-1152. <a href="https://doi.org/10.1021/acs.jmedchem.7b01598" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01598</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-%25257Bcis-3-%25255BMethyl%2525287H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529amino%25255Dcyclobutyl%25257Dpropane-1-sulfonamide%252B%252528PF-04965842%252529%25253A%252BA%252BSelective%252BJAK1%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DVazquez%26aufirst%3DMichael%2BL.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30102017%26date%3D23012018%26date%3D08022018%26date%3D03012018%26volume%3D61%26issue%3D3%26spage%3D1130%26epage%3D1152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Prachi  Singh</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>, <span class="hlFld-ContribAuthor ">Jeannie X. T.  Lee</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8336-8357. <a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BLigand%252BEfficient%252BDual%252BInhibitors%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BBased%252Bon%252BRuxolitinib%252Band%252BVorinostat%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11052017%26date%3D10102017%26date%3D26102017%26date%3D27092017%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Brian  Juba</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">Tsung  Lin</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Robert M.  Czerwinski</span>, <span class="hlFld-ContribAuthor ">Agustin  Casimiro-Garcia</span>, <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Sidney  Liang</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Ye  Che</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Matthew  Hayward</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Louis  Leung</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Sarah  Soucy</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Jotham  Coe</span>, <span class="hlFld-ContribAuthor ">Jonathan  Langille</span>, <span class="hlFld-ContribAuthor ">Felix  Vajdos</span>, <span class="hlFld-ContribAuthor ">Jill  Chrencik</span>, and <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1971-1993. <a href="https://doi.org/10.1021/acs.jmedchem.6b01694" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Ba%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BSpecific%252BInhibitor%252B1-%252528%2525282S%25252C5R%252529-5-%252528%2525287H-Pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529amino%252529-2-methylpiperidin-1-yl%252529prop-2-en-1-one%252B%252528PF-06651600%252529%252BAllowing%252Bfor%252Bthe%252BInterrogation%252Bof%252BJAK3%252BSignaling%252Bin%252BHumans%26aulast%3DThorarensen%26aufirst%3DAtli%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D23112016%26date%3D16022017%26date%3D09032017%26date%3D31012017%26volume%3D60%26issue%3D5%26spage%3D1971%26epage%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Jones</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Yogesh A.  Sabnis</span>, <span class="hlFld-ContribAuthor ">Florian M.  Wakenhut</span>, <span class="hlFld-ContribAuthor ">Gavin A.  Whitlock</span>, <span class="hlFld-ContribAuthor ">Katherine S.  England</span>, <span class="hlFld-ContribAuthor ">Takasuke  Mukaiyama</span>, <span class="hlFld-ContribAuthor ">Christoph M.  Dehnhardt</span>, <span class="hlFld-ContribAuthor ">Jotham W.  Coe</span>, <span class="hlFld-ContribAuthor ">Steve W.  Kortum</span>, <span class="hlFld-ContribAuthor ">Jill E.  Chrencik</span>, <span class="hlFld-ContribAuthor ">David G.  Brown</span>, <span class="hlFld-ContribAuthor ">Rhys M.  Jones</span>, <span class="hlFld-ContribAuthor ">John R.  Murphy</span>, <span class="hlFld-ContribAuthor ">Thean  Yeoh</span>, <span class="hlFld-ContribAuthor ">Paul  Morgan</span>, and <span class="hlFld-ContribAuthor ">Iain  Kilty</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 767-786. <a href="https://doi.org/10.1021/acs.jmedchem.6b01634" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252Ba%252BPan-Janus%252BKinase%252BInhibitor%252BClinical%252BCandidate%252B%252528PF-06263276%252529%252BSuitable%252Bfor%252BInhaled%252Band%252BTopical%252BDelivery%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BDiseases%252Bof%252Bthe%252BLungs%252Band%252BSkin%26aulast%3DJones%26aufirst%3DPeter%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D08112016%26date%3D04012017%26date%3D26012017%26date%3D16122016%26volume%3D60%26issue%3D2%26spage%3D767%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">Tsung  Lin</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Erick  Moy</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yajuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Kimberly  Crouse</span>, <span class="hlFld-ContribAuthor ">Caitlyn  Dickinson</span>, <span class="hlFld-ContribAuthor ">Peter  Symanowicz</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>, <span class="hlFld-ContribAuthor ">Sidney  Liang</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Matthew  Hayward</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Jonathan  Bauman</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Agustin  Casimiro-Garcia</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">Louis  Leung</span>, <span class="hlFld-ContribAuthor ">Kieran F.  Geoghegan</span>, <span class="hlFld-ContribAuthor ">Amira  Quazi</span>, <span class="hlFld-ContribAuthor ">Dejun  Xuan</span>, <span class="hlFld-ContribAuthor ">Lyn  Jones</span>, <span class="hlFld-ContribAuthor ">Erik  Hett</span>, <span class="hlFld-ContribAuthor ">Katherine  Wright</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, and <span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (12)
                                     , 3442-3451. <a href="https://doi.org/10.1021/acschembio.6b00677" title="DOI URL">https://doi.org/10.1021/acschembio.6b00677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.6b00677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.6b00677%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252BJAK3-Selective%252BInhibitor%25253A%252BFunctional%252BDifferentiation%252Bof%252BJAK3-Selective%252BInhibition%252Bover%252Bpan-JAK%252Bor%252BJAK1-Selective%252BInhibition%26aulast%3DTelliez%26aufirst%3DJean-Baptiste%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05082016%26date%3D28102016%26date%3D10112016%26date%3D16122016%26date%3D28102016%26volume%3D11%26issue%3D12%26spage%3D3442%26epage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tavina L.  Offutt</span>, <span class="hlFld-ContribAuthor ">Robert V.  Swift</span>, and <span class="hlFld-ContribAuthor ">Rommie E.  Amaro</span>  . </span><span class="cited-content_cbyCitation_article-title">Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics Simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (10)
                                     , 1923-1935. <a href="https://doi.org/10.1021/acs.jcim.6b00261" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00261%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DEnhancing%252BVirtual%252BScreening%252BPerformance%252Bof%252BProtein%252BKinases%252Bwith%252BMolecular%252BDynamics%252BSimulations%26aulast%3DOffutt%26aufirst%3DTavina%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D06052016%26date%3D03102016%26date%3D24102016%26date%3D23092016%26volume%3D56%26issue%3D10%26spage%3D1923%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewu  Liang</span>, <span class="hlFld-ContribAuthor ">Jie  Zang</span>, <span class="hlFld-ContribAuthor ">Mengyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Qianwen  Gao</span>, <span class="hlFld-ContribAuthor ">Binghe  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, and <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (10)
                                     , 950-955. <a href="https://doi.org/10.1021/acsmedchemlett.6b00247" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00247%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BAntitumor%252BEvaluation%252Bof%252B4-Amino-%2525281H%252529-pyrazole%252BDerivatives%252Bas%252BJAKs%252BInhibitors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14072016%26date%3D23082016%26date%3D24082016%26date%3D13102016%26date%3D23082016%26volume%3D7%26issue%3D10%26spage%3D950%26epage%3D955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  RitzÃ©n</span>, <span class="hlFld-ContribAuthor ">Morten D.  SÃ¸rensen</span>, <span class="hlFld-ContribAuthor ">Kevin N.  Dack</span>, <span class="hlFld-ContribAuthor ">Daniel R.  Greve</span>, <span class="hlFld-ContribAuthor ">Anders  Jerre</span>, <span class="hlFld-ContribAuthor ">Martin A.  Carnerup</span>, <span class="hlFld-ContribAuthor ">Klaus A.  Rytved</span>, and <span class="hlFld-ContribAuthor ">Jesper  Bagger-Bahnsen</span>  . </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (6)
                                     , 641-646. <a href="https://doi.org/10.1021/acsmedchemlett.6b00087" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00087%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFragment-Based%252BDiscovery%252Bof%252B6-Arylindazole%252BJAK%252BInhibitors%26aulast%3DRitz%25C3%25A9n%26aufirst%3DAndreas%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26022016%26date%3D14042016%26date%3D19042016%26date%3D09062016%26date%3D14042016%26volume%3D7%26issue%3D6%26spage%3D641%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">DÃ¡vid  Bajusz</span>, <span class="hlFld-ContribAuthor ">GyÃ¶rgy G.  Ferenczy</span>, and <span class="hlFld-ContribAuthor ">GyÃ¶rgy M.  KeserÅ±</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (1)
                                     , 234-247. <a href="https://doi.org/10.1021/acs.jcim.5b00634" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BSubtype%252BSelective%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bby%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D18102015%26date%3D31122015%26date%3D25012016%26date%3D18122015%26volume%3D56%26issue%3D1%26spage%3D234%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luc J.  Farmer</span>, <span class="hlFld-ContribAuthor ">Mark W.  Ledeboer</span>, <span class="hlFld-ContribAuthor ">Thomas  Hoock</span>, <span class="hlFld-ContribAuthor ">Michael J.  Arnost</span>, <span class="hlFld-ContribAuthor ">Randy S.  Bethiel</span>, <span class="hlFld-ContribAuthor ">Youssef L.  Bennani</span>, <span class="hlFld-ContribAuthor ">James J.  Black</span>, <span class="hlFld-ContribAuthor ">Christopher L.  Brummel</span>, <span class="hlFld-ContribAuthor ">Ananthsrinivas  Chakilam</span>, <span class="hlFld-ContribAuthor ">Warren A.  Dorsch</span>, <span class="hlFld-ContribAuthor ">Bin  Fan</span>, <span class="hlFld-ContribAuthor ">John E.  Cochran</span>, <span class="hlFld-ContribAuthor ">Summer  Halas</span>, <span class="hlFld-ContribAuthor ">Edmund M.  Harrington</span>, <span class="hlFld-ContribAuthor ">James K.  Hogan</span>, <span class="hlFld-ContribAuthor ">David  Howe</span>, <span class="hlFld-ContribAuthor ">Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Dylan H.  Jacobs</span>, <span class="hlFld-ContribAuthor ">Leena M.  Laitinen</span>, <span class="hlFld-ContribAuthor ">Shengkai  Liao</span>, <span class="hlFld-ContribAuthor ">Sudipta  Mahajan</span>, <span class="hlFld-ContribAuthor ">Valerie  Marone</span>, <span class="hlFld-ContribAuthor ">Gabriel  Martinez-Botella</span>, <span class="hlFld-ContribAuthor ">Pamela  McCarthy</span>, <span class="hlFld-ContribAuthor ">David  Messersmith</span>, <span class="hlFld-ContribAuthor ">Mark  Namchuk</span>, <span class="hlFld-ContribAuthor ">Luke  Oh</span>, <span class="hlFld-ContribAuthor ">Marina S.  Penney</span>, <span class="hlFld-ContribAuthor ">Albert C.  Pierce</span>, <span class="hlFld-ContribAuthor ">Scott A.  Raybuck</span>, <span class="hlFld-ContribAuthor ">Arthur  Rugg</span>, <span class="hlFld-ContribAuthor ">Francesco G.  Salituro</span>, <span class="hlFld-ContribAuthor ">Kumkum  Saxena</span>, <span class="hlFld-ContribAuthor ">Dean  Shannon</span>, <span class="hlFld-ContribAuthor ">Dina  Shlyakter</span>, <span class="hlFld-ContribAuthor ">Lora  Swenson</span>, <span class="hlFld-ContribAuthor ">Shi-Kai  Tian</span>, <span class="hlFld-ContribAuthor ">Christopher  Town</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tiansheng  Wang</span>, <span class="hlFld-ContribAuthor ">M. Woods  Wannamaker</span>, <span class="hlFld-ContribAuthor ">Raymond J.  Winquist</span>, and <span class="hlFld-ContribAuthor ">Harmon J.  Zuccola</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (18)
                                     , 7195-7216. <a href="https://doi.org/10.1021/acs.jmedchem.5b00301" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00301%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BVX-509%252B%252528Decernotinib%252529%25253A%252BA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B3%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DFarmer%26aufirst%3DLuc%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D20022015%26date%3D10092015%26date%3D24092015%26date%3D31072015%26volume%3D58%26issue%3D18%26spage%3D7195%26epage%3D7216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Heerim  Shin</span>, <span class="hlFld-ContribAuthor ">Kwang-su  Park</span>, <span class="hlFld-ContribAuthor ">Hyungmi  Kim</span>, <span class="hlFld-ContribAuthor ">Jiseon  Park</span>, <span class="hlFld-ContribAuthor ">Kangjeon  Kim</span>, <span class="hlFld-ContribAuthor ">Joonwoo  Nam</span>, <span class="hlFld-ContribAuthor ">Hyunah  Choo</span>, and <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>  . </span><span class="cited-content_cbyCitation_article-title">Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (18)
                                     , 7596-7602. <a href="https://doi.org/10.1021/acs.jmedchem.5b01263" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzimidazole%252BDerivatives%252Bas%252BPotent%252BJAK1-Selective%252BInhibitors%26aulast%3DKim%26aufirst%3DMi%2BKyoung%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D10052015%26date%3D15092015%26date%3D24092015%26date%3D09092015%26volume%3D58%26issue%3D18%26spage%3D7596%26epage%3D7602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Koshi  Akahane</span>, <span class="hlFld-ContribAuthor ">Randall  McNally</span>, <span class="hlFld-ContribAuthor ">Kathleen M. S. E.  Reyskens</span>, <span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">Suhu  Liu</span>, <span class="hlFld-ContribAuthor ">Grit S.  Herter-Sprie</span>, <span class="hlFld-ContribAuthor ">Shohei  Koyama</span>, <span class="hlFld-ContribAuthor ">Michael J.  Pattison</span>, <span class="hlFld-ContribAuthor ">Katherine  Labella</span>, <span class="hlFld-ContribAuthor ">Liv  Johannessen</span>, <span class="hlFld-ContribAuthor ">Esra A.  Akbay</span>, <span class="hlFld-ContribAuthor ">Kwok-Kin  Wong</span>, <span class="hlFld-ContribAuthor ">David A.  Frank</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Look</span>, <span class="hlFld-ContribAuthor ">J. Simon C.  Arthur</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, and <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Selective Covalent Janus Kinase 3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (16)
                                     , 6589-6606. <a href="https://doi.org/10.1021/acs.jmedchem.5b00710" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BSelective%252BCovalent%252BJanus%252BKinase%252B3%252BInhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D07052015%26date%3D18082015%26date%3D27082015%26date%3D10082015%26volume%3D58%26issue%3D16%26spage%3D6589%26epage%3D6606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J.  Menet</span>, <span class="hlFld-ContribAuthor ">Stephen R  Fletcher</span>, <span class="hlFld-ContribAuthor ">Guy  Van Lommen</span>, <span class="hlFld-ContribAuthor ">Raphael  Geney</span>, <span class="hlFld-ContribAuthor ">Javier  Blanc</span>, <span class="hlFld-ContribAuthor ">Koen  Smits</span>, <span class="hlFld-ContribAuthor ">Nolwenn  Jouannigot</span>, <span class="hlFld-ContribAuthor ">Pierre  Deprez</span>, <span class="hlFld-ContribAuthor ">Ellen M.  van der Aar</span>, <span class="hlFld-ContribAuthor ">Philippe  Clement-Lacroix</span>, <span class="hlFld-ContribAuthor ">LiÃªn  Lepescheux</span>, <span class="hlFld-ContribAuthor ">RenÃ©  Galien</span>, <span class="hlFld-ContribAuthor ">BÃ©atrice  Vayssiere</span>, <span class="hlFld-ContribAuthor ">Luc  Nelles</span>, <span class="hlFld-ContribAuthor ">Thierry  Christophe</span>, <span class="hlFld-ContribAuthor ">Reginald  Brys</span>, <span class="hlFld-ContribAuthor ">Muriel  Uhring</span>, <span class="hlFld-ContribAuthor ">Fabrice  Ciesielski</span>, and <span class="hlFld-ContribAuthor ">Luc  Van Rompaey</span>  . </span><span class="cited-content_cbyCitation_article-title">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (22)
                                     , 9323-9342. <a href="https://doi.org/10.1021/jm501262q" title="DOI URL">https://doi.org/10.1021/jm501262q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501262q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTriazolopyridines%252Bas%252BSelective%252BJAK1%252BInhibitors%25253A%252BFrom%252BHit%252BIdentification%252Bto%252BGLPG0634%26aulast%3DMenet%26aufirst%3DChristel%2BJ.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D02042014%26date%3D17112014%26date%3D26112014%26date%3D04112014%26volume%3D57%26issue%3D22%26spage%3D9323%26epage%3D9342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoliang  Yang</span>, <span class="hlFld-ContribAuthor ">Naotomo  Kambe</span>, <span class="hlFld-ContribAuthor ">Riko  Takimoto-Ito</span>, <span class="hlFld-ContribAuthor ">Kenji  Kabashima</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>224 </em>, 107830. <a href="https://doi.org/10.1016/j.pharmthera.2021.107830" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107830%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DAdvances%252Bin%252Bthe%252Bpathophysiology%252Bof%252Batopic%252Bdermatitis%252Brevealed%252Bby%252Bnovel%252Btherapeutics%252Band%252Bclinical%252Btrials%26aulast%3DYang%26aufirst%3DXiaoliang%26date%3D2021%26volume%3D224%26spage%3D107830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suravi  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Karmtej Singh  Cheema</span>, <span class="hlFld-ContribAuthor ">Smriti K.  Raychaudhuri</span>, <span class="hlFld-ContribAuthor ">Siba P.  Raychaudhuri</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinaseâsignal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Rheumatology</span><span> <strong>2021,</strong> <em>33 </em>
                                    (4)
                                     , 348-355. <a href="https://doi.org/10.1097/BOR.0000000000000810" title="DOI URL">https://doi.org/10.1097/BOR.0000000000000810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/BOR.0000000000000810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FBOR.0000000000000810%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Rheumatology%26atitle%3DJanus%252Bkinase%2525E2%252580%252593signal%252Btransducers%252Band%252Bactivators%252Bof%252Btranscription%252Bcell%252Bsignaling%252Bin%252BSpondyloarthritis%25253A%252Brationale%252Band%252Bevidence%252Bfor%252BJAK%252Binhibition%26aulast%3DRaychaudhuri%26aufirst%3DSuravi%26date%3D2021%26date%3D2021%26volume%3D33%26issue%3D4%26spage%3D348%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingpeng  Xie</span>, <span class="hlFld-ContribAuthor ">Yuting  Wu</span>, <span class="hlFld-ContribAuthor ">Chuying  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhangbin  Tan</span>, <span class="hlFld-ContribAuthor ">Honglin  Xu</span>, <span class="hlFld-ContribAuthor ">Guanghong  Chen</span>, <span class="hlFld-ContribAuthor ">Hongmei  Chen</span>, <span class="hlFld-ContribAuthor ">Guiqiong  Huang</span>, <span class="hlFld-ContribAuthor ">Huijie  Fan</span>, <span class="hlFld-ContribAuthor ">Lei  Gao</span>, <span class="hlFld-ContribAuthor ">Bin  Liu</span>, <span class="hlFld-ContribAuthor ">Yingchun  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Piceatannol protects against sepsis-induced myocardial dysfunction via direct inhibition of JAK2. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2021,</strong> <em>96 </em>, 107639. <a href="https://doi.org/10.1016/j.intimp.2021.107639" title="DOI URL">https://doi.org/10.1016/j.intimp.2021.107639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2021.107639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2021.107639%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DPiceatannol%252Bprotects%252Bagainst%252Bsepsis-induced%252Bmyocardial%252Bdysfunction%252Bvia%252Bdirect%252Binhibition%252Bof%252BJAK2%26aulast%3DXie%26aufirst%3DLingpeng%26date%3D2021%26volume%3D96%26spage%3D107639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehrdad  Hajinejad</span>, <span class="hlFld-ContribAuthor ">Sajad  SahabâNegah</span>. </span><span class="cited-content_cbyCitation_article-title">Neuroinflammation: The next target of exosomal microRNAs derived from mesenchymal stem cells in the context of neurological disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2021,</strong> <em>14 </em><a href="https://doi.org/10.1002/jcp.30495" title="DOI URL">https://doi.org/10.1002/jcp.30495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.30495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.30495%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DNeuroinflammation%25253A%252BThe%252Bnext%252Btarget%252Bof%252Bexosomal%252BmicroRNAs%252Bderived%252Bfrom%252Bmesenchymal%252Bstem%252Bcells%252Bin%252Bthe%252Bcontext%252Bof%252Bneurological%252Bdisorders%26aulast%3DHajinejad%26aufirst%3DMehrdad%26date%3D2021%26date%3D2021%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin L  Winthrop</span>, <span class="hlFld-ContribAuthor ">Edward V  Loftus</span>, <span class="hlFld-ContribAuthor ">Daniel C  Baumgart</span>, <span class="hlFld-ContribAuthor ">Walter  Reinisch</span>, <span class="hlFld-ContribAuthor ">Chudy I  Nduaka</span>, <span class="hlFld-ContribAuthor ">Nervin  Lawendy</span>, <span class="hlFld-ContribAuthor ">Gary  Chan</span>, <span class="hlFld-ContribAuthor ">Rajiv  Mundayat</span>, <span class="hlFld-ContribAuthor ">Gary S  Friedman</span>, <span class="hlFld-ContribAuthor ">Leonardo  Salese</span>, <span class="hlFld-ContribAuthor ">Andrew J  Thorpe</span>, <span class="hlFld-ContribAuthor ">Chinyu  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2021,</strong> <em>15 </em>
                                    (6)
                                     , 914-929. <a href="https://doi.org/10.1093/ecco-jcc/jjaa233" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjaa233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjaa233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjaa233%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DTofacitinib%252Bfor%252Bthe%252BTreatment%252Bof%252BUlcerative%252BColitis%25253A%252BAnalysis%252Bof%252BInfection%252BRates%252Bfrom%252Bthe%252BUlcerative%252BColitis%252BClinical%252BProgramme%26aulast%3DWinthrop%26aufirst%3DKevin%2BL%26date%3D2021%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D914%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Casal-Dominguez</span>, <span class="hlFld-ContribAuthor ">Iago  Pinal-Fernandez</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Mammen</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Rheumatology</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1007/s40674-021-00182-1" title="DOI URL">https://doi.org/10.1007/s40674-021-00182-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40674-021-00182-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40674-021-00182-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Rheumatology%26atitle%3DInhibiting%252BInterferon%252BPathways%252Bin%252BDermatomyositis%25253A%252BRationale%252Band%252BPreliminary%252BEvidence%26aulast%3DCasal-Dominguez%26aufirst%3DMaria%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Gabriella  Raimondo</span>, <span class="hlFld-ContribAuthor ">Martina  Biggioggero</span>, <span class="hlFld-ContribAuthor ">Lavinia Agra  Coletto</span>, <span class="hlFld-ContribAuthor ">Andreas  Ramming</span>, <span class="hlFld-ContribAuthor ">Roberto  Caporali</span>, <span class="hlFld-ContribAuthor ">Ennio Giulio  Favalli</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Pharmacology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (6)
                                     , 661-670. <a href="https://doi.org/10.1080/17512433.2021.1913050" title="DOI URL">https://doi.org/10.1080/17512433.2021.1913050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17512433.2021.1913050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17512433.2021.1913050%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Pharmacology%26atitle%3DClinical%252Bpharmacology%252Bof%252Bfilgotinib%252Bin%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%25253A%252Bcurrent%252Binsights%26aulast%3DRaimondo%26aufirst%3DMaria%2BGabriella%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D6%26spage%3D661%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Hai  Wang</span>, <span class="hlFld-ContribAuthor ">Lian  Qin</span>, <span class="hlFld-ContribAuthor ">Jie  Ren</span>, <span class="hlFld-ContribAuthor ">Qiushuang  Sun</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhixia  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113394. <a href="https://doi.org/10.1016/j.ejmech.2021.113394" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113394%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bimidazopyrrolopyridines%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252Binhibitors%252Bof%252BJAK2%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2021%26volume%3D218%26spage%3D113394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Montero</span>, <span class="hlFld-ContribAuthor ">Javier  Milara</span>, <span class="hlFld-ContribAuthor ">InÃ©s  Roger</span>, <span class="hlFld-ContribAuthor ">Julio  Cortijo</span>. </span><span class="cited-content_cbyCitation_article-title">Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (12)
                                     , 6211. <a href="https://doi.org/10.3390/ijms22126211" title="DOI URL">https://doi.org/10.3390/ijms22126211</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22126211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22126211%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DRole%252Bof%252BJAK%25252FSTAT%252Bin%252BInterstitial%252BLung%252BDiseases%25253B%252BMolecular%252Band%252BCellular%252BMechanisms%26aulast%3DMontero%26aufirst%3DPaula%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D12%26spage%3D6211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Nguyen</span>, <span class="hlFld-ContribAuthor ">Natasha  Atanaskova Mesinkovska</span>. </span><span class="cited-content_cbyCitation_article-title">Alopecia areataâNew updates with longâterm use of JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Dermatological Reviews</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     , 136-145. <a href="https://doi.org/10.1002/der2.65" title="DOI URL">https://doi.org/10.1002/der2.65</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/der2.65&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fder2.65%26sid%3Dliteratum%253Aachs%26jtitle%3DDermatological%2520Reviews%26atitle%3DAlopecia%252Bareata%2525E2%252580%252594New%252Bupdates%252Bwith%252Blong%2525E2%252580%252590term%252Buse%252Bof%252BJAK%252Binhibitors%26aulast%3DNguyen%26aufirst%3DCristina%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3%26spage%3D136%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian G  Feagan</span>, <span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Edward V  Loftus</span>, <span class="hlFld-ContribAuthor ">SÃ©verine  Vermeire</span>, <span class="hlFld-ContribAuthor ">Stefan  Schreiber</span>, <span class="hlFld-ContribAuthor ">Timothy  Ritter</span>, <span class="hlFld-ContribAuthor ">Ronald  Fogel</span>, <span class="hlFld-ContribAuthor ">Rajiv  Mehta</span>, <span class="hlFld-ContribAuthor ">Sandeep  Nijhawan</span>, <span class="hlFld-ContribAuthor ">RadosÅaw  KempiÅski</span>, <span class="hlFld-ContribAuthor ">RafaÅ  Filip</span>, <span class="hlFld-ContribAuthor ">Ihor  Hospodarskyy</span>, <span class="hlFld-ContribAuthor ">Ursula  Seidler</span>, <span class="hlFld-ContribAuthor ">Frank  Seibold</span>, <span class="hlFld-ContribAuthor ">Ian L P  Beales</span>, <span class="hlFld-ContribAuthor ">Hyo Jong  Kim</span>, <span class="hlFld-ContribAuthor ">John  McNally</span>, <span class="hlFld-ContribAuthor ">Chohee  Yun</span>, <span class="hlFld-ContribAuthor ">Sally  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Liu</span>, <span class="hlFld-ContribAuthor ">Chia-Hsiang  Hsueh</span>, <span class="hlFld-ContribAuthor ">Chantal  Tasset</span>, <span class="hlFld-ContribAuthor ">Robin  Besuyen</span>, <span class="hlFld-ContribAuthor ">Mamoru  Watanabe</span>, <span class="hlFld-ContribAuthor ">William J  Sandborn</span>, <span class="hlFld-ContribAuthor ">Gerhard  Rogler</span>, <span class="hlFld-ContribAuthor ">Toshifumi  Hibi</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. </span><span class="cited-content_cbyCitation_journal-name">The Lancet</span><span> <strong>2021,</strong> <em>397 </em>
                                    (10292)
                                     , 2372-2384. <a href="https://doi.org/10.1016/S0140-6736(21)00666-8" title="DOI URL">https://doi.org/10.1016/S0140-6736(21)00666-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0140-6736(21)00666-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0140-6736%2821%2900666-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%26atitle%3DFilgotinib%252Bas%252Binduction%252Band%252Bmaintenance%252Btherapy%252Bfor%252Bulcerative%252Bcolitis%252B%252528SELECTION%252529%25253A%252Ba%252Bphase%252B2b%25252F3%252Bdouble-blind%25252C%252Brandomised%25252C%252Bplacebo-controlled%252Btrial%26aulast%3DFeagan%26aufirst%3DBrian%2BG%26date%3D2021%26volume%3D397%26issue%3D10292%26spage%3D2372%26epage%3D2384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nurullah  Akkoc</span>, <span class="hlFld-ContribAuthor ">Muhammad A.  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?. </span><span class="cited-content_cbyCitation_journal-name">Current Rheumatology Reports</span><span> <strong>2021,</strong> <em>23 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s11926-021-01001-1" title="DOI URL">https://doi.org/10.1007/s11926-021-01001-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11926-021-01001-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11926-021-01001-1%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Rheumatology%2520Reports%26atitle%3DJAK%252BInhibitors%252Bfor%252BAxial%252BSpondyloarthritis%25253A%252BWhat%252Bdoes%252Bthe%252BFuture%252BHold%25253F%26aulast%3DAkkoc%26aufirst%3DNurullah%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie  Keeling</span>, <span class="hlFld-ContribAuthor ">Walter P.  Maksymowych</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Immunology</span><span> <strong>2021,</strong> <em>41 </em>, 1-15. <a href="https://doi.org/10.1080/1744666X.2021.1925541" title="DOI URL">https://doi.org/10.1080/1744666X.2021.1925541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1744666X.2021.1925541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1744666X.2021.1925541%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Immunology%26atitle%3DJAK%252Binhibitors%25252C%252Bpsoriatic%252Barthritis%25252C%252Band%252Baxial%252Bspondyloarthritis%25253A%252Ba%252Bcritical%252Breview%252Bof%252Bclinical%252Btrials%26aulast%3DKeeling%26aufirst%3DStephanie%26date%3D2021%26date%3D2021%26volume%3D41%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjun  Du</span>, <span class="hlFld-ContribAuthor ">Fuli  Zhang</span>, <span class="hlFld-ContribAuthor ">Pei  Yan</span>, <span class="hlFld-ContribAuthor ">Qingfu  Lai</span>, <span class="hlFld-ContribAuthor ">Junjian  Li</span>, <span class="hlFld-ContribAuthor ">Daqian  Zhu</span>, <span class="hlFld-ContribAuthor ">Lianbao  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Activity Evaluation and Molecular Docking Study of Novel Janus kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (17)
                                     , 4212-4216. <a href="https://doi.org/10.1002/slct.202100707" title="DOI URL">https://doi.org/10.1002/slct.202100707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100707%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BActivity%252BEvaluation%252Band%252BMolecular%252BDocking%252BStudy%252Bof%252BNovel%252BJanus%252Bkinase%252BInhibitors%26aulast%3DDu%26aufirst%3DWenjun%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D17%26spage%3D4212%26epage%3D4216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun Young  Moon</span>, <span class="hlFld-ContribAuthor ">Kwang Dong  Kim</span>, <span class="hlFld-ContribAuthor ">Jiyun  Yoo</span>, <span class="hlFld-ContribAuthor ">Jeong-Hyung  Lee</span>, <span class="hlFld-ContribAuthor ">Cheol  Hwangbo</span>. </span><span class="cited-content_cbyCitation_article-title">Phytochemicals Targeting JAKâSTAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2824. <a href="https://doi.org/10.3390/molecules26092824" title="DOI URL">https://doi.org/10.3390/molecules26092824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092824%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPhytochemicals%252BTargeting%252BJAK%2525E2%252580%252593STAT%252BPathways%252Bin%252BInflammatory%252BBowel%252BDisease%25253A%252BInsights%252Bfrom%252BAnimal%252BModels%26aulast%3DMoon%26aufirst%3DSun%2BYoung%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murat  ErdaÄ</span>, <span class="hlFld-ContribAuthor ">Mehmet  Balbaba</span>, <span class="hlFld-ContribAuthor ">Nevin  Ä°lhan</span>, <span class="hlFld-ContribAuthor ">Ä°lknur  ÃalÄ±k</span>, <span class="hlFld-ContribAuthor ">Fatih  UlaÅ</span>, <span class="hlFld-ContribAuthor ">Yesari  ErÃ¶ksÃ¼z</span>, <span class="hlFld-ContribAuthor ">Hakan  YÄ±ldÄ±rÄ±m</span>. </span><span class="cited-content_cbyCitation_article-title">Protective effect of filgotinib in rat endotoxin-induced uveitis model. </span><span class="cited-content_cbyCitation_journal-name">International Ophthalmology</span><span> <strong>2021,</strong> <em>121 </em><a href="https://doi.org/10.1007/s10792-021-01851-9" title="DOI URL">https://doi.org/10.1007/s10792-021-01851-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10792-021-01851-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10792-021-01851-9%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Ophthalmology%26atitle%3DProtective%252Beffect%252Bof%252Bfilgotinib%252Bin%252Brat%252Bendotoxin-induced%252Buveitis%252Bmodel%26aulast%3DErda%25C4%259F%26aufirst%3DMurat%26date%3D2021%26date%3D2021%26volume%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi-Ae  Kang</span>, <span class="hlFld-ContribAuthor ">Jongsung  Lee</span>, <span class="hlFld-ContribAuthor ">Chang Min  Lee</span>, <span class="hlFld-ContribAuthor ">Ho Sung  Park</span>, <span class="hlFld-ContribAuthor ">Kyu Yun  Jang</span>, <span class="hlFld-ContribAuthor ">See-Hyoung  Park</span>. </span><span class="cited-content_cbyCitation_article-title">IL13RÎ±2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway. </span><span class="cited-content_cbyCitation_journal-name">Journal of Personalized Medicine</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 284. <a href="https://doi.org/10.3390/jpm11040284" title="DOI URL">https://doi.org/10.3390/jpm11040284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jpm11040284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjpm11040284%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Personalized%2520Medicine%26atitle%3DIL13R%2525CE%2525B12%252BIs%252BInvolved%252Bin%252Bthe%252BProgress%252Bof%252BRenal%252BCell%252BCarcinoma%252Bthrough%252Bthe%252BJAK2%25252FFOXO3%252BPathway%26aulast%3DKang%26aufirst%3DMi-Ae%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca  Begley</span>, <span class="hlFld-ContribAuthor ">Kacey  Anderson</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Watkins</span>, <span class="hlFld-ContribAuthor ">Winnie  Weng</span>, <span class="hlFld-ContribAuthor ">Lorraine  Ampaw</span>, <span class="hlFld-ContribAuthor ">Ann  Qin</span>, <span class="hlFld-ContribAuthor ">Brian P.  Kearney</span>, <span class="hlFld-ContribAuthor ">Anita  Mathias</span>. </span><span class="cited-content_cbyCitation_article-title">Lack of DrugâDrug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2021,</strong> <em>10 </em>
                                    (4)
                                     , 376-383. <a href="https://doi.org/10.1002/cpdd.870" title="DOI URL">https://doi.org/10.1002/cpdd.870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.870%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DLack%252Bof%252BDrug%2525E2%252580%252590Drug%252BInteraction%252BBetween%252BFilgotinib%25252C%252Ba%252BSelective%252BJAK1%252BInhibitor%25252C%252Band%252BOral%252BHormonal%252BContraceptives%252BLevonorgestrel%25252FEthinyl%252BEstradiol%252Bin%252BHealthy%252BVolunteers%26aulast%3DBegley%26aufirst%3DRebecca%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D376%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fani  Karagianni</span>, <span class="hlFld-ContribAuthor ">Christina  Piperi</span>, <span class="hlFld-ContribAuthor ">Vassiliki  Mpakou</span>, <span class="hlFld-ContribAuthor ">Aris  Spathis</span>, <span class="hlFld-ContribAuthor ">Periklis G.  Foukas</span>, <span class="hlFld-ContribAuthor ">Maria  Dalamaga</span>, <span class="hlFld-ContribAuthor ">Vasiliki  Pappa</span>, <span class="hlFld-ContribAuthor ">Evangelia  Papadavid</span>, . </span><span class="cited-content_cbyCitation_article-title">Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , e0248298. <a href="https://doi.org/10.1371/journal.pone.0248298" title="DOI URL">https://doi.org/10.1371/journal.pone.0248298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0248298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0248298%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DRuxolitinib%252Bwith%252Bresminostat%252Bexert%252Bsynergistic%252Bantitumor%252Beffects%252Bin%252BCutaneous%252BT-cell%252BLymphoma%26aulast%3DKaragianni%26aufirst%3DFani%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D3%26spage%3De0248298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karima  Alim</span>, <span class="hlFld-ContribAuthor ">Arnaud  BruyÃ¨re</span>, <span class="hlFld-ContribAuthor ">Alain  Lescoat</span>, <span class="hlFld-ContribAuthor ">Elodie  Jouan</span>, <span class="hlFld-ContribAuthor ">ValÃ©rie  Lecureur</span>, <span class="hlFld-ContribAuthor ">Marc  Le VÃ©e</span>, <span class="hlFld-ContribAuthor ">Olivier  Fardel</span>. </span><span class="cited-content_cbyCitation_article-title">Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , 259-271. <a href="https://doi.org/10.1080/17425255.2021.1862084" title="DOI URL">https://doi.org/10.1080/17425255.2021.1862084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1862084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1862084%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DInteractions%252Bof%252Bjanus%252Bkinase%252Binhibitors%252Bwith%252Bdrug%252Btransporters%252Band%252Bconsequences%252Bfor%252Bpharmacokinetics%252Band%252Btoxicity%26aulast%3DAlim%26aufirst%3DKarima%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3D259%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qin  Xu</span>, <span class="hlFld-ContribAuthor ">Xuexiao  Jin</span>, <span class="hlFld-ContribAuthor ">Yu  Jiang</span>, <span class="hlFld-ContribAuthor ">Xin  Dang</span>, <span class="hlFld-ContribAuthor ">Yongmei  Han</span>. </span><span class="cited-content_cbyCitation_article-title">The relationship between JAK2(V617F) mutation and dermatomyositisâa case report and literature review. </span><span class="cited-content_cbyCitation_journal-name">Clinical Rheumatology</span><span> <strong>2021,</strong> <em>40 </em>
                                    (3)
                                     , 1147-1157. <a href="https://doi.org/10.1007/s10067-020-05286-y" title="DOI URL">https://doi.org/10.1007/s10067-020-05286-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10067-020-05286-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10067-020-05286-y%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Rheumatology%26atitle%3DThe%252Brelationship%252Bbetween%252BJAK2%252528V617F%252529%252Bmutation%252Band%252Bdermatomyositis%2525E2%252580%252594a%252Bcase%252Breport%252Band%252Bliterature%252Breview%26aulast%3DXu%26aufirst%3DQin%26date%3D2021%26date%3D2020%26volume%3D40%26issue%3D3%26spage%3D1147%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fanxun  Zeng</span>, <span class="hlFld-ContribAuthor ">Shiliang  Li</span>, <span class="hlFld-ContribAuthor ">Guantian  Yang</span>, <span class="hlFld-ContribAuthor ">Yating  Luo</span>, <span class="hlFld-ContribAuthor ">Tiantian  Qi</span>, <span class="hlFld-ContribAuthor ">Yingfan  Liang</span>, <span class="hlFld-ContribAuthor ">Tingyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Letian  Zhang</span>, <span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 795-809. <a href="https://doi.org/10.1016/j.apsb.2020.10.008" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bmolecular%252Bmodeling%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bacrylamide%252Bderivatives%252Bas%252Bpotent%252Binhibitors%252Bof%252Bhuman%252Bdihydroorotate%252Bdehydrogenase%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DZeng%26aufirst%3DFanxun%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D795%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elvira  Favoino</span>, <span class="hlFld-ContribAuthor ">Marcella  Prete</span>, <span class="hlFld-ContribAuthor ">Giacomo  Catacchio</span>, <span class="hlFld-ContribAuthor ">Piero  Ruscitti</span>, <span class="hlFld-ContribAuthor ">Luca  Navarini</span>, <span class="hlFld-ContribAuthor ">Roberto  Giacomelli</span>, <span class="hlFld-ContribAuthor ">Federico  Perosa</span>. </span><span class="cited-content_cbyCitation_article-title">Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. </span><span class="cited-content_cbyCitation_journal-name">Autoimmunity Reviews</span><span> <strong>2021,</strong> <em>20 </em>
                                    (3)
                                     , 102750. <a href="https://doi.org/10.1016/j.autrev.2021.102750" title="DOI URL">https://doi.org/10.1016/j.autrev.2021.102750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.autrev.2021.102750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.autrev.2021.102750%26sid%3Dliteratum%253Aachs%26jtitle%3DAutoimmunity%2520Reviews%26atitle%3DWorking%252Band%252Bsafety%252Bprofiles%252Bof%252BJAK%25252FSTAT%252Bsignaling%252Binhibitors.%252BAre%252Bthese%252Bsmall%252Bmolecules%252Balso%252Bsmart%25253F%26aulast%3DFavoino%26aufirst%3DElvira%26date%3D2021%26volume%3D20%26issue%3D3%26spage%3D102750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kishor D.  Mane</span>, <span class="hlFld-ContribAuthor ">Rohit B.  Kamble</span>, <span class="hlFld-ContribAuthor ">Gurunath  Suryavanshi</span>. </span><span class="cited-content_cbyCitation_article-title">Short enantioselective total synthesis of (+)-tofacitinib. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>67 </em>, 152838. <a href="https://doi.org/10.1016/j.tetlet.2021.152838" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.152838</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.152838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.152838%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DShort%252Benantioselective%252Btotal%252Bsynthesis%252Bof%252B%252528%25252B%252529-tofacitinib%26aulast%3DMane%26aufirst%3DKishor%2BD.%26date%3D2021%26volume%3D67%26spage%3D152838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irene E.  Braithwaite</span>, <span class="hlFld-ContribAuthor ">Fang  Cai</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Tom</span>, <span class="hlFld-ContribAuthor ">Joshua M.  Galanter</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Owen</span>, <span class="hlFld-ContribAuthor ">Rui  Zhu</span>, <span class="hlFld-ContribAuthor ">Mathew  Williams</span>, <span class="hlFld-ContribAuthor ">Anna G.  McGregor</span>, <span class="hlFld-ContribAuthor ">Avi  Eliahu</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Durk</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Maria E.  Wilson</span>, <span class="hlFld-ContribAuthor ">Richard  Beasley</span>, <span class="hlFld-ContribAuthor ">Hubert  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: AÂ randomized, controlled, proof-of-activity trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Allergy and Clinical Immunology</span><span> <strong>2021,</strong> <em>391 </em><a href="https://doi.org/10.1016/j.jaci.2021.02.042" title="DOI URL">https://doi.org/10.1016/j.jaci.2021.02.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaci.2021.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaci.2021.02.042%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Allergy%2520and%2520Clinical%2520Immunology%26atitle%3DInhaled%252BJAK%252Binhibitor%252BGDC-0214%252Breduces%252Bexhaled%252Bnitric%252Boxide%252Bin%252Bpatients%252Bwith%252Bmild%252Basthma%25253A%252BA%2525C2%2525A0randomized%25252C%252Bcontrolled%25252C%252Bproof-of-activity%252Btrial%26aulast%3DBraithwaite%26aufirst%3DIrene%2BE.%26date%3D2021%26volume%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlos  Taxonera</span>, <span class="hlFld-ContribAuthor ">David  Olivares</span>, <span class="hlFld-ContribAuthor ">Cristina  Alba</span>. </span><span class="cited-content_cbyCitation_article-title">Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1093/ibd/izab011" title="DOI URL">https://doi.org/10.1093/ibd/izab011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izab011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizab011%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DReal-World%252BEffectiveness%252Band%252BSafety%252Bof%252BTofacitinib%252Bin%252BPatients%252BWith%252BUlcerative%252BColitis%25253A%252BSystematic%252BReview%252BWith%252BMeta-Analysis%26aulast%3DTaxonera%26aufirst%3DCarlos%26date%3D2021%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun Hee  Jang</span>, <span class="hlFld-ContribAuthor ">Ji Hyeon  Ju</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinase inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Korean Medical Association</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 105-108. <a href="https://doi.org/10.5124/jkma.2021.64.2.105" title="DOI URL">https://doi.org/10.5124/jkma.2021.64.2.105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5124/jkma.2021.64.2.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5124%2Fjkma.2021.64.2.105%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Korean%2520Medical%2520Association%26atitle%3DJanus%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DJang%26aufirst%3DSun%2BHee%26date%3D2021%26volume%3D64%26issue%3D2%26spage%3D105%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Yun</span>, <span class="hlFld-ContribAuthor ">Jingyu  Chen</span>, <span class="hlFld-ContribAuthor ">Xuejiao  Wang</span>, <span class="hlFld-ContribAuthor ">Yingzhuo  Li</span>, <span class="hlFld-ContribAuthor ">Zhifan  Hu</span>, <span class="hlFld-ContribAuthor ">Pingting  Yang</span>, <span class="hlFld-ContribAuthor ">Ling  Qin</span>, . </span><span class="cited-content_cbyCitation_article-title">Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2021,</strong> <em>2021 </em>, 1-9. <a href="https://doi.org/10.1155/2021/8877056" title="DOI URL">https://doi.org/10.1155/2021/8877056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2021/8877056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2021%2F8877056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DTofacitinib%252BAmeliorates%252BLipopolysaccharide-Induced%252BAcute%252BKidney%252BInjury%252Bby%252BBlocking%252Bthe%252BJAK-STAT1%25252FSTAT3%252BSignaling%252BPathway%26aulast%3DYun%26aufirst%3DYang%26date%3D2021%26volume%3D2021%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masahiro  Kondo</span>, <span class="hlFld-ContribAuthor ">Yohko  Murakawa</span>, <span class="hlFld-ContribAuthor ">Manabu  Honda</span>, <span class="hlFld-ContribAuthor ">Takashi  Yanagawa</span>, <span class="hlFld-ContribAuthor ">Makoto  Nagasaki</span>, <span class="hlFld-ContribAuthor ">Mayuko  Moriyama</span>, <span class="hlFld-ContribAuthor ">Yohei  Watanabe</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Kakimaru</span>. </span><span class="cited-content_cbyCitation_article-title">A case of rheumatoid arthritis with multiple lung rheumatoid nodules successfully treated with tofacitinib. </span><span class="cited-content_cbyCitation_journal-name">Modern Rheumatology Case Reports</span><span> <strong>2021,</strong> <em>5 </em>
                                    (1)
                                     , 1-5. <a href="https://doi.org/10.1080/24725625.2020.1777677" title="DOI URL">https://doi.org/10.1080/24725625.2020.1777677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/24725625.2020.1777677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F24725625.2020.1777677%26sid%3Dliteratum%253Aachs%26jtitle%3DModern%2520Rheumatology%2520Case%2520Reports%26atitle%3DA%252Bcase%252Bof%252Brheumatoid%252Barthritis%252Bwith%252Bmultiple%252Blung%252Brheumatoid%252Bnodules%252Bsuccessfully%252Btreated%252Bwith%252Btofacitinib%26aulast%3DKondo%26aufirst%3DMasahiro%26date%3D2021%26date%3D2020%26volume%3D5%26issue%3D1%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Mary E.  Banker</span>, <span class="hlFld-ContribAuthor ">Robert M.  Czerwinski</span>, <span class="hlFld-ContribAuthor ">Max  Kuhn</span>, <span class="hlFld-ContribAuthor ">Tristan S.  Maurer</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Arthur J.  Wittwer</span>. </span><span class="cited-content_cbyCitation_article-title">The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>29 </em>, 115865. <a href="https://doi.org/10.1016/j.bmc.2020.115865" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115865%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Badvantages%252Bof%252Bdescribing%252Bcovalent%252Binhibitor%252Bin%252Bvitro%252Bpotencies%252Bby%252BIC50%252Bat%252Ba%252Bfixed%252Btime%252Bpoint.%252BIC50%252Bdetermination%252Bof%252Bcovalent%252Binhibitors%252Bprovides%252Bmeaningful%252Bdata%252Bto%252Bmedicinal%252Bchemistry%252Bfor%252BSAR%252Boptimization%26aulast%3DThorarensen%26aufirst%3DAtli%26date%3D2021%26volume%3D29%26spage%3D115865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grzegorz  GrzeÅk</span>, <span class="hlFld-ContribAuthor ">Anita  WoÅºniak-WiÅniewska</span>, <span class="hlFld-ContribAuthor ">Jan  BÅaÅ¼ejewski</span>, <span class="hlFld-ContribAuthor ">Bartosz  GÃ³rny</span>, <span class="hlFld-ContribAuthor ">Åukasz  WoÅowiec</span>, <span class="hlFld-ContribAuthor ">Daniel  Rogowicz</span>, <span class="hlFld-ContribAuthor ">Alicja  Nowaczyk</span>. </span><span class="cited-content_cbyCitation_article-title">The Interactions of Nintedanib and Oral AnticoagulantsâMolecular Mechanisms and Clinical Implications. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 282. <a href="https://doi.org/10.3390/ijms22010282" title="DOI URL">https://doi.org/10.3390/ijms22010282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22010282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22010282%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BInteractions%252Bof%252BNintedanib%252Band%252BOral%252BAnticoagulants%2525E2%252580%252594Molecular%252BMechanisms%252Band%252BClinical%252BImplications%26aulast%3DGrze%25C5%259Bk%26aufirst%3DGrzegorz%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charalampos  Skarlis</span>, <span class="hlFld-ContribAuthor ">Clio P.  Mavragani</span>. </span><span class="cited-content_cbyCitation_article-title">Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00071-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00071-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00071-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00071-2%26sid%3Dliteratum%253Aachs%26atitle%3DImmune%252BDysfunction%252Band%252BDrug%252BTargets%252Bin%252BAutoinflammatory%252BSyndromes%26aulast%3DSkarlis%26aufirst%3DCharalampos%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elleni J  Pippis</span>, <span class="hlFld-ContribAuthor ">Bruce R  Yacyshyn</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2020,</strong> <em>18 </em><a href="https://doi.org/10.1093/ibd/izaa318" title="DOI URL">https://doi.org/10.1093/ibd/izaa318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izaa318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizaa318%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DClinical%252Band%252BMechanistic%252BCharacteristics%252Bof%252BCurrent%252BJAK%252BInhibitors%252Bin%252BIBD%26aulast%3DPippis%26aufirst%3DElleni%2BJ%26date%3D2020%26date%3D2020%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Genu  George</span>, <span class="hlFld-ContribAuthor ">G. L.  Shyni</span>, <span class="hlFld-ContribAuthor ">K. G.  Raghu</span>. </span><span class="cited-content_cbyCitation_article-title">Current and novel therapeutic targets in the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Inflammopharmacology</span><span> <strong>2020,</strong> <em>28 </em>
                                    (6)
                                     , 1457-1476. <a href="https://doi.org/10.1007/s10787-020-00757-9" title="DOI URL">https://doi.org/10.1007/s10787-020-00757-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10787-020-00757-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10787-020-00757-9%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammopharmacology%26atitle%3DCurrent%252Band%252Bnovel%252Btherapeutic%252Btargets%252Bin%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DGeorge%26aufirst%3DGenu%26date%3D2020%26date%3D2020%26volume%3D28%26issue%3D6%26spage%3D1457%26epage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanxiao  You</span>, <span class="hlFld-ContribAuthor ">Dong  Xu</span>, <span class="hlFld-ContribAuthor ">Jiuliang  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Xinping  Tian</span>, <span class="hlFld-ContribAuthor ">Mengtao  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofeng  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibitors: Prospects in Connective Tissue Diseases. </span><span class="cited-content_cbyCitation_journal-name">Clinical Reviews in Allergy & Immunology</span><span> <strong>2020,</strong> <em>59 </em>
                                    (3)
                                     , 334-351. <a href="https://doi.org/10.1007/s12016-020-08786-6" title="DOI URL">https://doi.org/10.1007/s12016-020-08786-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12016-020-08786-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12016-020-08786-6%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Reviews%2520in%2520Allergy%2520%2526%2520Immunology%26atitle%3DJAK%252BInhibitors%25253A%252BProspects%252Bin%252BConnective%252BTissue%252BDiseases%26aulast%3DYou%26aufirst%3DHanxiao%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D3%26spage%3D334%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayida  Al Khalili</span>, <span class="hlFld-ContribAuthor ">Jan P.  Dutz</span>. </span><span class="cited-content_cbyCitation_article-title">Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Rheumatology</span><span> <strong>2020,</strong> <em>6 </em>
                                    (4)
                                     , 406-417. <a href="https://doi.org/10.1007/s40674-020-00155-w" title="DOI URL">https://doi.org/10.1007/s40674-020-00155-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40674-020-00155-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40674-020-00155-w%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Rheumatology%26atitle%3DJanus%252BKinase%252BInhibition%252Band%252BSLE%25253A%252BIs%252Bthis%252Ba%252BPlausible%252BTreatment%252BOption%252Bfor%252BSLE%25253F%26aulast%3DAl%2BKhalili%26aufirst%3DAyida%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D4%26spage%3D406%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">FrÃ©dÃ©ric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susanna  Tse</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Sujatha  Menon</span>, <span class="hlFld-ContribAuthor ">Pankaj  Gupta</span>, <span class="hlFld-ContribAuthor ">Sriram  Krishnaswami</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential DrugâDrug Interactions or in Special Populations: An Example Using Tofacitinib. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Pharmacology</span><span> <strong>2020,</strong> <em>60 </em>
                                    (12)
                                     , 1617-1628. <a href="https://doi.org/10.1002/jcph.1679" title="DOI URL">https://doi.org/10.1002/jcph.1679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcph.1679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcph.1679%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DApplication%252Bof%252BPhysiologically%252BBased%252BPharmacokinetic%252BModeling%252Bto%252BPredict%252BDrug%252BExposure%252Band%252BSupport%252BDosing%252BRecommendations%252Bfor%252BPotential%252BDrug%2525E2%252580%252590Drug%252BInteractions%252Bor%252Bin%252BSpecial%252BPopulations%25253A%252BAn%252BExample%252BUsing%252BTofacitinib%26aulast%3DTse%26aufirst%3DSusanna%26date%3D2020%26date%3D2020%26volume%3D60%26issue%3D12%26spage%3D1617%26epage%3D1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian S.  Gerstenberger</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Roger  Gifford</span>, <span class="hlFld-ContribAuthor ">Matthew C.  Griffor</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Brett D.  Hollingshead</span>, <span class="hlFld-ContribAuthor ">John D.  Knafels</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">James F.  Smith</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>. </span><span class="cited-content_cbyCitation_article-title">Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-65762-y" title="DOI URL">https://doi.org/10.1038/s41598-020-65762-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-65762-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-65762-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDemonstration%252Bof%252BIn%252BVitro%252Bto%252BIn%252BVivo%252BTranslation%252Bof%252Ba%252BTYK2%252BInhibitor%252BThat%252BShows%252BCross%252BSpecies%252BPotency%252BDifferences%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuya  Fujita</span>, <span class="hlFld-ContribAuthor ">Naoki  Matsuoka</span>, <span class="hlFld-ContribAuthor ">Jumpei  Temmoku</span>, <span class="hlFld-ContribAuthor ">Makiko  Furuya-Yashiro</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Asano</span>, <span class="hlFld-ContribAuthor ">Shuzo  Sato</span>, <span class="hlFld-ContribAuthor ">Haruki  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Watanabe</span>, <span class="hlFld-ContribAuthor ">Hideko  Kozuru</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Yatsuhashi</span>, <span class="hlFld-ContribAuthor ">Atsushi  Kawakami</span>, <span class="hlFld-ContribAuthor ">Kiyoshi  Migita</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. </span><span class="cited-content_cbyCitation_journal-name">BMC Immunology</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12865-020-00365-w" title="DOI URL">https://doi.org/10.1186/s12865-020-00365-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12865-020-00365-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12865-020-00365-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Immunology%26atitle%3DJAK%252Binhibitors%252Bimpair%252BGM-CSF-mediated%252Bsignaling%252Bin%252Binnate%252Bimmune%252Bcells%26aulast%3DFujita%26aufirst%3DYuya%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael F.  Robinson</span>, <span class="hlFld-ContribAuthor ">Nemanja  Damjanov</span>, <span class="hlFld-ContribAuthor ">Bojana  Stamenkovic</span>, <span class="hlFld-ContribAuthor ">Goran  Radunovic</span>, <span class="hlFld-ContribAuthor ">Alan  Kivitz</span>, <span class="hlFld-ContribAuthor ">Lori  Cox</span>, <span class="hlFld-ContribAuthor ">Zorayr  Manukyan</span>, <span class="hlFld-ContribAuthor ">Christopher  Banfield</span>, <span class="hlFld-ContribAuthor ">Michael  Saunders</span>, <span class="hlFld-ContribAuthor ">Deepa  Chandra</span>, <span class="hlFld-ContribAuthor ">Michael S.  Vincent</span>, <span class="hlFld-ContribAuthor ">Jessica  Mancuso</span>, <span class="hlFld-ContribAuthor ">Elena  Peeva</span>, <span class="hlFld-ContribAuthor ">Jean S.  Beebe</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Safety of PFâ06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With ModerateâtoâSevere Rheumatoid Arthritis and an Inadequate Response to Methotrexate. </span><span class="cited-content_cbyCitation_journal-name">Arthritis & Rheumatology</span><span> <strong>2020,</strong> <em>72 </em>
                                    (10)
                                     , 1621-1631. <a href="https://doi.org/10.1002/art.41316" title="DOI URL">https://doi.org/10.1002/art.41316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/art.41316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fart.41316%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520%2526%2520Rheumatology%26atitle%3DEfficacy%252Band%252BSafety%252Bof%252BPF%2525E2%252580%25259006651600%252B%252528Ritlecitinib%252529%25252C%252Ba%252BNovel%252BJAK3%25252FTEC%252BInhibitor%25252C%252Bin%252BPatients%252BWith%252BModerate%2525E2%252580%252590to%2525E2%252580%252590Severe%252BRheumatoid%252BArthritis%252Band%252Ban%252BInadequate%252BResponse%252Bto%252BMethotrexate%26aulast%3DRobinson%26aufirst%3DMichael%2BF.%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D10%26spage%3D1621%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marc R.  Becker</span>, <span class="hlFld-ContribAuthor ">Emily R.  Wearing</span>, <span class="hlFld-ContribAuthor ">Corinna S.  Schindler</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of azetidines via visible-light-mediated intermolecular [2+2] photocycloadditions. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 898-905. <a href="https://doi.org/10.1038/s41557-020-0541-1" title="DOI URL">https://doi.org/10.1038/s41557-020-0541-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41557-020-0541-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41557-020-0541-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bazetidines%252Bvia%252Bvisible-light-mediated%252Bintermolecular%252B%25255B2%25252B2%25255D%252Bphotocycloadditions%26aulast%3DBecker%26aufirst%3DMarc%2BR.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D898%26epage%3D905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akio  Morinobu</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Immunological Medicine</span><span> <strong>2020,</strong> <em>43 </em>
                                    (4)
                                     , 148-155. <a href="https://doi.org/10.1080/25785826.2020.1770948" title="DOI URL">https://doi.org/10.1080/25785826.2020.1770948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/25785826.2020.1770948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F25785826.2020.1770948%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunological%2520Medicine%26atitle%3DJAK%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DMorinobu%26aufirst%3DAkio%26date%3D2020%26date%3D2020%26volume%3D43%26issue%3D4%26spage%3D148%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuko  Kaneko</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and safety of peficitinib in rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Modern Rheumatology</span><span> <strong>2020,</strong> <em>30 </em>
                                    (5)
                                     , 773-778. <a href="https://doi.org/10.1080/14397595.2020.1794103" title="DOI URL">https://doi.org/10.1080/14397595.2020.1794103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14397595.2020.1794103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14397595.2020.1794103%26sid%3Dliteratum%253Aachs%26jtitle%3DModern%2520Rheumatology%26atitle%3DEfficacy%252Band%252Bsafety%252Bof%252Bpeficitinib%252Bin%252Brheumatoid%252Barthritis%26aulast%3DKaneko%26aufirst%3DYuko%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D773%26epage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arezoo  Hosseini</span>, <span class="hlFld-ContribAuthor ">Tohid  Gharibi</span>, <span class="hlFld-ContribAuthor ">Faroogh  Marofi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Javadian</span>, <span class="hlFld-ContribAuthor ">Zohreh  Babaloo</span>, <span class="hlFld-ContribAuthor ">Behzad  Baradaran</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2020,</strong> <em>235 </em>
                                    (9)
                                     , 5903-5924. <a href="https://doi.org/10.1002/jcp.29593" title="DOI URL">https://doi.org/10.1002/jcp.29593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.29593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.29593%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DJanus%252Bkinase%252Binhibitors%25253A%252BA%252Btherapeutic%252Bstrategy%252Bfor%252Bcancer%252Band%252Bautoimmune%252Bdiseases%26aulast%3DHosseini%26aufirst%3DArezoo%26date%3D2020%26date%3D2020%26volume%3D235%26issue%3D9%26spage%3D5903%26epage%3D5924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Reddy</span>, <span class="hlFld-ContribAuthor ">Stanley  Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibitors: What Is New?. </span><span class="cited-content_cbyCitation_journal-name">Current Rheumatology Reports</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s11926-020-00931-6" title="DOI URL">https://doi.org/10.1007/s11926-020-00931-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11926-020-00931-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11926-020-00931-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Rheumatology%2520Reports%26atitle%3DJAK%252BInhibitors%25253A%252BWhat%252BIs%252BNew%25253F%26aulast%3DReddy%26aufirst%3DVirginia%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rocio  Sedano</span>, <span class="hlFld-ContribAuthor ">Ahmed  Almradi</span>, <span class="hlFld-ContribAuthor ">Christopher  Ma</span>, <span class="hlFld-ContribAuthor ">Vipul  Jairath</span>, <span class="hlFld-ContribAuthor ">Brian G.  Feagan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Gastroenterology</span><span> <strong>2020,</strong> <em>18 </em>
                                    (3)
                                     , 442-461. <a href="https://doi.org/10.1007/s11938-020-00299-7" title="DOI URL">https://doi.org/10.1007/s11938-020-00299-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11938-020-00299-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11938-020-00299-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Gastroenterology%26atitle%3DNovel%252BTherapeutics%252Bfor%252Bthe%252BTreatment%252Bof%252BIBD%25253A%252BCurrent%252BStatus%252Band%252BFuture%252BDirections%26aulast%3DSedano%26aufirst%3DRocio%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D3%26spage%3D442%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Safa  Daoud</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore modeling of JAK1: A target infested with activity-cliffs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>99 </em>, 107615. <a href="https://doi.org/10.1016/j.jmgm.2020.107615" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107615%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DPharmacophore%252Bmodeling%252Bof%252BJAK1%25253A%252BA%252Btarget%252Binfested%252Bwith%252Bactivity-cliffs%26aulast%3DDaoud%26aufirst%3DSafa%26date%3D2020%26volume%3D99%26spage%3D107615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enriqueta  Vallejo-YagÃ¼e</span>, <span class="hlFld-ContribAuthor ">Stefan  Weiler</span>, <span class="hlFld-ContribAuthor ">Raphael  Micheroli</span>, <span class="hlFld-ContribAuthor ">Andrea M.  Burden</span>. </span><span class="cited-content_cbyCitation_article-title">Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase. </span><span class="cited-content_cbyCitation_journal-name">Drug Safety</span><span> <strong>2020,</strong> <em>43 </em>
                                    (9)
                                     , 881-891. <a href="https://doi.org/10.1007/s40264-020-00958-9" title="DOI URL">https://doi.org/10.1007/s40264-020-00958-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40264-020-00958-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40264-020-00958-9%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Safety%26atitle%3DThromboembolic%252BSafety%252BReporting%252Bof%252BTofacitinib%252Band%252BBaricitinib%25253A%252BAn%252BAnalysis%252Bof%252Bthe%252BWHO%252BVigiBase%26aulast%3DVallejo-Yag%25C3%25BCe%26aufirst%3DEnriqueta%26date%3D2020%26date%3D2020%26volume%3D43%26issue%3D9%26spage%3D881%26epage%3D891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjiv  Singh</span>, <span class="hlFld-ContribAuthor ">Shantanu  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2020,</strong> <em>86 </em>, 106731. <a href="https://doi.org/10.1016/j.intimp.2020.106731" title="DOI URL">https://doi.org/10.1016/j.intimp.2020.106731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2020.106731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2020.106731%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DJAK-STAT%252Binhibitors%25253A%252BImmersing%252Btherapeutic%252Bapproach%252Bfor%252Bmanagement%252Bof%252Brheumatoid%252Barthritis%26aulast%3DSingh%26aufirst%3DSanjiv%26date%3D2020%26volume%3D86%26spage%3D106731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Rivera-Izquierdo</span>, <span class="hlFld-ContribAuthor ">Maria del Carmen  Valero-Ubierna</span>, <span class="hlFld-ContribAuthor ">Pelayo  Nieto-GÃ³mez</span>, <span class="hlFld-ContribAuthor ">MarÃ­a Dolores  MartÃ­nez-BellÃ³n</span>, <span class="hlFld-ContribAuthor ">NicolÃ¡s Francisco  FernÃ¡ndez-MartÃ­nez</span>, <span class="hlFld-ContribAuthor ">JosÃ© Luis  Barranco-Quintana</span>. </span><span class="cited-content_cbyCitation_article-title">Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Vaccines</span><span> <strong>2020,</strong> <em>19 </em>
                                    (8)
                                     , 727-744. <a href="https://doi.org/10.1080/14760584.2020.1800462" title="DOI URL">https://doi.org/10.1080/14760584.2020.1800462</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14760584.2020.1800462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14760584.2020.1800462%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Vaccines%26atitle%3DVaccination%252Bin%252Bpatients%252Bunder%252Bmonoclonal%252Bantibody%252Btreatment%25253A%252Ban%252Bupdated%252Bcomprehensive%252Breview%26aulast%3DRivera-Izquierdo%26aufirst%3DMario%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D8%26spage%3D727%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adriana  Coricello</span>, <span class="hlFld-ContribAuthor ">Francesco  Mesiti</span>, <span class="hlFld-ContribAuthor ">Antonio  Lupia</span>, <span class="hlFld-ContribAuthor ">Annalisa  Maruca</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>. </span><span class="cited-content_cbyCitation_article-title">Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (15)
                                     , 3321. <a href="https://doi.org/10.3390/molecules25153321" title="DOI URL">https://doi.org/10.3390/molecules25153321</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25153321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25153321%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DInside%252BPerspective%252Bof%252Bthe%252BSynthetic%252Band%252BComputational%252BToolbox%252Bof%252BJAK%252BInhibitors%25253A%252BRecent%252BUpdates%26aulast%3DCoricello%26aufirst%3DAdriana%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D15%26spage%3D3321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuan  Lu</span>, <span class="hlFld-ContribAuthor ">Weibin  Wu</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zijian  Liu</span>, <span class="hlFld-ContribAuthor ">Boren  Xiao</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Anqi  Li</span>, <span class="hlFld-ContribAuthor ">Dawei  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (14)
                                     , 127225. <a href="https://doi.org/10.1016/j.bmcl.2020.127225" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127225%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Btriazolo%252B%25255B1%25252C5-a%25255D%252Bpyridine%252Bderivatives%252Bas%252Bnovel%252BJAK1%25252F2%252Binhibitors%26aulast%3DLu%26aufirst%3DKuan%26date%3D2020%26volume%3D30%26issue%3D14%26spage%3D127225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arisa  Yaekura</span>, <span class="hlFld-ContribAuthor ">Kohsuke  Yoshida</span>, <span class="hlFld-ContribAuthor ">Kanta  Morii</span>, <span class="hlFld-ContribAuthor ">Yuto  Oketani</span>, <span class="hlFld-ContribAuthor ">Ikumi  Okumura</span>, <span class="hlFld-ContribAuthor ">Kenta  Kaneshiro</span>, <span class="hlFld-ContribAuthor ">Nao  Shibanuma</span>, <span class="hlFld-ContribAuthor ">Yoshitada  Sakai</span>, <span class="hlFld-ContribAuthor ">Akira  Hashiramoto</span>. </span><span class="cited-content_cbyCitation_article-title">Chronotherapy targeting cytokine secretion attenuates collagen-induced arthritis in mice. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2020,</strong> <em>84 </em>, 106549. <a href="https://doi.org/10.1016/j.intimp.2020.106549" title="DOI URL">https://doi.org/10.1016/j.intimp.2020.106549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2020.106549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2020.106549%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DChronotherapy%252Btargeting%252Bcytokine%252Bsecretion%252Battenuates%252Bcollagen-induced%252Barthritis%252Bin%252Bmice%26aulast%3DYaekura%26aufirst%3DArisa%26date%3D2020%26volume%3D84%26spage%3D106549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio Salvatore  Macaluso</span>, <span class="hlFld-ContribAuthor ">Iago  RodrÃ­guez-Lago</span>. </span><span class="cited-content_cbyCitation_article-title">JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Metabolism</span><span> <strong>2020,</strong> <em>21 </em>
                                    (4)
                                     , 247-255. <a href="https://doi.org/10.2174/1389200221666200310111409" title="DOI URL">https://doi.org/10.2174/1389200221666200310111409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389200221666200310111409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389200221666200310111409%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26atitle%3DJAK%252BInhibition%252Bas%252Ba%252BTherapeutic%252BStrategy%252Bfor%252BInflammatory%252BBowel%252BDisease%26aulast%3DMacaluso%26aufirst%3DFabio%2BSalvatore%26date%3D2020%26volume%3D21%26issue%3D4%26spage%3D247%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danielle  Peterson</span>, <span class="hlFld-ContribAuthor ">William  Damsky</span>, <span class="hlFld-ContribAuthor ">Brett  King</span>. </span><span class="cited-content_cbyCitation_article-title">The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Academy of Dermatology</span><span> <strong>2020,</strong> <em>82 </em>
                                    (6)
                                     , e223-e226. <a href="https://doi.org/10.1016/j.jaad.2020.03.099" title="DOI URL">https://doi.org/10.1016/j.jaad.2020.03.099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaad.2020.03.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaad.2020.03.099%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Academy%2520of%2520Dermatology%26atitle%3DThe%252Buse%252Bof%252BJanus%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btime%252Bof%252Bsevere%252Bacute%252Brespiratory%252Bsyndrome%252Bcoronavirus%252B2%252B%252528SARS-CoV-2%252529%26aulast%3DPeterson%26aufirst%3DDanielle%26date%3D2020%26volume%3D82%26issue%3D6%26spage%3De223%26epage%3De226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azucena  Salas</span>, <span class="hlFld-ContribAuthor ">Cristian  Hernandez-Rocha</span>, <span class="hlFld-ContribAuthor ">Marjolijn  Duijvestein</span>, <span class="hlFld-ContribAuthor ">William  Faubion</span>, <span class="hlFld-ContribAuthor ">Dermot  McGovern</span>, <span class="hlFld-ContribAuthor ">Severine  Vermeire</span>, <span class="hlFld-ContribAuthor ">Stefania  Vetrano</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">JAKâSTAT pathway targeting for the treatment of inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Gastroenterology & Hepatology</span><span> <strong>2020,</strong> <em>17 </em>
                                    (6)
                                     , 323-337. <a href="https://doi.org/10.1038/s41575-020-0273-0" title="DOI URL">https://doi.org/10.1038/s41575-020-0273-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41575-020-0273-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41575-020-0273-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DJAK%2525E2%252580%252593STAT%252Bpathway%252Btargeting%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DSalas%26aufirst%3DAzucena%26date%3D2020%26date%3D2020%26volume%3D17%26issue%3D6%26spage%3D323%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura A.  Lucaciu</span>, <span class="hlFld-ContribAuthor ">Radu  Seicean</span>, <span class="hlFld-ContribAuthor ">Andrada  Seicean</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? â a systematic review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Gastroenterology & Hepatology</span><span> <strong>2020,</strong> <em>32 </em>
                                    (6)
                                     , 669-677. <a href="https://doi.org/10.1097/MEG.0000000000001730" title="DOI URL">https://doi.org/10.1097/MEG.0000000000001730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MEG.0000000000001730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMEG.0000000000001730%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DSmall%252Bmolecule%252Bdrugs%252Bin%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bbowel%252Bdiseases%25253A%252Bwhich%252Bone%25252C%252Bwhen%252Band%252Bwhy%25253F%252B%2525E2%252580%252593%252Ba%252Bsystematic%252Breview%26aulast%3DLucaciu%26aufirst%3DLaura%2BA.%26date%3D2020%26volume%3D32%26issue%3D6%26spage%3D669%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Qianqian  Yu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Wenqing  Liang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00083" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00083%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DTheoretical%252BExploring%252BSelective-Binding%252BMechanisms%252Bof%252BJAK3%252Bby%252B3D-QSAR%25252C%252BMolecular%252BDynamics%252BSimulation%252Band%252BFree%252BEnergy%252BCalculation%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David F.  Choy</span>, <span class="hlFld-ContribAuthor ">Joseph R.  Arron</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond type 2 cytokines in asthma - new insights from old clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2020,</strong> <em>24 </em>
                                    (5)
                                     , 463-475. <a href="https://doi.org/10.1080/14728222.2020.1744567" title="DOI URL">https://doi.org/10.1080/14728222.2020.1744567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728222.2020.1744567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728222.2020.1744567%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DBeyond%252Btype%252B2%252Bcytokines%252Bin%252Basthma%252B-%252Bnew%252Binsights%252Bfrom%252Bold%252Bclinical%252Btrials%26aulast%3DChoy%26aufirst%3DDavid%2BF.%26date%3D2020%26date%3D2020%26volume%3D24%26issue%3D5%26spage%3D463%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm401490p&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm401490p%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=255&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0012.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cytokine receptor superfamilies and associated signal transduction pathways. Protein kinases feature prominently as mediators in signal transduction. The complex nature of these signaling pathways lead to redundancies in some cases. However, there are no known compensatory pathways around JAK/STAT. Furthermore, many cytokine receptors lack intrinsic kinase activity, instead relying on associated tyrosine kinases, such as the JAKs to transmit signals from the extracellular environment to the nucleus. Consequently, many cytokines and growth factors important for a variety of immune, inflammatory, and hematopoietic functions signal through JAK/STAT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cytokine signaling through the JAK/STAT pathway. Cytokine binding to the receptor leads to JAK activation and phosphorylation of the JAKs and associated receptors. Phosphorylation of the receptors in turn initiates recruitment of the STATs via their SH2 domains and subsequent phosphorylation of STAT proteins. The phosphorylated STAT homodimers or heterodimers then translocate to the nucleus where they bind to specific DNA binding sites regulating gene transcription that leads to changes in cellular function.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biological significance of signaling through different JAK combinations. Cytokine signaling is mediated by specific JAK and STAT combinations due to preferential binding to the intracellular domains of the individual cytokine receptor chains. For example, JAK3 only associates with the Î³-common chain and therefore only mediates IL-2, -4, -7, -9, -15, and -21 signaling, whereas JAK1 plays a broader role in cytokine signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic of JAK structural domains. The JAKs all contain seven homology regions (JH) and four structural domains. A characteristic feature of the JAKs is the presence of a pseudo-kinase domain JH2 that exerts regulatory function over the catalytic kinase domain JH1. The SH2 and FERM domains provide structural and regulatory control over the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Schematic of JAK3 structure and site specific inactivating mutations leading to a SCID phenotype or activating mutations leading to hematological malignancies. (A) Many mutations have been identified in JAK3 that lead to a SCID phenotype in humans. This phenotype results from the disruption of normal signaling of the Î³<sub>c</sub>-dependent cytokines that are important for T cell function, development, and homeostasis. Mutations have been identified in all of the structural domains of the kinase. Therefore, abrogation of normal catalytic activity can result from abnormalities in structural, regulatory, or catalytic function. (B) Gain of function mutations have also been identified in JAK3. These mutations are associated with lymphoproliferative disorders.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Homology in JAK family ATP binding site. The JAKs exhibit a high degree of homology in the ATP binding site. This sequence alignment illustrates in color and in three dimensions, where amino acid differences occur across the JAK family.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal structure of tofacitinib (purple) with JAK3 showing overlay with ATP (green). This overlay illustrates the ATP competitive behavior of tofacitinib (<b>1</b>). The pyrrolopyrimidine heterocycle of <b>1</b> binds to the hinge region of the kinase where the purine of ATP binds. The piperidine headgroup scaffold of <b>1</b> positions the cyanoacetamide group toward the glycine-rich loop (P-loop) and the ring methyl into a lipophilic pocket toward the C-terminal lobe at the base of the active site. This binding mode and arrangement of structural features of the inhibitor are believed to impart the high degree of kinome selectivity observed for the JAK family.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibitors exhibiting enhanced selectivity within the JAK family. By targeting of specific amino acid residues and aided by single crystal X-ray structures, it is possible to achieve some degree of enhanced selectivity within the JAK family. Compound <b>2</b> from Genentech achieves enhanced JAK1 selectivity by specifically targeting an interaction with E966 (JAK1). Rocheâs inhibitor (<b>3</b>) exhibits enhanced selectivity for JAK3 through a targeted, lipophilic interaction with C909 of JAK3. Novartisâ JAK3 inhibitor (<b>4</b>) derives its selectivity through specific lipophilic interactions and a key through water hydrogen bond with the backbone of JAK3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Experimental and approved JAK inhibitors. Compounds <b>1</b> and <b>5</b> are the only JAK inhibitors, to date, to have received regulatory approvals. The other inhibitors are in various stages of clinical development across several inflammatory indications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Evolution of compound structures from HTS lead (<b>9</b>) to tofacitinib (<b>1</b>). Progression of the Pfizer JAK inhibitor from HTS lead to clinical candidate (<b>1</b>) is shown. This schematic of seminal compounds represents an approximately 3-year medicinal chemistry effort wherein greater than 1000 synthetic analogues in this pyrrolopyrimidine series were prepared and evaluated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/medium/jm-2013-01490p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Progression of Galapagos lead to filgotinib (<b>8</b>). Two sites of the original lead molecule <b>15</b> were optimized leading to <b>8</b>. The conserved triazolopyridine cyclopropanecarboxamide moiety is reported to be a key hinge-binding pharmacophoric feature for the series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm401490p/production/images/large/jm-2013-01490p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401490p&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 84 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leonard, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">JAKS and STATS: biological implications</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1146%2Fannurev.immunol.16.1.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=9597132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK1cXislygurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=293-322&author=W.+J.+Leonardauthor=J.+J.+O%E2%80%99Shea&title=JAKS+and+STATS%3A+biological+implications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">JAKS and STATS: Biological implications</span></div><div class="casAuthors">Leonard, Warren J.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-322</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 185 refs.  Cytokines and interferons are mols. that play central roles in the regulation of a wide array of cellular functions in the lympho-hematopoietic system.  These factors stimulate proliferation, differentiation, and survival signals, as well as specialized functions in host resistance to pathogens.  Although cytokines are known to activate multiple signaling pathways that together mediate these important functions, one of these pathways, the Jak-STAT pathway, is the focus of this chapter.  This pathway is triggered by both cytokines and interferons, and it very rapidly allows the transduction of an extracellular signal into the nucleus.  The pathway uses a novel mechanism in which cytosolic latent transcription factors, known as signal transducers and activators of transcription (STATs), are tyrosine phosphorylated by Janus family tyrosine kinases (Jaks), allowing STAT protein dimerization and nuclear translocation.  STATs then can modulate the expression of target genes.  The basic biol. of this system, including the range of known Jaks and STATs, is discussed, as are the defects in animals and human lacking some of these signaling mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkrO-nJd5D_LVg90H21EOLACvtfcHk0lifSojH19VW1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislygurs%253D&md5=ac5eeeb0159c2c8769e2cb28720cdf98</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.16.1.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.16.1.293%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAKS%2520and%2520STATS%253A%2520biological%2520implications%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1998%26volume%3D16%26spage%3D293%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases in immune cell signaling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">â</span> <span class="NLM_lpage">287</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+in+immune+cell+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lifSojH19VW1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520in%2520immune%2520cell%2520signaling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1002%2Fjlb.60.4.441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=8864127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1996&pages=441-452&author=J.+A.+Johnstonauthor=C.+M.+Baconauthor=M.+C.+Riedyauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+IL-2+and+related+cytokines%3A+JAKs%2C+STATs%2C+and+relationship+to+immunodeficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency</span></div><div class="casAuthors">Johnston, James A.; Bacon, Chris M.; Riedy, M. C.; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review with 153 refs.  Cytokines that bind to the interleukin-2 (IL-2) receptor common gamma chain (Î³c), including IL-2, IL-4, IL-7, IL-9, and IL-15, are important for the growth and differentiation of T and B lymphocytes, natural killer cells, macrophages, and monocytes.  These cytokines have overlapping biol. effects that in part result from the use of the shared receptor subunit Î³c.  Recently it has become clear that these cytokines activate a no. of important intracellular signaling mols., including the Janus kinases JAK1 and JAK3 and members of the transcription factor family of signal transducers and activators of transcription (STATs).  The discovery of these signaling pathways has led to important new insights into their role of lymphocyte maturation, as it has emerged that mutations in the genes encoding both Î³c and JAK3 result in similar forms of severe combined immunodeficiency (SCID).  In this review we examine the structure and function of cytokine receptors and the signaling pathways involved in their regulation of gene expression.  Furthermore, we discuss recent advances that have led to a better understanding of how cytokines elicit intracellular responses, as well as their role in normal lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBS-4Fw4Io7Vg90H21EOLACvtfcHk0lg8Jt-f51S5Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVSls78%253D&md5=6ccea65ed0126878728f639506a565ac</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1002%2Fjlb.60.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlb.60.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DBacon%26aufirst%3DC.%2BM.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520IL-2%2520and%2520related%2520cytokines%253A%2520JAKs%252C%2520STATs%252C%2520and%2520relationship%2520to%2520immunodeficiency%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D1996%26volume%3D60%26spage%3D441%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plenge, R.</span><span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">550</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kontzias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">â</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.coph.2012.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22819198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=464-470&author=A.+Kontziasauthor=A.+Kotlyarauthor=A.+Laurenceauthor=P.+Changelianauthor=J.+J.+O%E2%80%99Shea&title=Jakinibs%3A+a+new+class+of+kinase+inhibitors+in+cancer+and+autoimmune+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease</span></div><div class="casAuthors">Kontzias, Apostolos; Kotlyar, Alexander; Laurence, Arian; Changelian, Paul; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-470</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines are crit. for normal cell growth and immunoregulation but also contribute to growth of malignant cells and drive immune-mediated disease.  A large subset of immunoregulatory cytokines uses the type I and type II cytokine receptors and pharmacol. targeting of these cytokines/cytokines receptors has proven to be efficacious in treating immune and inflammatory diseases.  These receptors rely on Janus family of kinases (Jaks) for signal transduction.  Recently the first Jak inhibitor (jakinib) has been approved by the FDA and a second has been recommended for approval.  Many other Jakinibs are likely to follow and in this brief review, we will discuss the state-of-the art of this new class of pharmacol. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJV4I6HPAx7Vg90H21EOLACvtfcHk0lg8Jt-f51S5Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVymsLbE&md5=22bcfa4414642f3d72214c4d4be84e2c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DKontzias%26aufirst%3DA.%26aulast%3DKotlyar%26aufirst%3DA.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DChangelian%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJakinibs%253A%2520a%2520new%2520class%2520of%2520kinase%2520inhibitors%2520in%2520cancer%2520and%2520autoimmune%2520disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D464%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lg8Jt-f51S5Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J.</span><span> </span><span class="NLM_article-title">JAK kinases in health and disease: an update</span> <span class="citation_source-journal">Open Rheumatol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+kinases+in+health+and+disease%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0ljrN5vnBA6COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520kinases%2520in%2520health%2520and%2520disease%253A%2520an%2520update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutra, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span> </span><span class="NLM_article-title">Genomic sequence, organization, and chromosomal localization of human JAK3</span> <span class="citation_source-journal">Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">â</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=57-61&author=M.+C.+Riedyauthor=A.+S.+Dutraauthor=T.+B.+Blakeauthor=W.+Modiauthor=B.+K.+Lalauthor=J.+Davisauthor=A.+Bosseauthor=J.+J.+O%E2%80%99Sheaauthor=J.+A.+Johnston&title=Genomic+sequence%2C+organization%2C+and+chromosomal+localization+of+human+JAK3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DDutra%26aufirst%3DA.%2BS.%26aulast%3DBlake%26aufirst%3DT.%2BB.%26aulast%3DModi%26aufirst%3DW.%26aulast%3DLal%26aufirst%3DB.%2BK.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DBosse%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26atitle%3DGenomic%2520sequence%252C%2520organization%252C%2520and%2520chromosomal%2520localization%2520of%2520human%2520JAK3%26jtitle%3DGenomics%26date%3D1996%26volume%3D37%26spage%3D57%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Firmbach-Kraft, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shows, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla-Favera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolewski, J. J.</span><span> </span><span class="NLM_article-title">tyk2, prototype of a novel class of non-receptor tyrosine kinase genes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">â</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=tyk2%2C+prototype+of+a+novel+class+of+non-receptor+tyrosine+kinase+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0ljrN5vnBA6COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3Dtyk2%252C%2520prototype%2520of%2520a%2520novel%2520class%2520of%2520non-receptor%2520tyrosine%2520kinase%2520genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">â</span> <span class="NLM_lpage">6737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0ljrN5vnBA6COA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mavers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruderman, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, H.</span><span> </span><span class="NLM_article-title">Intracellular signal pathways: potential for therapies</span> <span class="citation_source-journal">Curr. Rheumatol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1007%2Fs11926-009-0054-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19772834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=378-385&author=M.+Maversauthor=E.+M.+Rudermanauthor=H.+Perlman&title=Intracellular+signal+pathways%3A+potential+for+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal pathways: potential for therapies</span></div><div class="casAuthors">Mavers, Melissa; Ruderman, Eric M.; Perlman, Harris</div><div class="citationInfo"><span class="NLM_cas:title">Current Rheumatology Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">CRRUCI</span>;
        ISSN:<span class="NLM_cas:issn">1523-3774</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drawbacks to current therapies for rheumatoid arthritis and the high cost of many of these drugs have lead to the investigation of novel approaches for treatment of this disease.  One such tactic is the targeting of proteins involved in intracellular signal transduction.  Inhibitors of p38 kinase have largely failed in clin. trials, due to both lack of efficacy and adverse events.  The degree of adverse events may reflect off-target effects or, conversely, may be a mechanism-related event subsequent to successful inhibition of p38.  Drugs targeting Janus kinases or spleen tyrosine kinase have shown greater success in clin. trials.  A thorough anal. of specificity, as well as publication of both pos. and neg. results, must be the goal of continuing trials of these and other inhibitors of signal transduction mols.  The success of many clin. trials in this novel class of drugs provides optimism that more cost-effective and improved therapies will soon be available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBrleay_ctfrVg90H21EOLACvtfcHk0lgqeDSk85EBLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeku7jE&md5=f3a18d64ac9620db5e43ca55df40c83b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs11926-009-0054-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11926-009-0054-9%26sid%3Dliteratum%253Aachs%26aulast%3DMavers%26aufirst%3DM.%26aulast%3DRuderman%26aufirst%3DE.%2BM.%26aulast%3DPerlman%26aufirst%3DH.%26atitle%3DIntracellular%2520signal%2520pathways%253A%2520potential%2520for%2520therapies%26jtitle%3DCurr.%2520Rheumatol.%2520Rep.%26date%3D2009%26volume%3D11%26spage%3D378%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinobu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lighvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visconti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by type I and II cytokine receptors: ten years after</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2FS0952-7915%2800%2900228-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=363-373&author=M.+Gadinaauthor=D.+Hiltonauthor=J.+A.+Johnstonauthor=A.+Morinobuauthor=A.+Lighvaniauthor=Y.-J.+Zhouauthor=R.+Viscontiauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+type+I+and+II+cytokine+receptors%3A+ten+years+after"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by type I and II cytokine receptors: ten years after</span></div><div class="casAuthors">Gadina, Massimo; Hilton, Douglas; Johnston, James A.; Morinobu, Akio; Lighvani, Arash; Zhou, Yong-Jie; Visconti, Roberta; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Discovered during the past ten years, Janus kinases and signal transducers and activators of transcription have emerged as crit. elements in cytokine signaling and immunoregulation.  Recently, knockout mice for all the members of these families have been generated, with remarkably specific outcomes.  Equally exciting is the discovery of a new class of inhibitors, the suppressor of cytokine signaling family.  The phenotypes of mice deficient in these mols. are also striking, underscoring the importance of neg. regulation in cytokine signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG4srLWQWES7Vg90H21EOLACvtfcHk0lgqeDSk85EBLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D&md5=ee2b4d8b8aebd180e22f1e80c688f717</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900228-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900228-4%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DHilton%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DMorinobu%26aufirst%3DA.%26aulast%3DLighvani%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DVisconti%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520type%2520I%2520and%2520II%2520cytokine%2520receptors%253A%2520ten%2520years%2520after%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2001%26volume%3D13%26spage%3D363%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signalling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">â</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signalling+in+the+immune+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lgqeDSk85EBLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signalling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Levesque, M. C.</span><span> </span><span class="NLM_article-title">Biologic rheumatoid arthritis therapies: Do we need more comparative effectiveness data?</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">70</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=65-70&author=M.+C.+Levesque&title=Biologic+rheumatoid+arthritis+therapies%3A+Do+we+need+more+comparative+effectiveness+data%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevesque%26aufirst%3DM.%2BC.%26atitle%3DBiologic%2520rheumatoid%2520arthritis%2520therapies%253A%2520Do%2520we%2520need%2520more%2520comparative%2520effectiveness%2520data%253F%26jtitle%3DBioDrugs%26date%3D2012%26volume%3D26%26spage%3D65%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">Cytokines in the pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri2094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17525752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-442&author=I.+B.+McInnesauthor=G.+Schett&title=Cytokines+in+the+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in the pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Iain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-442</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines regulate a broad range of inflammatory processes that are implicated in the pathogenesis of rheumatoid arthritis.  In rheumatoid joints, it is well known that an imbalance between pro- and anti-inflammatory cytokine activities favors the induction of autoimmunity, chronic inflammation and thereby joint damage.  However, it remains less clear how cytokines are organized within a hierarchical regulatory network, and therefore which cytokines may be the best targets for clin. intervention a priori.  Here, we discuss the crucial effector function of cytokines in the immunol. processes that are central to the pathogenesis of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0RdTFn7jhXLVg90H21EOLACvtfcHk0lgFWfIjX5xJiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D&md5=139510ac7d6607fbd46c6d32f781dfc6</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnri2094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2094%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DCytokines%2520in%2520the%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koncz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodszky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ersek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulacsi, L.</span><span> </span><span class="NLM_article-title">Adherence to biologic DMARD therapies in rheumatoid arthritis</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">â</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F14712598.2010.510508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFWrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1367-1378&author=T.+Konczauthor=M.+Pentekauthor=V.+Brodszkyauthor=K.+Ersekauthor=E.+Orlewskaauthor=L.+Gulacsi&title=Adherence+to+biologic+DMARD+therapies+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Adherence to biologic DMARD therapies in rheumatoid arthritis</span></div><div class="casAuthors">Koncz, Tamas; Pentek, Marta; Brodszky, Valentin; Ersek, Katalin; Orlewska, Ewa; Gulacsi, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1367-1378</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The efficacy of the biol. disease-modifying antirheumatic drugs (DMARDs) shown in clin. trials may be jeopardized due to prevalent poor patient adherence.  Areas covered in this review: Patient adherence including compliance and persistence with biol. DMARDs in rheumatoid arthritis.  What the reader will gain: This is a comprehensive review of the literature.  The various definitions and methodologies of measurement used in adherence research are reviewed and data are presented by sepg. compliance and persistence.  Differences in compliance rates were mainly based on numerical trends.  There was evidence for and against greater persistence with infliximab vs. adalimumab and etanercept.  There was a trend in favor of greater compliance and lower persistence with TNF-Î± inhibitor monotherapy vs. in combination therapy with methotrexate.  Take home message: The evidence suggests that adherence to biol. DMARDs is suboptimal.  When further research is applied in the field, agreed definitions and methodol. need to be used to allow for cross-study comparisons.  In addn., adherence should be assessed in conjunction with clin. outcomes and not on its own so that it can be better understood what levels of adherence provide the required clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIzufe0IGkLVg90H21EOLACvtfcHk0lgFWfIjX5xJiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFWrur4%253D&md5=575566f4bf349db9675c926696f2bcfc</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1517%2F14712598.2010.510508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2010.510508%26sid%3Dliteratum%253Aachs%26aulast%3DKoncz%26aufirst%3DT.%26aulast%3DPentek%26aufirst%3DM.%26aulast%3DBrodszky%26aufirst%3DV.%26aulast%3DErsek%26aufirst%3DK.%26aulast%3DOrlewska%26aufirst%3DE.%26aulast%3DGulacsi%26aufirst%3DL.%26atitle%3DAdherence%2520to%2520biologic%2520DMARD%2520therapies%2520in%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D1367%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Harrold, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, J. D.</span><span> </span><span class="NLM_article-title">The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi">Â DOI: 10.1136/annrheumdis-2013-203936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1136%2Fannrheumdis-2013-203936" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=L.+R.+Harroldauthor=G.+W.+Reedauthor=J.+M.+Kremerauthor=J.+R.+Curtisauthor=D.+H.+Solomonauthor=M.+C.+Hochbergauthor=J.+D.+Greenberg&title=The+comparative+effectiveness+of+abatacept+versus+anti-tumour+necrosis+factor+switching+for+rheumatoid+arthritis+patients+previously+treated+with+an+anti-tumour+necrosis+factor&doi=10.1136%2Fannrheumdis-2013-203936"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2013-203936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2013-203936%26sid%3Dliteratum%253Aachs%26aulast%3DHarrold%26aufirst%3DL.%2BR.%26aulast%3DReed%26aufirst%3DG.%2BW.%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSolomon%26aufirst%3DD.%2BH.%26aulast%3DHochberg%26aufirst%3DM.%2BC.%26aulast%3DGreenberg%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520comparative%2520effectiveness%2520of%2520abatacept%2520versus%2520anti-tumour%2520necrosis%2520factor%2520switching%2520for%2520rheumatoid%2520arthritis%2520patients%2520previously%2520treated%2520with%2520an%2520anti-tumour%2520necrosis%2520factor%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26doi%3D10.1136%2Fannrheumdis-2013-203936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span> </span><span class="NLM_article-title">Novel small-molecular therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2FBOR.0b013e32835190ef" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22357358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=335-341&author=R.+Fleischmann&title=Novel+small-molecular+therapeutics+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small-molecular therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the introduction of biol. therapies into the treatment paradigm of rheumatoid arthritis (RA), there has been hope that oral small mol. immune modulators would be developed that would have a risk : benefit profile at least similar to biol. therapies, be more convenient for the patient and, hopefully, be less expensive.  This article reviews the progress made in the development of these compds. over the past year.  Recent findings: Addnl. information has become available in the past year on five oral compds. including kinase inhibitors (tofacitinib, fostamatinib, VX-509), an S1P lyase inhibitor (LX 3305) and a chemokine receptor-1 antagonist (CCX354-C).  Efficacy has been shown in phase III with tofacitinib and in phase II with fostamatinib and VX-509; safety was the primary endpoint of the trials of CCX354-C and LX3305.  Regarding side effects, liver test elevation and neutropenia occurred with tofacitinib, VX-509 and fostamatinib; lipid elevation with tofacitinib and VX-509; creatinine elevation and anemia with tofacitinib, and hypertension and diarrhea with fostamatinib.  Summary: Compds. that inhibit tyrosine kinase pathways involved in cellular signalling have been shown to be effective in the treatment of RA with a reasonable risk : benefit ratio.  It is too early to tell about inhibitors of other pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALXnYT2mHjLVg90H21EOLACvtfcHk0liFHlFT8_hw7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D&md5=46627d79c7fe388c3a9d0fe05d83b040</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e32835190ef&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e32835190ef%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26atitle%3DNovel%2520small-molecular%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2012%26volume%3D24%26spage%3D335%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Vijayakrishnan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataramanan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulati, P.</span><span> </span><span class="NLM_article-title">Treating inflammation with the Janus kinase inhibitor CP-690,550</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">â</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=25-34&author=L.+Vijayakrishnanauthor=R.+Venkataramananauthor=P.+Gulati&title=Treating+inflammation+with+the+Janus+kinase+inhibitor+CP-690%2C550"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVijayakrishnan%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DR.%26aulast%3DGulati%26aufirst%3DP.%26atitle%3DTreating%2520inflammation%2520with%2520the%2520Janus%2520kinase%2520inhibitor%2520CP-690%252C550%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D25%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hofmann, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ettinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Cytokines and their role in lymphoid development, differentiation and homeostasis</span> <span class="citation_source-journal">Curr. Opin. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2013</span><span class="NLM_x">) </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2F00130832-200212000-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=495-506&issue=2013&author=S.+R.+Hofmannauthor=R.+Ettingerauthor=Y.-J.+Zhouauthor=M.+Gadinaauthor=P.+Lipskyauthor=R.+Siegelauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Shea&title=Cytokines+and+their+role+in+lymphoid+development%2C+differentiation+and+homeostasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines and their role in lymphoid development, differentiation and homeostasis</span></div><div class="casAuthors">Hofmann Sigrun R; Ettinger Rachel; Zhou Yong-Jie; Gadina Massimo; Lipsky Peter; Siegel Richard; Candotti Fabio; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">495-506</span>
        ISSN:<span class="NLM_cas:issn">1528-4050</span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  The development of lymphoid tissues as well as the ultimate differentiation of naive and memory T cells are dependent on cytokines.  In this review, we will focus on recent advances in the understanding of molecular mechanisms that regulate lymphoid development, homeostasis and tolerance.  RECENT FINDINGS:  Cytokines play a critical role in the development and differentiation of lymphoid cells.  In addition, newer data indicate important roles of interleukin-7 and interleukin-15 in lymphoid homeostasis and memory.  Furthermore, a new family of heterodimeric cytokines comprising interleukin-12, interleukin-23 and -27 is important for differentiation of helper T cells and cell-mediated immunity.  Finally the importance of tumor necrosis factor superfamily members in the development of lymphoid organs has recently been elucidated and will be discussed in detail.  SUMMARY:  New cytokines and receptors continue to be identified.  The discovery and characterization of cytokines, their receptors and signaling molecules will provide a more complete understanding of normal lymphoid development, differentiation and function.  In addition, this knowledge should improve our understanding of the pathogenesis of immunological diseases and hopefully will provide new treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTci7HKMzLxgUNHe_gFldTbfW6udTcc2eZq3_evCZmU9rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252Flt1Wrsw%253D%253D&md5=9480ae8620e9053745c038149a08a607</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1097%2F00130832-200212000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130832-200212000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DS.%2BR.%26aulast%3DEttinger%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DCytokines%2520and%2520their%2520role%2520in%2520lymphoid%2520development%252C%2520differentiation%2520and%2520homeostasis%26jtitle%3DCurr.%2520Opin.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2002%26volume%3D2%26issue%3D2013%26spage%3D495%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des, E. S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science (Washington, DC, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">â</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=S.-P.+Changauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=E.+S.+G.+Desauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.-S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.-J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0ljl8ApZ_IHwqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%26aufirst%3DE.%2BS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.-S.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.-J.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Russell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tayebi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedy, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migone, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x"> (</span><span class="NLM_issue">5237</span><span class="NLM_x">) </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=797-800&issue=5237&author=S.+M.+Russellauthor=N.+Tayebiauthor=H.+Nakajimaauthor=M.+C.+Riedyauthor=J.+L.+Robertsauthor=M.+J.+Amanauthor=T.+S.+Migoneauthor=M.+Noguchiauthor=M.+L.+Markertauthor=R.+H.+Buckleyauthor=J.+J.+O%E2%80%99Sheaauthor=W.+J.+Leonard&title=Mutation+of+Jak3+in+a+patient+with+SCID%3A+essential+role+of+Jak3+in+lymphoid+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DS.%2BM.%26aulast%3DTayebi%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DRiedy%26aufirst%3DM.%2BC.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DAman%26aufirst%3DM.%2BJ.%26aulast%3DMigone%26aufirst%3DT.%2BS.%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DMarkert%26aufirst%3DM.%2BL.%26aulast%3DBuckley%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DMutation%2520of%2520Jak3%2520in%2520a%2520patient%2520with%2520SCID%253A%2520essential%2520role%2520of%2520Jak3%2520in%2520lymphoid%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D270%26issue%3D5237%26spage%3D797%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Casanova, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Inborn errors of human JAKs and STATs</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=515-528&author=J.-L.+Casanovaauthor=S.+M.+Hollandauthor=L.+D.+Notarangelo&title=Inborn+errors+of+human+JAKs+and+STATs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DInborn%2520errors%2520of%2520human%2520JAKs%2520and%2520STATs%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2ebEvZ9ibEHdObntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">373</span><span class="NLM_x">â</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&issue=3&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+Jaks+in+cytokine-induced+biologic+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520Jaks%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">397</span><span class="NLM_x">â</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&issue=3&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D397%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&issue=3&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+van+Deursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26issue%3D3%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinobu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lighvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visconti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Signaling by type I and II cytokine receptors: ten years after</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2FS0952-7915%2800%2900228-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=363-373&issue=3&author=M.+Gadinaauthor=D.+Hiltonauthor=J.+A.+Johnstonauthor=A.+Morinobuauthor=A.+Lighvaniauthor=Y.+J.+Zhouauthor=R.+Viscontiauthor=J.+J.+O%E2%80%99Shea&title=Signaling+by+type+I+and+II+cytokine+receptors%3A+ten+years+after"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by type I and II cytokine receptors: ten years after</span></div><div class="casAuthors">Gadina, Massimo; Hilton, Douglas; Johnston, James A.; Morinobu, Akio; Lighvani, Arash; Zhou, Yong-Jie; Visconti, Roberta; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-373</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 94 refs.  Discovered during the past ten years, Janus kinases and signal transducers and activators of transcription have emerged as crit. elements in cytokine signaling and immunoregulation.  Recently, knockout mice for all the members of these families have been generated, with remarkably specific outcomes.  Equally exciting is the discovery of a new class of inhibitors, the suppressor of cytokine signaling family.  The phenotypes of mice deficient in these mols. are also striking, underscoring the importance of neg. regulation in cytokine signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG4srLWQWES7Vg90H21EOLACvtfcHk0liUA_5Vys2NIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjslWiurw%253D&md5=ee2b4d8b8aebd180e22f1e80c688f717</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900228-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900228-4%26sid%3Dliteratum%253Aachs%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DHilton%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DMorinobu%26aufirst%3DA.%26aulast%3DLighvani%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DVisconti%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSignaling%2520by%2520type%2520I%2520and%2520II%2520cytokine%2520receptors%253A%2520ten%2520years%2520after%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2001%26volume%3D13%26issue%3D3%26spage%3D363%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kilic, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacimustafaoglu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boisson-Dupuis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreins, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanova, J. L.</span><span> </span><span class="NLM_article-title">A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome</span> <span class="citation_source-journal">J. Pediatr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1055</span><span class="NLM_x">â</span> <span class="NLM_lpage">1057</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jpeds.2012.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC38vlvFOjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2012&pages=1055-1057&issue=6&author=S.+S.+Kilicauthor=M.+Hacimustafaogluauthor=S.+Boisson-Dupuisauthor=A.+Y.+Kreinsauthor=A.+V.+Grantauthor=L.+Abelauthor=J.+L.+Casanova&title=A+patient+with+tyrosine+kinase+2+deficiency+without+hyper-IgE+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome</span></div><div class="casAuthors">Kilic Sara S; Hacimustafaoglu Mustafa; Boisson-Dupuis Stephanie; Kreins Alexandra Y; Grant Audrey V; Abel Laurent; Casanova Jean-Laurent</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pediatrics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1055-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe a Turkish patient with tyrosine kinase 2 deficiency who suffered from disseminated Bacille Calmette-Guerin infection, neurobrucellosis, and cutaneous herpes zoster infection.  Tyrosine kinase 2 deficiency should be considered in patients susceptible to herpes viruses and intramacrophage pathogens even in the absence of atopy, high serum IgE, and staphylococcal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQojBYLpTn-mbBItaL1WaVAfW6udTcc2ebABdtL2Vcikbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vlvFOjug%253D%253D&md5=90788c5590881e202705da37184ecb09</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.jpeds.2012.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpeds.2012.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DHacimustafaoglu%26aufirst%3DM.%26aulast%3DBoisson-Dupuis%26aufirst%3DS.%26aulast%3DKreins%26aufirst%3DA.%2BY.%26aulast%3DGrant%26aufirst%3DA.%2BV.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26atitle%3DA%2520patient%2520with%2520tyrosine%2520kinase%25202%2520deficiency%2520without%2520hyper-IgE%2520syndrome%26jtitle%3DJ.%2520Pediatr.%26date%3D2012%26volume%3D160%26issue%3D6%26spage%3D1055%26epage%3D1057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yachie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renner, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belohradsky, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">745</span><span class="NLM_x">â</span> <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&issue=5&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26issue%3D5%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Casanova, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Inborn errors of human JAKs and STATs</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=515-528&issue=4&author=J.+L.+Casanovaauthor=S.+M.+Hollandauthor=L.+D.+Notarangelo&title=Inborn+errors+of+human+JAKs+and+STATs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanova%26aufirst%3DJ.%2BL.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DInborn%2520errors%2520of%2520human%2520JAKs%2520and%2520STATs%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26issue%3D4%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">JAK2, a third member of the JAK family of protein tyrosine kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">2013</span><span class="NLM_x">) </span> <span class="NLM_fpage">1347</span><span class="NLM_x">â</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1992&pages=1347-1353&issue=2013&author=A.+G.+Harpurauthor=A.+C.+Andresauthor=A.+Ziemieckiauthor=R.+R.+Astonauthor=A.+F.+Wilks&title=JAK2%2C+a+third+member+of+the+JAK+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26aulast%3DZiemiecki%26aufirst%3DA.%26aulast%3DAston%26aufirst%3DR.%2BR.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DJAK2%252C%2520a%2520third%2520member%2520of%2520the%2520JAK%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DOncogene%26date%3D1992%26volume%3D7%26issue%3D2013%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaluoma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">Regulation of the Jak2 tyrosine kinase by its pseudokinase domain</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3387</span><span class="NLM_x">â</span> <span class="NLM_lpage">3395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1128%2FMCB.20.10.3387-3395.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=10779328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFyhtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=3387-3395&author=P.+Saharinenauthor=K.+Takaluomaauthor=O.+Silvennoinen&title=Regulation+of+the+Jak2+tyrosine+kinase+by+its+pseudokinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Jak2 tyrosine kinase by its pseudokinase domain</span></div><div class="casAuthors">Saharinen, Pipsa; Takaluoma, Kati; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3387-3395</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Activation of Jak tyrosine kinases through hematopoietic cytokine receptors occurs as a consequence of ligand-induced aggregation of receptor-assocd. Jaks and their subsequent autophosphorylation.  Jak kinases consist of a C-terminal tyrosine kinase domain, a pseudokinase domain of unknown function, and Jak homol. (JH) domains 3 to 7, implicated in receptor-Jak interaction.  We analyzed the functional roles of the different protein domains in activation of Jak2.  Deletion anal. of Jak2 showed that the pseudokinase domain but not JH domains 3 to 7 neg. regulated the catalytic activity of Jak2 as well Jak2-mediated activation of Stat5.  Phosphorylation of Stat5 by wild-type Jak2 was dependent on the SH2 domain of Stat5; however, this requirement was lost upon deletion of the pseudokinase domain of Jak2.  Investigation of the mechanisms of the pseudokinase domain-mediated inhibition of Jak2 suggested that this regulation did not involve protein tyrosine phosphatases.  Instead, anal. of interactions between the tyrosine kinase domain and Jak2 suggested that the pseudokinase domain interacted with the kinase domain.  Furthermore, co-expression of the pseudokinase domain inhibited the activity of the single tyrosine kinase domain.  Finally, deletion of the pseudokinase domain of Jak2 deregulated signal transduction through the gamma interferon receptor by significantly increasing ligand-independent activation of Stat transcription factors.  These results indicate that the pseudokinase domain neg. regulates the activity of Jak2, probably through an interaction with the kinase domain, and this regulation is required to keep Jak2 inactive in the absence of ligand stimulation.  Furthermore, the pseudokinase domain may have a role in regulation of Jak2-substrate interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFiXFK81wIJ7Vg90H21EOLACvtfcHk0lhLFT8khxZGSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFyhtrw%253D&md5=17ac4581ee9c36e03e95f0f88405339c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.10.3387-3395.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.10.3387-3395.2000%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DTakaluoma%26aufirst%3DK.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DRegulation%2520of%2520the%2520Jak2%2520tyrosine%2520kinase%2520by%2520its%2520pseudokinase%2520domain%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D3387%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">47954</span><span class="NLM_x">â</span> <span class="NLM_lpage">47963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=47954-47963&author=P.+Saharinenauthor=O.+Silvennoinen&title=The+pseudokinase+domain+is+required+for+suppression+of+basal+activity+of+Jak2+and+Jak3+tyrosine+kinases+and+for+cytokine-inducible+activation+of+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520pseudokinase%2520domain%2520is%2520required%2520for%2520suppression%2520of%2520basal%2520activity%2520of%2520Jak2%2520and%2520Jak3%2520tyrosine%2520kinases%2520and%2520for%2520cytokine-inducible%2520activation%2520of%2520signal%2520transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D47954%26epage%3D47963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ungureanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekkala, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niranjan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubert, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoda, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span> </span><span class="NLM_article-title">The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">971</span><span class="NLM_x">â</span> <span class="NLM_lpage">976</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnsmb.2099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWmur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=971-976&issue=9&author=D.+Ungureanuauthor=J.+Wuauthor=T.+Pekkalaauthor=Y.+Niranjanauthor=C.+Youngauthor=O.+N.+Jensenauthor=C.+F.+Xuauthor=T.+A.+Neubertauthor=R.+C.+Skodaauthor=S.+R.+Hubbardauthor=O.+Silvennoinen&title=The+pseudokinase+domain+of+JAK2+is+a+dual-specificity+protein+kinase+that+negatively+regulates+cytokine+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling</span></div><div class="casAuthors">Ungureanu, Daniela; Wu, Jinhua; Pekkala, Tuija; Niranjan, Yashavanthi; Young, Clifford; Jensen, Ole N.; Xu, Chong-Feng; Neubert, Thomas A.; Skoda, Radek C.; Hubbard, Stevan R.; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">971-976</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human JAK2 tyrosine kinase mediates signaling through numerous cytokine receptors.  The JAK2 JH2 domain functions as a neg. regulator and is presumed to be a catalytically inactive pseudokinase, but the mechanism(s) for its inhibition of JAK2 remains unknown.  Mutations in JH2 lead to increased JAK2 activity, contributing to myeloproliferative neoplasms (MPNs).  Here we show that JH2 is a dual-specificity protein kinase that phosphorylates two neg. regulatory sites in JAK2: Ser523 and Tyr570.  Inactivation of JH2 catalytic activity increased JAK2 basal activity and downstream signaling.  Notably, different MPN mutations abrogated JH2 activity in cells, and in MPN (V617F) patient cells phosphorylation of Tyr570 was reduced, suggesting that loss of JH2 activity contributes to the pathogenesis of MPNs.  These results identify the catalytic activity of JH2 as a previously unrecognized mechanism to control basal activity and signaling of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGxnYmkTj5rVg90H21EOLACvtfcHk0lj6yeKN6nh9Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWmur7J&md5=381c93988ea9d0a720fe759ec7d09e27</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2099%26sid%3Dliteratum%253Aachs%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DPekkala%26aufirst%3DT.%26aulast%3DNiranjan%26aufirst%3DY.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DO.%2BN.%26aulast%3DXu%26aufirst%3DC.%2BF.%26aulast%3DNeubert%26aufirst%3DT.%2BA.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520pseudokinase%2520domain%2520of%2520JAK2%2520is%2520a%2520dual-specificity%2520protein%2520kinase%2520that%2520negatively%2520regulates%2520cytokine%2520signaling%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2011%26volume%3D18%26issue%3D9%26spage%3D971%26epage%3D976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Radtke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerissen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermanns, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbach, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyczek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz-VandeLeur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haan, C.</span><span> </span><span class="NLM_article-title">The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">25760</span><span class="NLM_x">â</span> <span class="NLM_lpage">25768</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=25760-25768&author=S.+Radtkeauthor=S.+Haanauthor=A.+Joerissenauthor=H.+M.+Hermannsauthor=S.+Diefenbachauthor=T.+Smyczekauthor=H.+Schmitz-VandeLeurauthor=P.+C.+Heinrichauthor=I.+Behrmannauthor=C.+Haan&title=The+Jak1+SH2+domain+does+not+fulfill+a+classical+SH2+function+in+Jak%2FSTAT+signaling+but+plays+a+structural+role+for+receptor+interaction+and+up-regulation+of+receptor+surface+expression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRadtke%26aufirst%3DS.%26aulast%3DHaan%26aufirst%3DS.%26aulast%3DJoerissen%26aufirst%3DA.%26aulast%3DHermanns%26aufirst%3DH.%2BM.%26aulast%3DDiefenbach%26aufirst%3DS.%26aulast%3DSmyczek%26aufirst%3DT.%26aulast%3DSchmitz-VandeLeur%26aufirst%3DH.%26aulast%3DHeinrich%26aufirst%3DP.%2BC.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DHaan%26aufirst%3DC.%26atitle%3DThe%2520Jak1%2520SH2%2520domain%2520does%2520not%2520fulfill%2520a%2520classical%2520SH2%2520function%2520in%2520Jak%252FSTAT%2520signaling%2520but%2520plays%2520a%2520structural%2520role%2520for%2520receptor%2520interaction%2520and%2520up-regulation%2520of%2520receptor%2520surface%2520expression%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D25760%26epage%3D25768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Girault, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labesse, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mornon, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callebaut, I.</span><span> </span><span class="NLM_article-title">Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction</span> <span class="citation_source-journal">Mol. Med. (N. Y.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFyisrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=751-769&author=J.-A.+Giraultauthor=G.+Labesseauthor=J.-P.+Mornonauthor=I.+Callebaut&title=Janus+kinases+and+focal+adhesion+kinases+play+in+the+4.1+band%3A+a+superfamily+of+band+4.1+domains+important+for+cell+structure+and+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction</span></div><div class="casAuthors">Girault, Jean-Antoine; Labesse, Gilles; Mornon, Jean-Paul; Callebaut, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (New York)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">751-769</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag New York Inc.</span>)
        </div><div class="casAbstract">A review, with 137 refs.  The band 4.1 domain was first identified in the red blood cell protein band 4.1, and subsequently in ezrin, radixin, and moesin (ERM proteins) and other proteins, including tumor suppressor merlin/schwannomin, talin, unconventional myosins VIIa and X, and protein tyrosine phosphatases.  Recently, the presence of a structurally related domain has been demonstrated in the N-terminal region of two groups of tyrosine kinases: the focal adhesion kinases (FAK) and the Janus kinases (JAK).  Addnl. proteins contg. the 4.1/JEF (JAK, ERM, FAK) domain include plant kinesin-like calmodulin-binding proteins (KCBP) and a no. of uncharacterized open reading frames identified by systematic DNA sequencing.  Phylogenetic anal. of amino acid sequences suggests that band 4.1/JEF domains can be grouped in several families that have probably diverged early during evolution.  Hydrophobic cluster anal. indicates that the band 4.1/JEF domains might consist of a duplicated module of â¼140 residues and a central hinge region.  A conserved property of the domain is its capacity to bind to the membrane-proximal region of the C-terminal cytoplasmic tail of proteins with a single transmembrane segment.  Many proteins with band 4.1/JEF domains undergo regulated intra- or intermol. homotypic interactions.  Addnl. properties common to band 4.1/JEF domains of several proteins are binding of phosphoinositides and regulation by GTPases of the Rho family.  Many proteins with band 4.1/JEF domains are assocd. with the actin-based cytoskeleton and are enriched at points of contact with other cells or the extracellular matrix, from which they can exert control over cell growth.  Thus, proteins with band 4.1/JEF domain are at the crossroads between cytoskeletal organization and signal transduction in multicellular organisms.  Their importance is underlined by the variety of diseases that can result from their mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD2L3dA2cE77Vg90H21EOLACvtfcHk0lj6yeKN6nh9Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFyisrw%253D&md5=97f78937667dd2bd09631828a9465e77</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGirault%26aufirst%3DJ.-A.%26aulast%3DLabesse%26aufirst%3DG.%26aulast%3DMornon%26aufirst%3DJ.-P.%26aulast%3DCallebaut%26aufirst%3DI.%26atitle%3DJanus%2520kinases%2520and%2520focal%2520adhesion%2520kinases%2520play%2520in%2520the%25204.1%2520band%253A%2520a%2520superfamily%2520of%2520band%25204.1%2520domains%2520important%2520for%2520cell%2520structure%2520and%2520signal%2520transduction%26jtitle%3DMol.%2520Med.%2520%2528N.%2520Y.%2529%26date%3D1998%26volume%3D4%26spage%3D751%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macchi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sacco, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frattini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugazio, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notarangelo, L. D.</span><span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span> <span class="citation_source-journal">Nature (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Sheaauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common Î³-chain (Î³c), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the Î³c-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100âCys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0liLXq50grKRFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%2520%2528London%2529%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Minegishi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yachie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakiguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abinun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renner, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belohradsky, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizutani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasuyama, H.</span><span> </span><span class="NLM_article-title">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">â</span> <span class="NLM_lpage">755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+tyrosine+kinase+2+deficiency+reveals+its+requisite+roles+in+multiple+cytokine+signals+involved+in+innate+and+acquired+immunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0liLXq50grKRFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520tyrosine%2520kinase%25202%2520deficiency%2520reveals%2520its%2520requisite%2520roles%2520in%2520multiple%2520cytokine%2520signals%2520involved%2520in%2520innate%2520and%2520acquired%2520immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Deon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaletta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, I.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivashkiv, L. B.</span><span> </span><span class="NLM_article-title">Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">5395</span><span class="NLM_x">â</span> <span class="NLM_lpage">5403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2001&pages=5395-5403&author=D.+Deonauthor=S.+Ahmedauthor=K.+Taiauthor=N.+Scalettaauthor=C.+Herreroauthor=I.-H.+Leeauthor=A.+Krauseauthor=L.+B.+Ivashkiv&title=Cross-talk+between+IL-1+and+IL-6+signaling+pathways+in+rheumatoid+arthritis+synovial+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeon%26aufirst%3DD.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DTai%26aufirst%3DK.%26aulast%3DScaletta%26aufirst%3DN.%26aulast%3DHerrero%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DI.-H.%26aulast%3DKrause%26aufirst%3DA.%26aulast%3DIvashkiv%26aufirst%3DL.%2BB.%26atitle%3DCross-talk%2520between%2520IL-1%2520and%2520IL-6%2520signaling%2520pathways%2520in%2520rheumatoid%2520arthritis%2520synovial%2520fibroblasts%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D167%26spage%3D5395%26epage%3D5403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoniv, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falck-Pedersen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivashkiv, L. B.</span><span> </span><span class="NLM_article-title">Sensitization of IFN-Î³ Jak-STAT signaling during macrophage activation</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">â</span> <span class="NLM_lpage">866</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27d&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fni828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27d&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ags7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=859-866&author=X.+Huauthor=C.+Herreroauthor=W.-P.+Liauthor=T.+T.+Antonivauthor=E.+Falck-Pedersenauthor=A.+E.+Kochauthor=J.+M.+Woodsauthor=G.+K.+Hainesauthor=L.+B.+Ivashkiv&title=Sensitization+of+IFN-%CE%B3+Jak-STAT+signaling+during+macrophage+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27dR"><div class="casContent"><span class="casTitleNuber">27d</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitization of IFN-Î³ Jak-STAT signaling during macrophage activation</span></div><div class="casAuthors">Hu, Xiaoyu; Herrero, Carmen; Li, Wai-Ping; Antoniv, Taras T.; Falck-Pedersen, Erik; Koch, Alisa E.; Woods, James M.; Haines, G. Kenneth; Ivashkiv, Lionel B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A general paradigm in signal transduction is ligand-induced feedback inhibition and the desensitization of signaling.  We found that subthreshold concns. of interferon-Î³ (IFN-Î³), which did not activate macrophages, increased their sensitivity to subsequent IFN-Î³ stimulation; this resulted in increased signal transducer and activator of transcription 1 (STAT1) activation and increased IFN-Î³-dependent gene activation.  Sensitization of IFN-Î³ signaling was mediated by the induction of STAT1 expression by low doses of IFN-Î³ that did not effectively induce feedback inhibition.  IFN-Î³ signaling was sensitized in vivo after IFN-Î³ injection, and STAT1 expression was increased after injection of lipopolysaccharide and in rheumatoid arthritis synovial cells.  These results identify a mechanism that sensitizes macrophages to low concns. of IFN-Î³ and regulates IFN-Î³ responses in acute and chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq15kv8A5SFdLVg90H21EOLACvtfcHk0li8j74qzK71gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ags7w%253D&md5=3672158efb50a86750b8cb95faa0035f</span></div><a href="/servlet/linkout?suffix=cit27d&amp;dbid=16384&amp;doi=10.1038%2Fni828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni828%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DHerrero%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DW.-P.%26aulast%3DAntoniv%26aufirst%3DT.%2BT.%26aulast%3DFalck-Pedersen%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DWoods%26aufirst%3DJ.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DIvashkiv%26aufirst%3DL.%2BB.%26atitle%3DSensitization%2520of%2520IFN-%25CE%25B3%2520Jak-STAT%2520signaling%2520during%2520macrophage%2520activation%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D859%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor Î³ chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell (Cambridge, MA, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2F0092-8674%2893%2990167-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=8462096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADyaK3sXktVOjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+%CE%B3+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-2 receptor Î³ chain mutation results in X-linked severe combined immunodeficiency in humans</span></div><div class="casAuthors">Noguchi, Masayuki; Yi, Huafang; Rosenblatt, Howard M.; Filipovich, Alexandra H.; Adelstein, Stephen; Modi, William S.; McBride, O. Wesley; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-57</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The interleukin-2 receptor Î³ chain (IL-2RÎ³) is a component of high and intermediate affinity IL-2 receptors that is required to achieve full ligand binding affinity and internalization.  The IL-2RÎ³ gene was localized to human chromosome Xq13.  Genetic linkage anal. indicates that the IL-2RÎ³ gene and the locus for X-linked severe combined immunodeficiency (XSCID) appear to be at the same position.  Moreover, each of 3 unrelated patients with XSCID has a different mutation in his IL-2RÎ³ gene resulting in a different premature stop codon and predicted C-terminal truncation.  These data establish that XSCID is assocd. with mutations of the IL-2RÎ³ gene product.  Since XSCID is characterized by absent or markedly reduced nos. of T cells, these findings imply that IL-2RÎ³ plays a vital role in thymic maturation of T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN9VGDNlllq7Vg90H21EOLACvtfcHk0li8j74qzK71gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVOjtro%253D&md5=5a13ffadf49bf72141237dfc376136dd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990167-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990167-O%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520%25CE%25B3%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%2520%2528Cambridge%252C%2520MA%252C%2520U.%2520S.%2529%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">JAK-mutant myeloproliferative neoplasms</span> <span class="citation_source-journal">Curr. Top. Microbiol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2012&pages=119-133&author=R.+L.+Levine&title=JAK-mutant+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK-mutant%2520myeloproliferative%2520neoplasms%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2012%26volume%3D355%26spage%3D119%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atlas, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifford, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhard, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reaman, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunger, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willman, C. L.</span><span> </span><span class="NLM_article-title">JAK mutations in high-risk childhood acute lymphoblastic leukemia</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">9414</span><span class="NLM_x">â</span> <span class="NLM_lpage">9418</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=9414-9418&author=C.+G.+Mullighanauthor=J.+Zhangauthor=R.+C.+Harveyauthor=J.+R.+Collins-Underwoodauthor=B.+A.+Schulmanauthor=L.+A.+Phillipsauthor=S.+K.+Tasianauthor=M.+L.+Lohauthor=X.+Suauthor=W.+Liuauthor=M.+Devidasauthor=S.+R.+Atlasauthor=I.+M.+Chenauthor=R.+J.+Cliffordauthor=D.+S.+Gerhardauthor=W.+L.+Carrollauthor=G.+H.+Reamanauthor=M.+Smithauthor=J.+R.+Downingauthor=S.+P.+Hungerauthor=C.+L.+Willman&title=JAK+mutations+in+high-risk+childhood+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHarvey%26aufirst%3DR.%2BC.%26aulast%3DCollins-Underwood%26aufirst%3DJ.%2BR.%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26aulast%3DPhillips%26aufirst%3DL.%2BA.%26aulast%3DTasian%26aufirst%3DS.%2BK.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DAtlas%26aufirst%3DS.%2BR.%26aulast%3DChen%26aufirst%3DI.%2BM.%26aulast%3DClifford%26aufirst%3DR.%2BJ.%26aulast%3DGerhard%26aufirst%3DD.%2BS.%26aulast%3DCarroll%26aufirst%3DW.%2BL.%26aulast%3DReaman%26aufirst%3DG.%2BH.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DWillman%26aufirst%3DC.%2BL.%26atitle%3DJAK%2520mutations%2520in%2520high-risk%2520childhood%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D9414%26epage%3D9418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Basquiera, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salquero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moiraghi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturich, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berretta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonafe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barral, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palazzo, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, J. J.</span><span> </span><span class="NLM_article-title">Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders</span> <span class="citation_source-journal">Hematology (Leeds, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">â</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlais7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=323-330&author=A.+L.+Basquieraauthor=N.+W.+Soriaauthor=R.+Ryserauthor=M.+Salqueroauthor=B.+Moiraghiauthor=F.+Sackmannauthor=A.+G.+Sturichauthor=A.+Borelloauthor=A.+Berrettaauthor=M.+Bonafeauthor=J.+M.+Barralauthor=E.+D.+Palazzoauthor=J.+J.+Garcia&title=Clinical+significance+of+V617F+mutation+of+the+JAK2+gene+in+patients+with+chronic+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders</span></div><div class="casAuthors">Basquiera, Ana L.; Soria, Nestor W.; Ryser, Ricardo; Salquero, Miriam; Moiraghi, Beatriz; Sackmann, Federico; Sturich, Ana G.; Borello, Adriana; Berretta, Adriana; Bonafe, Miriam; Barral, Jose Moreno; Palazzo, Emilio D.; Garcia, Juan J.</div><div class="citationInfo"><span class="NLM_cas:title">Hematology (Leeds, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-330</span>CODEN:
                <span class="NLM_cas:coden">HMATFL</span>;
        ISSN:<span class="NLM_cas:issn">1024-5332</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">The objective was to det. the prevalence of JAK2 V617F mutation and its clin. correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF).  Detection of JAK2 V617F mutation by allele specific-PCR.  One hundred and three patients with CMD were included in the study.  JAK2 V617F distribution was PV 40/45 (89%), ET 30/43 (69%), and IMF 7/15 (47%).  In PV and ET patients only, 18 had thrombosis at diagnosis and 12 during follow-up (these were microvascular: 11, venous: 7 and arterial: 12); of these 28/70 (40%) were JAK2pos vs. 2/18 (11%) JAK2neg; P=0.02.  In a median of 4 years, two patients with PV JAK2pos evolved to myelofibrosis and one patient with PV presented in leukemic transformation (JAK2pos before and after transformation); six patients died: four patients with IMF and two patients with PV.  We found an assocn. between JAK2 V617F and thrombotic events in patients with PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIveoppCLDNrVg90H21EOLACvtfcHk0liRwG31sGwOIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlais7c%253D&md5=1ca0927fe5648903988bc8a3ebe7ed36</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBasquiera%26aufirst%3DA.%2BL.%26aulast%3DSoria%26aufirst%3DN.%2BW.%26aulast%3DRyser%26aufirst%3DR.%26aulast%3DSalquero%26aufirst%3DM.%26aulast%3DMoiraghi%26aufirst%3DB.%26aulast%3DSackmann%26aufirst%3DF.%26aulast%3DSturich%26aufirst%3DA.%2BG.%26aulast%3DBorello%26aufirst%3DA.%26aulast%3DBerretta%26aufirst%3DA.%26aulast%3DBonafe%26aufirst%3DM.%26aulast%3DBarral%26aufirst%3DJ.%2BM.%26aulast%3DPalazzo%26aufirst%3DE.%2BD.%26aulast%3DGarcia%26aufirst%3DJ.%2BJ.%26atitle%3DClinical%2520significance%2520of%2520V617F%2520mutation%2520of%2520the%2520JAK2%2520gene%2520in%2520patients%2520with%2520chronic%2520myeloproliferative%2520disorders%26jtitle%3DHematology%2520%2528Leeds%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D14%26spage%3D323%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Elliott, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleveland, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldmann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, U. P.</span><span> </span><span class="NLM_article-title">FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">3911</span><span class="NLM_x">â</span> <span class="NLM_lpage">3921</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=3911-3921&issue=14&author=N.+E.+Elliottauthor=S.+M.+Clevelandauthor=V.+Grannauthor=J.+Janikauthor=T.+A.+Waldmannauthor=U.+P.+Dave&title=FERM+domain+mutations+induce+gain+of+function+in+JAK3+in+adult+T-cell+leukemia%2Flymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DN.%2BE.%26aulast%3DCleveland%26aufirst%3DS.%2BM.%26aulast%3DGrann%26aufirst%3DV.%26aulast%3DJanik%26aufirst%3DJ.%26aulast%3DWaldmann%26aufirst%3DT.%2BA.%26aulast%3DDave%26aufirst%3DU.%2BP.%26atitle%3DFERM%2520domain%2520mutations%2520induce%2520gain%2520of%2520function%2520in%2520JAK3%2520in%2520adult%2520T-cell%2520leukemia%252Flymphoma%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26issue%3D14%26spage%3D3911%26epage%3D3921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koo, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoh, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutcutache, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasegaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teh, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, S. T.</span><span> </span><span class="NLM_article-title">Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span><span class="NLM_x">â</span> <span class="NLM_lpage">597</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=591-597&issue=7&author=G.+C.+Kooauthor=S.+Y.+Tanauthor=T.+Tangauthor=S.+L.+Poonauthor=G.+E.+Allenauthor=L.+Tanauthor=S.+C.+Chongauthor=W.+S.+Ongauthor=K.+Tayauthor=M.+Taoauthor=R.+Quekauthor=S.+Loongauthor=K.+W.+Yeohauthor=S.+P.+Yapauthor=K.+A.+Leeauthor=L.+C.+Limauthor=D.+Tanauthor=C.+Gohauthor=I.+Cutcutacheauthor=W.+Yuauthor=C.+C.+Ngauthor=V.+Rajasegaranauthor=H.+L.+Hengauthor=A.+Ganauthor=C.+K.+Ongauthor=S.+Rozenauthor=P.+Tanauthor=B.+T.+Tehauthor=S.+T.+Lim&title=Janus+kinase+3-activating+mutations+identified+in+natural+killer%2FT-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoo%26aufirst%3DG.%2BC.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DPoon%26aufirst%3DS.%2BL.%26aulast%3DAllen%26aufirst%3DG.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DChong%26aufirst%3DS.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BS.%26aulast%3DTay%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DQuek%26aufirst%3DR.%26aulast%3DLoong%26aufirst%3DS.%26aulast%3DYeoh%26aufirst%3DK.%2BW.%26aulast%3DYap%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BA.%26aulast%3DLim%26aufirst%3DL.%2BC.%26aulast%3DTan%26aufirst%3DD.%26aulast%3DGoh%26aufirst%3DC.%26aulast%3DCutcutache%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DC.%2BC.%26aulast%3DRajasegaran%26aufirst%3DV.%26aulast%3DHeng%26aufirst%3DH.%2BL.%26aulast%3DGan%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DC.%2BK.%26aulast%3DRozen%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DTeh%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DS.%2BT.%26atitle%3DJanus%2520kinase%25203-activating%2520mutations%2520identified%2520in%2520natural%2520killer%252FT-cell%2520lymphoma%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D7%26spage%3D591%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmfeldt, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heatley, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne-Turner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pounds, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulyanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becksfort, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huether, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriwacki, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoldrick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobba, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbato, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coustan-Smith, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shurtleff, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondi, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimano, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermiston, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doulatov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunger, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devidas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunsmore, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obenauer, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pui, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeve, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span> </span><span class="NLM_article-title">The genetic basis of early T-cell precursor acute lymphoblastic leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">481</span><span class="NLM_x"> (</span><span class="NLM_issue">7380</span><span class="NLM_x">) </span> <span class="NLM_fpage">157</span><span class="NLM_x">â</span> <span class="NLM_lpage">163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=157-163&issue=7380&author=J.+Zhangauthor=L.+Dingauthor=L.+Holmfeldtauthor=G.+Wuauthor=S.+L.+Heatleyauthor=D.+Payne-Turnerauthor=J.+Eastonauthor=X.+Chenauthor=J.+Wangauthor=M.+Ruschauthor=C.+Luauthor=S.+C.+Chenauthor=L.+Weiauthor=J.+R.+Collins-Underwoodauthor=J.+Maauthor=K.+G.+Robertsauthor=S.+B.+Poundsauthor=A.+Ulyanovauthor=J.+Becksfortauthor=P.+Guptaauthor=R.+Huetherauthor=R.+W.+Kriwackiauthor=M.+Parkerauthor=D.+J.+McGoldrickauthor=D.+Zhaoauthor=D.+Alfordauthor=S.+Espyauthor=K.+C.+Bobbaauthor=G.+Songauthor=D.+Peiauthor=C.+Chengauthor=S.+Robertsauthor=M.+I.+Barbatoauthor=D.+Campanaauthor=E.+Coustan-Smithauthor=S.+A.+Shurtleffauthor=S.+C.+Raimondiauthor=M.+Kleppeauthor=J.+Coolsauthor=K.+A.+Shimanoauthor=M.+L.+Hermistonauthor=S.+Doulatovauthor=K.+Eppertauthor=E.+Laurentiauthor=F.+Nottaauthor=J.+E.+Dickauthor=G.+Bassoauthor=S.+P.+Hungerauthor=M.+L.+Lohauthor=M.+Devidasauthor=B.+Woodauthor=S.+Winterauthor=K.+P.+Dunsmoreauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=X.+Hongauthor=C.+C.+Harrisauthor=D.+J.+Doolingauthor=K.+Ochoaauthor=K.+J.+Johnsonauthor=J.+C.+Obenauerauthor=W.+E.+Evansauthor=C.+H.+Puiauthor=C.+W.+Naeveauthor=T.+J.+Leyauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=J.+R.+Downingauthor=C.+G.+Mullighan&title=The+genetic+basis+of+early+T-cell+precursor+acute+lymphoblastic+leukaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DHolmfeldt%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHeatley%26aufirst%3DS.%2BL.%26aulast%3DPayne-Turner%26aufirst%3DD.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DCollins-Underwood%26aufirst%3DJ.%2BR.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DPounds%26aufirst%3DS.%2BB.%26aulast%3DUlyanov%26aufirst%3DA.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%2BW.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DMcGoldrick%26aufirst%3DD.%2BJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DAlford%26aufirst%3DD.%26aulast%3DEspy%26aufirst%3DS.%26aulast%3DBobba%26aufirst%3DK.%2BC.%26aulast%3DSong%26aufirst%3DG.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DBarbato%26aufirst%3DM.%2BI.%26aulast%3DCampana%26aufirst%3DD.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DShurtleff%26aufirst%3DS.%2BA.%26aulast%3DRaimondi%26aufirst%3DS.%2BC.%26aulast%3DKleppe%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DShimano%26aufirst%3DK.%2BA.%26aulast%3DHermiston%26aufirst%3DM.%2BL.%26aulast%3DDoulatov%26aufirst%3DS.%26aulast%3DEppert%26aufirst%3DK.%26aulast%3DLaurenti%26aufirst%3DE.%26aulast%3DNotta%26aufirst%3DF.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26aulast%3DBasso%26aufirst%3DG.%26aulast%3DHunger%26aufirst%3DS.%2BP.%26aulast%3DLoh%26aufirst%3DM.%2BL.%26aulast%3DDevidas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DWinter%26aufirst%3DS.%26aulast%3DDunsmore%26aufirst%3DK.%2BP.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DK.%2BJ.%26aulast%3DObenauer%26aufirst%3DJ.%2BC.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DPui%26aufirst%3DC.%2BH.%26aulast%3DNaeve%26aufirst%3DC.%2BW.%26aulast%3DLey%26aufirst%3DT.%2BJ.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26atitle%3DThe%2520genetic%2520basis%2520of%2520early%2520T-cell%2520precursor%2520acute%2520lymphoblastic%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D481%26issue%3D7380%26spage%3D157%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">â</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+Jak3+kinase+domain+in+complex+with+a+staurosporine+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, Î³c.  Patients unable to signal via Î³c present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0lhSUAlo5Hp7gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520Jak3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">â</span> <span class="NLM_lpage">433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lhSUAlo5Hp7gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohnauthor=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0ljfpsIsp1OKCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Thompson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubbon, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicker, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankshun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J. A.</span><span> </span><span class="NLM_article-title">Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">â</span> <span class="NLM_lpage">1223</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1219-1223&author=J.+E.+Thompsonauthor=R.+M.+Cubbonauthor=R.+T.+Cummingsauthor=L.+S.+Wickerauthor=R.+Frankshunauthor=B.+R.+Cunninghamauthor=P.+M.+Cameronauthor=P.+T.+Meinkeauthor=N.+Livertonauthor=Y.+Wengauthor=J.+A.+DeMartino&title=Photochemical+preparation+of+a+pyridone+containing+tetracycle%3A+a+JAK+protein+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DJ.%2BE.%26aulast%3DCubbon%26aufirst%3DR.%2BM.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DWicker%26aufirst%3DL.%2BS.%26aulast%3DFrankshun%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DB.%2BR.%26aulast%3DCameron%26aufirst%3DP.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DLiverton%26aufirst%3DN.%26aulast%3DWeng%26aufirst%3DY.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26atitle%3DPhotochemical%2520preparation%2520of%2520a%2520pyridone%2520containing%2520tetracycle%253A%2520a%2520JAK%2520protein%2520kinase%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1219%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">â</span> <span class="NLM_lpage">5921</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=K.+P.+Birauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0ljfpsIsp1OKCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6176</span><span class="NLM_x">â</span> <span class="NLM_lpage">6193</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=K.+P.+Birauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavailable+JAK1+inhibitors+with+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2</span></div><div class="casAuthors">Zak, Mark; Mendonca, Rohan; Balazs, Mercedesz; Barrett, Kathy; Bergeron, Philippe; Blair, Wade S.; Chang, Christine; Deshmukh, Gauri; DeVoss, Jason; Dragovich, Peter S.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Gradl, Stefan; Hamman, Chris; Hanan, Emily J.; Harstad, Eric; Hewitt, Peter R.; Hurley, Christopher A.; Jin, Tian; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Koehler, Michael F. T.; Bir Kohli, Pawan; Kulagowski, Janusz J.; Labadie, Sharada; Liao, Jiangpeng; Liimatta, Marya; Lin, Zhonghua; Lupardus, Patrick J.; Maxey, Robert J.; Murray, Jeremy M.; Pulk, Rebecca; Rodriguez, Madeleine; Savage, Scott; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Xiao, Ling; Xiao, Yisong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6176-6193</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the discovery of the C-2 Me substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.  The C-2 Me substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compd. 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochem. and cell-based assays, resp.).  Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated.  Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20).  Details of the biol. characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclin. in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogQqQMRvwKbVg90H21EOLACvtfcHk0lh1uBGeuwA4wA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmtLg%253D&md5=8c57a4cb02fc245ed12f6f4efdb82318</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavailable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">â</span> <span class="NLM_lpage">4785</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=K.+P.+Birauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+A.+vanauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroxyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%26aufirst%3DK.%2BP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%26aufirst%3DA.%2BA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroxyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lynch, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVicente, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermann, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaime-Figueroa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tivitmahaisoon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, C.</span><span> </span><span class="NLM_article-title">Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2793</span><span class="NLM_x">â</span> <span class="NLM_lpage">2800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2793-2800&author=S.+M.+Lynchauthor=J.+DeVicenteauthor=J.+C.+Hermannauthor=S.+Jaime-Figueroaauthor=S.+Jinauthor=A.+Kuglstatterauthor=H.+Liauthor=A.+Loveyauthor=J.+Menkeauthor=L.+Niuauthor=V.+Patelauthor=D.+Royauthor=M.+Sothauthor=S.+Steinerauthor=P.+Tivitmahaisoonauthor=M.+D.+Vuauthor=C.+Yee&title=Strategic+use+of+conformational+bias+and+structure+based+design+to+identify+potent+JAK3+inhibitors+with+improved+selectivity+against+the+JAK+family+and+the+kinome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%2BM.%26aulast%3DDeVicente%26aufirst%3DJ.%26aulast%3DHermann%26aufirst%3DJ.%2BC.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DMenke%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DS.%26aulast%3DTivitmahaisoon%26aufirst%3DP.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DYee%26aufirst%3DC.%26atitle%3DStrategic%2520use%2520of%2520conformational%2520bias%2520and%2520structure%2520based%2520design%2520to%2520identify%2520potent%2520JAK3%2520inhibitors%2520with%2520improved%2520selectivity%2520against%2520the%2520JAK%2520family%2520and%2520the%2520kinome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2793%26epage%3D2800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H.-G.</span><span> </span><span class="NLM_article-title">Identification of a potent janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.-G.+Zerwes&title=Identification+of+a+potent+janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.-G.%26atitle%3DIdentification%2520of%2520a%2520potent%2520janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lin, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadros, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appell, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimble, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewet, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krykbaev, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidl, K. J.</span><span> </span><span class="NLM_article-title">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2283</span><span class="NLM_x">â</span> <span class="NLM_lpage">2293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1002%2Fart.27536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20506481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2283-2293&issue=8&author=T.+H.+Linauthor=M.+Hegenauthor=E.+Quadrosauthor=C.+L.+Nickerson-Nutterauthor=K.+C.+Appellauthor=A.+G.+Coleauthor=Y.+Shaoauthor=S.+Tamauthor=M.+Ohlmeyerauthor=B.+Wangauthor=D.+G.+Goodwinauthor=E.+F.+Kimbleauthor=J.+Quinteroauthor=M.+Gaoauthor=P.+Symanowiczauthor=C.+Wrocklageauthor=J.+Lussierauthor=S.+H.+Schellingauthor=A.+G.+Hewetauthor=D.+Xuanauthor=R.+Krykbaevauthor=J.+Togiasauthor=X.+Xuauthor=R.+Harrisonauthor=T.+Mansourauthor=M.+Collinsauthor=J.+D.+Clarkauthor=M.+L.+Webbauthor=K.+J.+Seidl&title=Selective+functional+inhibition+of+JAK-3+is+sufficient+for+efficacy+in+collagen-induced+arthritis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice</span></div><div class="casAuthors">Lin, Tsung H.; Hegen, Martin; Quadros, Elizabeth; Nickerson-Nutter, Cheryl L.; Appell, Kenneth C.; Cole, Andrew G.; Shao, Yuefei; Tam, Steve; Ohlmeyer, Michael; Wang, Bojing; Goodwin, Debra G.; Kimble, Earl F.; Quintero, Jorge; Gao, Min; Symanowicz, Peter; Wrocklage, Christopher; Lussier, Jennifer; Schelling, Scott H.; Hewet, Amha G.; Xuan, Dejun; Krykbaev, Rustem; Togias, Jenny; Xu, Xin; Harrison, Richard; Mansour, Tarek; Collins, Mary; Clark, James D.; Webb, Maria L.; Seidi, Katherine J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2283-2293</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. All Î³-chain cytokines signal through JAK-3 and JAK-1 acting in tandem.  We undertook this study to det. whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathol. without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.  Methods. JAK-3 kinase selective compds. were characterized by kinase assay and JAK-3-dependent (interleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF]) cell-based assays measuring proliferation or STAT phosphorylation.  In vivo, off-target signaling was measured by IL-22- and erythropoietin (EPO)-mediated models, while on-target signaling was measured by IL-2-mediated signaling.  Efficacy of JAK-3 inhibitors was detd. using delayed-type hypersensitivity (DTH) and collagen-induced arthritis (CIA) models in mice.  Results. In vitro, WYE-151650 potently suppressed IL-2-induced STAT-5 phosphorylation and cell proliferation, while exhibiting 10-29-fold less activity against JAK-3-independent IL-6- or GM-CSF-induced STAT phosphorylation.  Ex vivo, WYE-151650 suppressed IL-2-induced STAT phosphorylation, but not IL-6-induced STAT phosphorylation, as measured in whole blood.  In vivo, WYE-151650 inhibited JAK-3-mediated IL-2-induced interferon-Î³ prodn. and decreased the natural killer cell population in mice, while not affecting IL-22-induced serum amyloid A prodn. or EPO-induced reticulocytosis.  WYE-151650 was efficacious in mouse DTH and CIA models.  Conclusion. In vitro, ex vivo, and in vivo assays demonstrate that WYE-151650 is efficacious in mouse CIA despite JAK-3 selectivity.  These data question the need to broadly inhibit JAK-1-, JAK-2-, or Tyk-2-dependent cytokine pathways for efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogcss6tt3iw7Vg90H21EOLACvtfcHk0lhiQKLqycYYtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOiu7jP&md5=7fd4f4dae47df1d1a33d3fc0edf5e13d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fart.27536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27536%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DQuadros%26aufirst%3DE.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DAppell%26aufirst%3DK.%2BC.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DOhlmeyer%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGoodwin%26aufirst%3DD.%2BG.%26aulast%3DKimble%26aufirst%3DE.%2BF.%26aulast%3DQuintero%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DSchelling%26aufirst%3DS.%2BH.%26aulast%3DHewet%26aufirst%3DA.%2BG.%26aulast%3DXuan%26aufirst%3DD.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTogias%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DMansour%26aufirst%3DT.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DSeidl%26aufirst%3DK.%2BJ.%26atitle%3DSelective%2520functional%2520inhibition%2520of%2520JAK-3%2520is%2520sufficient%2520for%2520efficacy%2520in%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3D8%26spage%3D2283%26epage%3D2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span>Anonymous. <span> </span><span class="NLM_article-title">News in brief</span>.  <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous.+News+in+brief.+Nat.+Rev.+Drug+Discovery+2012%2C+11%2C+895."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DNews%2520in%2520brief%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span>Anonymous. <span> </span><span class="NLM_article-title">Tofacitinib (Xeljanz) for rheumatoid arthritis</span>.  <span class="citation_source-journal">Med. Lett. Drugs Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">3</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3s3ms1CktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous.+Tofacitinib+%28Xeljanz%29+for+rheumatoid+arthritis.+Med.+Lett.+Drugs+Ther.+2013%2C+55%2C+1%E2%80%933."target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib (Xeljanz) for rheumatoid arthritis</span></div><div class="casAuthors">Anonymous</div><div class="citationInfo"><span class="NLM_cas:title">The Medical letter on drugs and therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1407</span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUeOlD8ZOZmfxQvRxYU81tfW6udTcc2eZ6o6gR5mAytLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3ms1CktQ%253D%253D&md5=fef14b09b1940144c92fa778eee4dd60</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DTofacitinib%2520%2528Xeljanz%2529%2520for%2520rheumatoid%2520arthritis%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2013%26volume%3D55%26spage%3D1%26epage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimar, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescovitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">â</span> <span class="NLM_lpage">1718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-6143.2008.02307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1711-1718&author=G.+E.+vanauthor=W.+Weimarauthor=R.+Gastonauthor=D.+Brennanauthor=R.+Mendezauthor=J.+Pirschauthor=S.+Swanauthor=M.+D.+Pescovitzauthor=G.+Niauthor=C.+Wangauthor=S.+Krishnaswamiauthor=V.+Chowauthor=G.+Chan&title=Phase+1+dose-escalation+study+of+CP-690+550+in+stable+renal+allograft+recipients%3A+preliminary+findings+of+safety%2C+tolerability%2C+effects+on+lymphocyte+subsets+and+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics</span></div><div class="casAuthors">van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Pirsch, J.; Swan, S.; Pescovitz, M. D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1711-1718</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">CP-690 550 inhibits Janus kinase 3 with nanomolar potency.  In this dose-escalation study, we assessed the safety, tolerability, effects on lymphocyte subsets, and pharmacokinetics of CP-690 550 when coadministered with mycophenolate mofetil in stable renal allograft recipients for 28 days.  Twenty-eight patients were enrolled.  Six patients received CP-690 550 5 mg twice daily (BID), 6 patients received 15 mg BID, 10 patients received 30 mg BID, and 6 patients received placebo.  The most frequent adverse events were infections and gastrointestinal (abdominal pain, diarrhea, dyspepsia, and vomiting).  CP-690 550 15 mg BID and 30 mg BID were assocd. with a mean decrease in Hb from baseline of 11% and a mean decrease in abs. natural killer cell counts of 50%.  CP-690 550 30 mg BID was also assocd. with a mean increase in abs. CD19+ B-lymphocytes of 130%.  There were no changes in the no. of neutrophils, total lymphocytes, platelets, or CD4+ or CD8+ T cells; clin. chem.; vital signs; or electrocardiograms from the pretreatment baseline.  Administration of CP-690 550 without a concomitant calcineurin inhibitor resulted in CP-690 550 exposures consistent with previous studies in nontransplant subjects.  Addnl. dose-ranging studies are warranted to evaluate the safety and efficacy of CP-690 550 in renal transplant recipients over longer treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo69SNdm7tfMrVg90H21EOLACvtfcHk0ljHBivmn91nxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGhu7nJ&md5=14582e231681d5cb704f11d1cdfd54d5</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2008.02307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2008.02307.x%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%26aufirst%3DG.%2BE.%26aulast%3DWeimar%26aufirst%3DW.%26aulast%3DGaston%26aufirst%3DR.%26aulast%3DBrennan%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DR.%26aulast%3DPirsch%26aufirst%3DJ.%26aulast%3DSwan%26aufirst%3DS.%26aulast%3DPescovitz%26aufirst%3DM.%2BD.%26aulast%3DNi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DV.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DPhase%25201%2520dose-escalation%2520study%2520of%2520CP-690%2520550%2520in%2520stable%2520renal%2520allograft%2520recipients%253A%2520preliminary%2520findings%2520of%2520safety%252C%2520tolerability%252C%2520effects%2520on%2520lymphocyte%2520subsets%2520and%2520pharmacokinetics%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2008%26volume%3D8%26spage%3D1711%26epage%3D1718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Busque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klintmalm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulgaonkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromberg, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hariharan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slakey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peddi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawendy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1936</span><span class="NLM_x">â</span> <span class="NLM_lpage">1945</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1600-6143.2009.02720.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=19660021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1936-1945&author=S.+Busqueauthor=J.+Leventhalauthor=D.+C.+Brennanauthor=S.+Steinbergauthor=G.+Klintmalmauthor=T.+Shahauthor=S.+Mulgaonkarauthor=J.+S.+Brombergauthor=F.+Vincentiauthor=S.+Hariharanauthor=D.+Slakeyauthor=V.+R.+Peddiauthor=R.+A.+Fisherauthor=N.+Lawendyauthor=C.+Wangauthor=G.+Chan&title=Calcineurin-inhibitor-free+immunosuppression+based+on+the+JAK+inhibitor+CP-690%2C550%3A+a+pilot+study+in+de+novo+kidney+allograft+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in De novo kidney allograft recipients</span></div><div class="casAuthors">Busque, S.; Leventhal, J.; Brennan, D. C.; Steinberg, S.; Klintmalm, G.; Shah, T.; Mulgaonkar, S.; Bromberg, J. S.; Vincenti, F.; Hariharan, S.; Slakey, D.; Peddi, V. R.; Fisher, R. A.; Lawendy, N.; Wang, C.; Chan, G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Transplantation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1936-1945</span>CODEN:
                <span class="NLM_cas:coden">AJTMBR</span>;
        ISSN:<span class="NLM_cas:issn">1600-6135</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients.  Patients received an IL-2 receptor antagonist, concomitant mycophenolate mofetil (MMF) and corticosteroids.  CP-690,550 doses were reduced after 6 mo.  Due to a high incidence of BK virus nephropathy (BKN) in CP30, MMF was discontinued in this group.  The 6-mo biopsy-proven acute rejection rates were 1 of 20, 4 of 20 and 1 of 21 for CP15, CP30 and tacrolimus groups, resp.  BKN developed in 4 of 20 patients in CP30 group.  The 6-mo rates of cytomegalovirus disease were 2 of 20, 4 of 20 and none of 21 for CP15, CP30 and tacrolimus groups, resp.  Estd. glomerular filtration rate was >70 mL/min at 6 and 12 mo (all groups).  NK cells were reduced by <77% in CP-690,550-treated patients.  In the CP-690,550 arms, there were modest lipid elevations and a trend toward more frequent anemia and neutropenia during the first 6 mo.  These data suggest that coadministration of CP-690,550 30 mg BID with MMF is assocd. with overimmunosuppression.  At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection.  Further dose-ranging evaluation of CP-690,550 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptskDnsVhSnrVg90H21EOLACvtfcHk0ljHBivmn91nxg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGrurrP&md5=c63d35ad46e6041c3b63886aa75e424d</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-6143.2009.02720.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-6143.2009.02720.x%26sid%3Dliteratum%253Aachs%26aulast%3DBusque%26aufirst%3DS.%26aulast%3DLeventhal%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DD.%2BC.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DKlintmalm%26aufirst%3DG.%26aulast%3DShah%26aufirst%3DT.%26aulast%3DMulgaonkar%26aufirst%3DS.%26aulast%3DBromberg%26aufirst%3DJ.%2BS.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DHariharan%26aufirst%3DS.%26aulast%3DSlakey%26aufirst%3DD.%26aulast%3DPeddi%26aufirst%3DV.%2BR.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DCalcineurin-inhibitor-free%2520immunosuppression%2520based%2520on%2520the%2520JAK%2520inhibitor%2520CP-690%252C550%253A%2520a%2520pilot%2520study%2520in%2520de%2520novo%2520kidney%2520allograft%2520recipients%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2009%26volume%3D9%26spage%3D1936%26epage%3D1945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">â</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=S.-P.+Changauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lj2nC1L1wHMgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DS.-P.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsup, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward-Tharp, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x">, </span> <span class="NLM_fpage">4234</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=4234-4243&author=K.+Ghoreschiauthor=M.+I.+Jessonauthor=X.+Liauthor=J.+L.+Leeauthor=S.+Ghoshauthor=J.+W.+Alsupauthor=J.+D.+Warnerauthor=M.+Tanakaauthor=S.+M.+Steward-Tharpauthor=M.+Gadinaauthor=C.+J.+Thomasauthor=J.+C.+Minnerlyauthor=C.+E.+Storerauthor=T.+P.+LaBrancheauthor=Z.+A.+Radiauthor=M.+E.+Dowtyauthor=R.+D.+Headauthor=D.+M.+Meyerauthor=N.+Kishoreauthor=J.+J.+O%E2%80%99Shea&title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAlsup%26aufirst%3DJ.%2BW.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSteward-Tharp%26aufirst%3DS.%2BM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DRadi%26aufirst%3DZ.%2BA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHead%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DModulation%2520of%2520innate%2520and%2520adaptive%2520immune%2520responses%2520by%2520tofacitinib%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26spage%3D4234%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Watowich, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmore, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilton, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, H. F.</span><span> </span><span class="NLM_article-title">Homodimerization and constitutive activation of the erythropoietin receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2140</span><span class="NLM_x">â</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=2140-2144&issue=6&author=S.+S.+Watowichauthor=A.+Yoshimuraauthor=G.+D.+Longmoreauthor=D.+J.+Hiltonauthor=Y.+Yoshimuraauthor=H.+F.+Lodish&title=Homodimerization+and+constitutive+activation+of+the+erythropoietin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWatowich%26aufirst%3DS.%2BS.%26aulast%3DYoshimura%26aufirst%3DA.%26aulast%3DLongmore%26aufirst%3DG.%2BD.%26aulast%3DHilton%26aufirst%3DD.%2BJ.%26aulast%3DYoshimura%26aufirst%3DY.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DHomodimerization%2520and%2520constitutive%2520activation%2520of%2520the%2520erythropoietin%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1992%26volume%3D89%26issue%3D6%26spage%3D2140%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Perugini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booker, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojkoski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercus, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hibbs, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonda, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAndrea, R. J.</span><span> </span><span class="NLM_article-title">Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">3346</span><span class="NLM_x">â</span> <span class="NLM_lpage">3353</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3346-3353&issue=16&author=M.+Peruginiauthor=A.+L.+Brownauthor=D.+G.+Salernoauthor=G.+W.+Bookerauthor=C.+Stojkoskiauthor=T.+R.+Hercusauthor=A.+F.+Lopezauthor=M.+L.+Hibbsauthor=T.+J.+Gondaauthor=R.+J.+D%E2%80%99Andrea&title=Alternative+modes+of+GM-CSF+receptor+activation+revealed+using+activated+mutants+of+the+common+beta-subunit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerugini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DA.%2BL.%26aulast%3DSalerno%26aufirst%3DD.%2BG.%26aulast%3DBooker%26aufirst%3DG.%2BW.%26aulast%3DStojkoski%26aufirst%3DC.%26aulast%3DHercus%26aufirst%3DT.%2BR.%26aulast%3DLopez%26aufirst%3DA.%2BF.%26aulast%3DHibbs%26aufirst%3DM.%2BL.%26aulast%3DGonda%26aufirst%3DT.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DAlternative%2520modes%2520of%2520GM-CSF%2520receptor%2520activation%2520revealed%2520using%2520activated%2520mutants%2520of%2520the%2520common%2520beta-subunit%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26issue%3D16%26spage%3D3346%26epage%3D3353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgzlF-J4v6Ckg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audoly, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P.</span><span> </span><span class="NLM_article-title">Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">R14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R14&issue=1&author=A.+J.+Miliciauthor=E.+M.+Kudlaczauthor=L.+Audolyauthor=S.+Zwillichauthor=P.+Changelian&title=Cartilage+preservation+by+inhibition+of+Janus+kinase+3+in+two+rodent+models+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DAudoly%26aufirst%3DL.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DChangelian%26aufirst%3DP.%26atitle%3DCartilage%2520preservation%2520by%2520inhibition%2520of%2520Janus%2520kinase%25203%2520in%2520two%2520rodent%2520models%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2008%26volume%3D10%26issue%3D1%26spage%3DR14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsup, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward-Tharp, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radi, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâShea, J. J.</span><span> </span><span class="NLM_article-title">Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">186</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">4234</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2011&pages=4234-4243&issue=7&author=K.+Ghoreschiauthor=M.+I.+Jessonauthor=X.+Liauthor=J.+L.+Leeauthor=S.+Ghoshauthor=J.+W.+Alsupauthor=J.+D.+Warnerauthor=M.+Tanakaauthor=S.+M.+Steward-Tharpauthor=M.+Gadinaauthor=C.+J.+Thomasauthor=J.+C.+Minnerlyauthor=C.+E.+Storerauthor=T.+P.+LaBrancheauthor=Z.+A.+Radiauthor=M.+E.+Dowtyauthor=R.+D.+Headauthor=D.+M.+Meyerauthor=N.+Kishoreauthor=J.+J.+O%E2%80%99Shea&title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAlsup%26aufirst%3DJ.%2BW.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSteward-Tharp%26aufirst%3DS.%2BM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DRadi%26aufirst%3DZ.%2BA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DHead%26aufirst%3DR.%2BD.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DModulation%2520of%2520innate%2520and%2520adaptive%2520immune%2520responses%2520by%2520tofacitinib%2520%2528CP-690%252C550%2529%26jtitle%3DJ.%2520Immunol.%26date%3D2011%26volume%3D186%26issue%3D7%26spage%3D4234%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eZ9EHP3U8OoEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">LaBranche, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman-Brecks, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevlin, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Happa, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barve, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnerly, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, P. M.</span><span> </span><span class="NLM_article-title">Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">1388</span><span class="NLM_x">â</span> <span class="NLM_lpage">1396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.2353%2Fajpath.2010.100195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A280%3ADC%252BC3cjosVOnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2010&pages=1388-1396&issue=3&author=T.+P.+LaBrancheauthor=C.+L.+Hickman-Brecksauthor=D.+M.+Meyerauthor=C.+E.+Storerauthor=M.+I.+Jessonauthor=K.+M.+Shevlinauthor=F.+A.+Happaauthor=R.+A.+Barveauthor=D.+J.+Weissauthor=J.+C.+Minnerlyauthor=J.+L.+Raczauthor=P.+M.+Allen&title=Characterization+of+the+KRN+cell+transfer+model+of+rheumatoid+arthritis+%28KRN-CTM%29%2C+a+chronic+yet+synchronized+version+of+the+K%2FBxN+mouse"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse</span></div><div class="casAuthors">LaBranche Timothy P; Hickman-Brecks Cynthia L; Meyer Debra M; Storer Chad E; Jesson Michael I; Shevlin Kimberly M; Happa Fernando A; Barve Ruteja A; Weiss David J; Minnerly John C; Racz Jennifer L; Allen Paul M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1388-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this study, a chronic yet synchronized version of the K/BxN mouse, the KRN-cell transfer model (KRN-CTM), was developed and extensively characterized.  The transfer of purified splenic KRN T cells into T cell-deficient B6.TCR.Calpha(-/-)H-2(b/g7) mice induced anti-glucose 6-phosphate isomerase antibody-dependent chronic arthritis in 100% of the mice with uniform onset of disease 7 days after T cell transfer.  Cellular infiltrations were assessed by whole-ankle transcript microarray, cytokine and chemokine levels, and microscopic and immunohistochemical analyses 7 through 42 days after T cell transfer.  Transcripts identified an influx of monocytes/macrophages and neutrophils into the ankles and identified temporal progression of cartilage damage and bone resorption.  In both serum and ankle tissue there was a significant elevation in interleukin-6, whereas macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1 were only elevated in tissue.  Microscopic and immunohistochemical analyses revealed a time course for edema, synovial hypertrophy and hyperplasia, infiltration of F4/80-positive monocytes/macrophages and myeloperoxidase-positive neutrophils, destruction of articular cartilage, pannus invasion, bone resorption, extra-articular fibroplasia, and joint ankylosis.  The KRN cell transfer model replicates many features of chronic rheumatoid arthritis in humans in a synchronized manner and lends itself to manipulation of adoptively transferred T cells and characterizing specific genes and T cell subsets responsible for rheumatoid arthritis pathogenesis and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvU92OJyfajexsqfvU0ziafW6udTcc2eZVs8-oV45tHrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjosVOnsQ%253D%253D&md5=1944e48359e786c8ec0fd5f084ef522c</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2010.100195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2010.100195%26sid%3Dliteratum%253Aachs%26aulast%3DLaBranche%26aufirst%3DT.%2BP.%26aulast%3DHickman-Brecks%26aufirst%3DC.%2BL.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DStorer%26aufirst%3DC.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DShevlin%26aufirst%3DK.%2BM.%26aulast%3DHappa%26aufirst%3DF.%2BA.%26aulast%3DBarve%26aufirst%3DR.%2BA.%26aulast%3DWeiss%26aufirst%3DD.%2BJ.%26aulast%3DMinnerly%26aufirst%3DJ.%2BC.%26aulast%3DRacz%26aufirst%3DJ.%2BL.%26aulast%3DAllen%26aufirst%3DP.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520KRN%2520cell%2520transfer%2520model%2520of%2520rheumatoid%2520arthritis%2520%2528KRN-CTM%2529%252C%2520a%2520chronic%2520yet%2520synchronized%2520version%2520of%2520the%2520K%252FBxN%2520mouse%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2010%26volume%3D177%26issue%3D3%26spage%3D1388%26epage%3D1396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Fleischmann, R.</span><span> </span><span class="NLM_article-title">Novel small-molecular therapeutics for rheumatoid arthritis</span> <span class="citation_source-journal">Curr. Opin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1097%2FBOR.0b013e32835190ef" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22357358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=335-341&author=R.+Fleischmann&title=Novel+small-molecular+therapeutics+for+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small-molecular therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Fleischmann, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">CORHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-8711</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Since the introduction of biol. therapies into the treatment paradigm of rheumatoid arthritis (RA), there has been hope that oral small mol. immune modulators would be developed that would have a risk : benefit profile at least similar to biol. therapies, be more convenient for the patient and, hopefully, be less expensive.  This article reviews the progress made in the development of these compds. over the past year.  Recent findings: Addnl. information has become available in the past year on five oral compds. including kinase inhibitors (tofacitinib, fostamatinib, VX-509), an S1P lyase inhibitor (LX 3305) and a chemokine receptor-1 antagonist (CCX354-C).  Efficacy has been shown in phase III with tofacitinib and in phase II with fostamatinib and VX-509; safety was the primary endpoint of the trials of CCX354-C and LX3305.  Regarding side effects, liver test elevation and neutropenia occurred with tofacitinib, VX-509 and fostamatinib; lipid elevation with tofacitinib and VX-509; creatinine elevation and anemia with tofacitinib, and hypertension and diarrhea with fostamatinib.  Summary: Compds. that inhibit tyrosine kinase pathways involved in cellular signalling have been shown to be effective in the treatment of RA with a reasonable risk : benefit ratio.  It is too early to tell about inhibitors of other pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALXnYT2mHjLVg90H21EOLACvtfcHk0lgwFe0qQnyo-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOmsLk%253D&md5=46627d79c7fe388c3a9d0fe05d83b040</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2FBOR.0b013e32835190ef&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FBOR.0b013e32835190ef%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26atitle%3DNovel%2520small-molecular%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DCurr.%2520Opin.%2520Rheumatol.%26date%3D2012%26volume%3D24%26spage%3D335%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span>Xeljanz USPI.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Xeljanz+USPI."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Boy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, V. F.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clucas, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span> </span><span class="NLM_article-title">Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">2299</span><span class="NLM_x">â</span> <span class="NLM_lpage">2302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2009&pages=2299-2302&author=M.+G.+Boyauthor=C.+Wangauthor=B.+E.+Wilkinsonauthor=V.+F.-S.+Chowauthor=A.+T.+Clucasauthor=J.+G.+Kruegerauthor=A.+S.+Gawecoauthor=S.+H.+Zwillichauthor=P.+S.+Changelianauthor=G.+Chan&title=Double-blind%2C+placebo-controlled%2C+dose-escalation+study+to+evaluate+the+pharmacologic+effect+of+CP-690%2C550+in+patients+with+psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoy%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DChow%26aufirst%3DV.%2BF.-S.%26aulast%3DClucas%26aufirst%3DA.%2BT.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DChan%26aufirst%3DG.%26atitle%3DDouble-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520study%2520to%2520evaluate%2520the%2520pharmacologic%2520effect%2520of%2520CP-690%252C550%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2009%26volume%3D129%26spage%3D2299%26epage%3D2302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strober, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harness, J. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1111%2Fj.1365-2133.2012.11168.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GrsL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=668-677&author=K.+A.+Pappauthor=A.+Menterauthor=B.+Stroberauthor=R.+G.+Langleyauthor=M.+Buonannoauthor=R.+Wolkauthor=P.+Guptaauthor=S.+Krishnaswamiauthor=H.+Tanauthor=J.+A.+Harness&title=Efficacy+and+safety+of+tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+the+treatment+of+psoriasis%3A+a+phase+2b+randomized+placebo-controlled+dose-ranging+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study</span></div><div class="casAuthors">Papp, K. A.; Menter, A.; Strober, B.; Langley, R. G.; Buonanno, M.; Wolk, R.; Gupta, P.; Krishnaswami, S.; Tan, H.; Harness, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">668-677</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis.  This Phase 2b, 12-wk, dose-ranging study (A3921047, NCT00678210) aimed to characterize the exposure-response, efficacy and safety of tofacitinib vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  One hundred and ninety-seven patients were randomized.  The primary endpoint was the proportion of patients achieving a â¥ 75% redn. in the Psoriasis Area and Severity Index (PASI 75) score at week 12.  At week 12, PASI 75 response rates were significantly higher for all tofacitinib twice-daily groups: 25Â·0% (2 mg; P < 0Â·001), 40Â·8% (5 mg; P < 0Â·0001) and 66Â·7% (15 mg; P < 0Â·0001), compared with placebo (2Â·0%).  Significant increases in the proportion of PASI 75 responses were seen by week 4 and were maintained at week 12.  Exposure-response over the 0-15 mg tofacitinib twice-daily dose range was successfully characterized.  PASI 50, PASI 90 and Physician's Global Assessment response rates were also higher for tofacitinib vs. placebo.  The most frequently reported adverse events (AEs) were infections and infestations: 22Â·4% (2 mg twice daily), 20Â·4% (5 mg twice daily), 36Â·7% (15 mg twice daily) and 32Â·0% (placebo).  Discontinuations due to AEs were 6Â·0%, 2Â·0%, 4Â·1% and 6Â·1% of patients in the placebo, and 2, 5 and 15 mg twice-daily tofacitinib groups, resp.  Dose-dependent increases from baseline in mean serum high-d. lipoprotein, low-d. lipoprotein and total cholesterol, and decreases in Hb and neutrophils were obsd.  Short-term treatment with oral tofacitinib results in significant clin. improvement in patients with moderate-to-severe plaque psoriasis and is generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmKDEpf3aYmrVg90H21EOLACvtfcHk0ljJh-K6m0WB5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GrsL3L&md5=ca139728efe1e709442630b8da243ab2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2012.11168.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2012.11168.x%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DStrober%26aufirst%3DB.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DWolk%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DHarness%26aufirst%3DJ.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520tofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520psoriasis%253A%2520a%2520phase%25202b%2520randomized%2520placebo-controlled%2520dose-ranging%2520study%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2012%26volume%3D167%26spage%3D668%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Sandborn, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niezychowski, W.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">â</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMoa1112168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22894574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=616-624&author=W.+J.+Sandbornauthor=S.+Ghoshauthor=J.+Panesauthor=I.+Vranicauthor=C.+Suauthor=S.+Rousellauthor=W.+Niezychowski&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+in+active+ulcerative+colitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">616-624</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.  One addnl. treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-contg. cytokines including interleukins 2, 4, 7, 9, 15, and 21.  These cytokines are integral to lymphocyte activation, function, and proliferation.  Methods: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.  Patients were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or placebo twice daily for 8 wk.  The primary outcome was a clin. response at 8 wk, defined as an abs. decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an abs. rectal bleeding subscore of 0 or 1.  Results: The primary outcome, clin. response at 8 wk, occurred in 32%, 48%, 61%, and 78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 10 mg (P = 0.10), and 15 mg (P<0.001), resp., as compared with 42% of patients receiving placebo.  Clin. remission (defined as a Mayo score â¤2, with no subscore >1) at 8 wk occurred in 13%, 33%, 48%, and 41% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg (P<0.001), resp., as compared with 10% of patients receiving placebo.  There was a dose-dependent increase in both low-d. and high-d. lipoprotein cholesterol.  Three patients treated with tofacitinib had an abs. neutrophil count of less than 1500.  Conclusions: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clin. response and remission than those receiving placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_Al47Ev_6rVg90H21EOLACvtfcHk0lhyh-PwWQ8lhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Chu77K&md5=1ae8898c6de9bd24113b1f0a8e7fbed8</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112168%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DPanes%26aufirst%3DJ.%26aulast%3DVranic%26aufirst%3DI.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DRousell%26aufirst%3DS.%26aulast%3DNiezychowski%26aufirst%3DW.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520active%2520ulcerative%2520colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D616%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">â</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56aR"><div class="casContent"><span class="casTitleNuber">56a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lhyh-PwWQ8lhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. N.</span><span> </span><span class="NLM_article-title">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span> <span class="citation_source-journal">Ther. Adv. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1177%2F2040620712459746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=341-354&author=C.+Harrisonauthor=A.+N.+Vannucchi&title=Ruxolitinib%3A+a+potent+and+selective+Janus+kinase+1+and+2+inhibitor+in+patients+with+myelofibrosis.+An+update+for+clinicians"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians</span></div><div class="casAuthors">Harrison, Claire; Vannucchi, Alessandro N.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012.  Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently.  In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1M-lwEgpCrVg90H21EOLACvtfcHk0lgYojmX5gZ_dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslWntA%253D%253D&md5=6c88ade9fb3df126e6b0188b69a68d3c</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1177%2F2040620712459746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620712459746%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DVannucchi%26aufirst%3DA.%2BN.%26atitle%3DRuxolitinib%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%25201%2520and%25202%2520inhibitor%2520in%2520patients%2520with%2520myelofibrosis.%2520An%2520update%2520for%2520clinicians%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2012%26volume%3D3%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit56c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span> </span><span class="NLM_article-title">Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2397</span><span class="NLM_x">â</span> <span class="NLM_lpage">2407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56c&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F14656566.2012.732998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56c&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=2397-2407&author=K.+Vaddiauthor=N.+J.+Sarlisauthor=V.+Gupta&title=Ruxolitinib%2C+an+oral+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56cR"><div class="casContent"><span class="casTitleNuber">56c</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Vaddi, Kris; Sarlis, Nicholas J.; Gupta, Vikas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2397-2407</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) is a debilitating hematol. malignancy characterized by progressive splenomegaly, burdensome symptoms, cytopenias and shortened survival.  Chronic alterations in Janus-assocd. kinase-signal transducer and activator of transcription (JAK-STAT) signaling have been identified in the pathogenesis of MF, making this pathway a target for drug development.  Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration.  This review describes the characteristics of MF, the current therapeutic options and need for effective therapies, the contribution of aberrant JAK-STAT signaling to various disease-specific manifestations and the pharmacodynamics, pharmacokinetics, efficacy and tolerability of ruxolitinib.  Articles describing MF disease burden and results of ruxolitinib pre-clin. and clin. trials were identified and summarized.  Conventional MF treatments alleviate some MF symptoms but have limited efficacy, do not modify the natural history of the disease and are not approved for MF.  The JAK1 and JAK2 inhibitor ruxolitinib has shown promising results in pre-clin. and clin. trials.  In Phase III trials, ruxolitinib was shown to reduce splenomegaly and improve MF-related symptoms.  Recent evidence also suggests that ruxolitinib may improve survival.  The most common adverse events were anemia and thrombocytopenia, which were managed with dose adjustments (or red blood cell transfusions for anemia).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkaW-We0y2vrVg90H21EOLACvtfcHk0lgYojmX5gZ_dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtrrL&md5=460b020ad17c3828f8948ba9c24131cc</span></div><a href="/servlet/linkout?suffix=cit56c&amp;dbid=16384&amp;doi=10.1517%2F14656566.2012.732998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2012.732998%26sid%3Dliteratum%253Aachs%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DSarlis%26aufirst%3DN.%2BJ.%26aulast%3DGupta%26aufirst%3DV.%26atitle%3DRuxolitinib%252C%2520an%2520oral%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2012%26volume%3D13%26spage%3D2397%26epage%3D2407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Deisseroth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3212</span><span class="NLM_x">â</span> <span class="NLM_lpage">3217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+approval%3A+ruxolitinib+for+the+treatment+of+patients+with+intermediate+and+high-risk+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of â¥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a â¥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a â¥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a â¥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0lixlsYF4cWOAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520approval%253A%2520ruxolitinib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520intermediate%2520and%2520high-risk%2520myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3212%26epage%3D3217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Friedman, P. A.; Fridman, J. S.; Luchi, M. E.; Williams, W. V.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidine derivatives as Janus kinase inhibitors for treatment of dry eye and other eye related diseases</span>. WO2010039939A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=P.+A.+Friedman&author=J.+S.+Fridman&author=M.+E.+Luchi&author=W.+V.+Williams&title=Preparation+of+pyrrolopyrimidine+derivatives+as+Janus+kinase+inhibitors+for+treatment+of+dry+eye+and+other+eye+related+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DP.%2BA.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidine%2520derivatives%2520as%2520Janus%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520dry%2520eye%2520and%2520other%2520eye%2520related%2520diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit58b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rodgers, J. D.; Shepard, S.; Li, Y.-L.; Zhou, J.; Liu, P.; Meloni, D.; Xia, M.</span><span> </span><span class="NLM_article-title">Preparation of azetidine and cyclobutane derivatives as JAK inhibitors</span>. WO2009114512A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+D.+Rodgers&author=S.+Shepard&author=Y.-L.+Li&author=J.+Zhou&author=P.+Liu&author=D.+Meloni&author=M.+Xia&title=Preparation+of+azetidine+and+cyclobutane+derivatives+as+JAK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520azetidine%2520and%2520cyclobutane%2520derivatives%2520as%2520JAK%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit58c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rodgers, J. D.; Shepard, S.; Maduskuie, T. P.; Wang, H.; Falahatpisheh, N.; Rafalski, M.; Arvanitis, A. G.; Storace, L.; Jalluri, R. K.; Fridman, J. S.; Vaddi, K.</span><span> </span><span class="NLM_article-title">Preparation of heteroaryl substituted pyrrolo[2,3-<i>b</i>]pyridines and pyrrolo[2,3-<i>b</i>]pyrimidines as Janus kinase inhibitors</span>. US20070135461A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+D.+Rodgers&author=S.+Shepard&author=T.+P.+Maduskuie&author=H.+Wang&author=N.+Falahatpisheh&author=M.+Rafalski&author=A.+G.+Arvanitis&author=L.+Storace&author=R.+K.+Jalluri&author=J.+S.+Fridman&author=K.+Vaddi&title=Preparation+of+heteroaryl+substituted+pyrrolo%5B2%2C3-b%5Dpyridines+and+pyrrolo%5B2%2C3-b%5Dpyrimidines+as+Janus+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DPreparation%2520of%2520heteroaryl%2520substituted%2520pyrrolo%255B2%252C3-b%255Dpyridines%2520and%2520pyrrolo%255B2%252C3-b%255Dpyrimidines%2520as%2520Janus%2520kinase%2520inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">844</span><span class="NLM_x">â</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMe1115119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=844-846&issue=9&author=A.+Tefferi&title=Challenges+facing+JAK+inhibitor+therapy+for+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">844-846</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnem-u-DDG1rVg90H21EOLACvtfcHk0lixlsYF4cWOAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qu78%253D&md5=5623bc5a33b70efe6c54301078454ba5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1115119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1115119%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DChallenges%2520facing%2520JAK%2520inhibitor%2520therapy%2520for%2520myeloproliferative%2520neoplasms%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26issue%3D9%26spage%3D844%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span>ClinicalTrials.gov identifier: NCT01633372.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+identifier%3A+NCT01633372."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Fridman, J.; Scherle, P.; Collins, R.; Li, Y.; Shepard, S.; Sparks, R.; Arvanitis, A.; Shi, G.; Combs, A.; Rodgers, J.; Neilan, C.; Contel, N.; Haley, P.; Yeleswaram, S.; Newton, R.; Friedman, S.; Vaddi, K.</span><span> </span><span class="NLM_article-title">Efficacy and Tolerability of Novel JAK Inhibitors in Animal Models of Rheumatoid Arthritis</span>. Presented at the 2007 Annual Scientific Meeting of the American College of Rheumatology,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Abstract 1771.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Fridman&author=P.+Scherle&author=R.+Collins&author=Y.+Li&author=S.+Shepard&author=R.+Sparks&author=A.+Arvanitis&author=G.+Shi&author=A.+Combs&author=J.+Rodgers&author=C.+Neilan&author=N.+Contel&author=P.+Haley&author=S.+Yeleswaram&author=R.+Newton&author=S.+Friedman&author=K.+Vaddi&title=Efficacy+and+Tolerability+of+Novel+JAK+Inhibitors+in+Animal+Models+of+Rheumatoid+Arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520Tolerability%2520of%2520Novel%2520JAK%2520Inhibitors%2520in%2520Animal%2520Models%2520of%2520Rheumatoid%2520Arthritis%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W.</span><span> </span><span class="NLM_article-title">24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S1049</span><span class="NLM_x">â</span> <span class="NLM_lpage">S1050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S1049-S1050&author=M.+C.+Genoveseauthor=E.+Keystoneauthor=P.+Taylorauthor=E.+Drescherauthor=P.-Y.+Berclazauthor=C.+H.+Leeauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=W.+Macias&title=24-week+results+of+a+blinded+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease+modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DBerclaz%26aufirst%3DP.-Y.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DMacias%26aufirst%3DW.%26atitle%3D24-week%2520results%2520of%2520a%2520blinded%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease%2520modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS1049%26epage%3DS1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roddriguez, J. C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, C. L.</span><span> </span><span class="NLM_article-title">12-and 24-week patient reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/jJanus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S214</span><span class="NLM_x">â</span> <span class="NLM_lpage">S220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S214-S220&author=J.+S.+Smolenauthor=D.+E.+Schlichtingauthor=K.+L.+Sterlingauthor=E.+Keystoneauthor=P.+Taylorauthor=M.+C.+Genoveseauthor=L.+Johnsonauthor=J.+C.+R.+Roddriguezauthor=C.+H.+Leeauthor=C.+L.+Gaich&title=12-and+24-week+patient+reported+outcomes+from+a+phase+2b+dose-ranging+study+of+baricitinib%2C+an+oral+Janus+kinase+1%2FjJanus+kinase+2+inhibitor%2C+in+combination+with+traditional+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSterling%26aufirst%3DK.%2BL.%26aulast%3DKeystone%26aufirst%3DE.%26aulast%3DTaylor%26aufirst%3DP.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DRoddriguez%26aufirst%3DJ.%2BC.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DGaich%26aufirst%3DC.%2BL.%26atitle%3D12-and%252024-week%2520patient%2520reported%2520outcomes%2520from%2520a%2520phase%25202b%2520dose-ranging%2520study%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%25201%252FjJanus%2520kinase%25202%2520inhibitor%252C%2520in%2520combination%2520with%2520traditional%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS214%26epage%3DS220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span> </span><span class="NLM_article-title">Decernotinib: Statement on a Nonproprietary Name Adopted by the USAN Council</span>; July 31,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>USAN (ZZ-20) = decernotinib.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Decernotinib%3A+Statement+on+a+Nonproprietary+Name+Adopted+by+the+USAN+Council%3B+July+31%2C+2013%3B+USAN+%28ZZ-20%29+%3D+decernotinib."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DDecernotinib%253A%2520Statement%2520on%2520a%2520Nonproprietary%2520Name%2520Adopted%2520by%2520the%2520USAN%2520Council%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Thakkar, M.; Koul, S.; Bhuniya, D.; Singh, U.</span><span> </span><span class="NLM_article-title">Preparation of substituted heterobicyclic compounds, compositions and medicinal applications thereof</span>. WO2013157021A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Thakkar&author=S.+Koul&author=D.+Bhuniya&author=U.+Singh&title=Preparation+of+substituted+heterobicyclic+compounds%2C+compositions+and+medicinal+applications+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThakkar%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520substituted%2520heterobicyclic%2520compounds%252C%2520compositions%2520and%2520medicinal%2520applications%2520thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Farmer, L.; Martinez-Botella, G.; Pierce, A.; Salituro, F.; Wang, J.; Wannamker, M.; Wang, T.</span><span> </span><span class="NLM_article-title">Azaindoles useful as inhibitors of Janus kinases and their preparation and use in the treatment of diseases</span>. WO2007084557A2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Farmer&author=G.+Martinez-Botella&author=A.+Pierce&author=F.+Salituro&author=J.+Wang&author=M.+Wannamker&author=T.+Wang&title=Azaindoles+useful+as+inhibitors+of+Janus+kinases+and+their+preparation+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DL.%26atitle%3DAzaindoles%2520useful%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">â</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+Tyk2+inhibitor+patents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0lhPQ_Zy2NkBKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520Tyk2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J. M.; Hodges, A. J.; Vater, H. D.</span><span> </span><span class="NLM_article-title">Preparation of pyrazolopyridines as JAK inhibitors useful in the treatment of degenerative and inflammatory diseases</span>. WO2012146659A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+M.+Menet&author=A.+J.+Hodges&author=H.+D.+Vater&title=Preparation+of+pyrazolopyridines+as+JAK+inhibitors+useful+in+the+treatment+of+degenerative+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520pyrazolopyridines%2520as%2520JAK%2520inhibitors%2520useful%2520in%2520the%2520treatment%2520of%2520degenerative%2520and%2520inflammatory%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C. J. M.; Hodges, A. J.; Vater, H. D.</span><span> </span><span class="NLM_article-title">Preparation of pyrazolopyridine derivatives for use as JAK kinase inhibitors</span>. WO2012146657A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+J.+M.+Menet&author=A.+J.+Hodges&author=H.+D.+Vater&title=Preparation+of+pyrazolopyridine+derivatives+for+use+as+JAK+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520pyrazolopyridine%2520derivatives%2520for%2520use%2520as%2520JAK%2520kinase%2520inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span>Clinicaltrialsregister.eu, EudraCT no.: 2012-003635-31.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinicaltrialsregister.eu%2C+EudraCT+no.%3A+2012-003635-31."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span> <span class="citation_source-book">WHO Drug Information</span>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">26</span>, No. <span class="NLM_issue">4</span>, p  <span class="NLM_fpage">419</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=WHO+Drug+Information%3B+World+Health+Organization%3A+Geneva%2C+Switzerland%2C+2012%3B+Vol.+26%2C+No.+4%2C+p+419."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWHO%2520Drug%2520Information%26pub%3DWorld%2520Health%2520Organization%26date%3D2012%26volume%3D26%26issue%3D4%26spage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J. M.; Smits, K. K.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-(triazolopyridinyl)carboxamides as JAK kinase inhibitors and useful in treatment of diseases</span>. WO2010149769A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+J.+M.+Menet&author=K.+K.+Smits&title=Preparation+of+N-%28triazolopyridinyl%29carboxamides+as+JAK+kinase+inhibitors+and+useful+in+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DPreparation%2520of%2520N-%2528triazolopyridinyl%2529carboxamides%2520as%2520JAK%2520kinase%2520inhibitors%2520and%2520useful%2520in%2520treatment%2520of%2520diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit71b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Menet, C. J. M.; Van, R. L. J. C.; Fletcher, S. R.; Blanc, J.; Jouannigot, N.; Hodges, A. J.; Smits, K. K.</span><span> </span><span class="NLM_article-title">Novel triazolopyridine compounds as JAK kinase inhibitors useful for the treatment of degenerative and inflammatory diseases and their preparation</span>. WO2010010190A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+J.+M.+Menet&author=R.+L.+J.+C.+Van&author=S.+R.+Fletcher&author=J.+Blanc&author=N.+Jouannigot&author=A.+J.+Hodges&author=K.+K.+Smits&title=Novel+triazolopyridine+compounds+as+JAK+kinase+inhibitors+useful+for+the+treatment+of+degenerative+and+inflammatory+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%2BM.%26atitle%3DNovel%2520triazolopyridine%2520compounds%2520as%2520JAK%2520kinase%2520inhibitors%2520useful%2520for%2520the%2520treatment%2520of%2520degenerative%2520and%2520inflammatory%2520diseases%2520and%2520their%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Van, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van, d. A. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeghinste, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanât Klooster, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menet, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">3568</span><span class="NLM_x">â</span> <span class="NLM_lpage">3577</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&issue=7&author=R.+L.+Vanauthor=R.+Galienauthor=d.+A.+E.+M.+vanauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van%E2%80%99t+Kloosterauthor=J.+H.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%26aufirst%3DR.%2BL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%26aufirst%3Dd.%2BA.%2BE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26issue%3D7%26spage%3D3568%26epage%3D3577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Namour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyle, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoutte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Aa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smets, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klooster, G.</span><span> </span><span class="NLM_article-title">Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">S573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=S573&author=F.+Namourauthor=R.+Galienauthor=L.+Gheyleauthor=F.+Vanhoutteauthor=B.+Vayssiereauthor=A.+Van+der+Aaauthor=B.+Smetsauthor=G.+Klooster&title=Once+daily+high+dose+regimens+of+GLPG0634+in+healthy+volunteers+are+safe+and+provide+continuous+inhibition+of+JAK1+but+not+JAK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DGheyle%26aufirst%3DL.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DKlooster%26aufirst%3DG.%26atitle%3DOnce%2520daily%2520high%2520dose%2520regimens%2520of%2520GLPG0634%2520in%2520healthy%2520volunteers%2520are%2520safe%2520and%2520provide%2520continuous%2520inhibition%2520of%2520JAK1%2520but%2520not%2520JAK2%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3DS573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Galien, R.; VayssiÃ¨re, B.; Vos, S.; Auberval, M.; Vandeghinste, N.; Dupont, S.; ClÃ©ment-Lacroix, P.; Delerive, P.; Vanhoutte, F.; Brys, R.; Van der Aa, A.; Van Rompaey, L.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Analysis of the JAK1 Selectivity of GLPG0634 and Its Main Metabolite in Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients</span>. Presented at the Annual Meeting of ACR/ARHP, San Diego, CA, Oct 26â30,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 478.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Galien&author=B.+Vayssi%C3%A8re&author=S.+Vos&author=M.+Auberval&author=N.+Vandeghinste&author=S.+Dupont&author=P.+Cl%C3%A9ment-Lacroix&author=P.+Delerive&author=F.+Vanhoutte&author=R.+Brys&author=A.+Van+der+Aa&author=L.+Van+Rompaey&author=G.+van%E2%80%99t+Klooster&title=Analysis+of+the+JAK1+Selectivity+of+GLPG0634+and+Its+Main+Metabolite+in+Different+Species%2C+Healthy+Volunteers+and+Rheumatoid+Arthritis+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGalien%26aufirst%3DR.%26atitle%3DAnalysis%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520GLPG0634%2520and%2520Its%2520Main%2520Metabolite%2520in%2520Different%2520Species%252C%2520Healthy%2520Volunteers%2520and%2520Rheumatoid%2520Arthritis%2520Patients%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Namour, F.; Galien, R.; Vanhoutte, F. P.; Wigerinck, P.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, Is Supported by Its Active Metabolite</span>. Presented at EULAR 2013, Madrid, Spain, June 12â15,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract THU0236.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Namour&author=R.+Galien&author=F.+P.+Vanhoutte&author=P.+Wigerinck&author=G.+van%E2%80%99t+Klooster&title=Once-Daily+Dosing+of+GLPG0634%2C+a+Selective+JAK1+Inhibitor%2C+Is+Supported+by+Its+Active+Metabolite"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DNamour%26aufirst%3DF.%26atitle%3DOnce-Daily%2520Dosing%2520of%2520GLPG0634%252C%2520a%2520Selective%2520JAK1%2520Inhibitor%252C%2520Is%2520Supported%2520by%2520Its%2520Active%2520Metabolite%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Tasset, C.; Harrison, P.; Van der Aa, A.; Meuleners, L.; Vanhoutte, F.; vanât Klooster, G.</span><span> </span><span class="NLM_article-title">The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity in Patients with Moderate to Severe Rheumatoid Arthritis; Results of a 4-Week Dose Ranging Study</span>. Presented at the Annual Meeting of ACR/ARHP, San Diego, CA, Oct 26â30,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 2381.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Tasset&author=P.+Harrison&author=A.+Van+der+Aa&author=L.+Meuleners&author=F.+Vanhoutte&author=G.+van%E2%80%99t+Klooster&title=The+JAK1-Selective+Inhibitor+GLPG0634+Is+Safe+and+Rapidly+Reduces+Disease+Activity+in+Patients+with+Moderate+to+Severe+Rheumatoid+Arthritis%3B+Results+of+a+4-Week+Dose+Ranging+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTasset%26aufirst%3DC.%26atitle%3DThe%2520JAK1-Selective%2520Inhibitor%2520GLPG0634%2520Is%2520Safe%2520and%2520Rapidly%2520Reduces%2520Disease%2520Activity%2520in%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Rheumatoid%2520Arthritis%253B%2520Results%2520of%2520a%25204-Week%2520Dose%2520Ranging%2520Study%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span> </span><span class="NLM_article-title">AC430, a potent JAK2 inhibitor, provides protection in multiple inflammatory and autoimmune disease models</span> <span class="citation_source-journal">Arthritis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=269&issue=Suppl.+10&author=B.+Belliauthor=D.+Brighamauthor=A.+Daoauthor=R.+Nepomucenoauthor=E.+Settiauthor=G..+Liuauthor=M.+Haddauthor=S.+Bhagwatauthor=W.+Wierengaauthor=M.+Holladayauthor=R.+C.+Armstrong&title=AC430%2C+a+potent+JAK2+inhibitor%2C+provides+protection+in+multiple+inflammatory+and+autoimmune+disease+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DDao%26aufirst%3DA.%26aulast%3DNepomuceno%26aufirst%3DR.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DG..%26aulast%3DHadd%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DWierenga%26aufirst%3DW.%26aulast%3DHolladay%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26atitle%3DAC430%252C%2520a%2520potent%2520JAK2%2520inhibitor%252C%2520provides%2520protection%2520in%2520multiple%2520inflammatory%2520and%2520autoimmune%2520disease%2520models%26jtitle%3DArthritis%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Tanaka, Y.</span><span> </span><span class="NLM_article-title">Kinase inhibition by low molecular weight products in the treatment of autoimmune diseases</span> <span class="citation_source-journal">Saishin Igaku</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">â</span> <span class="NLM_lpage">703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Slurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=692-703&author=Y.+Tanaka&title=Kinase+inhibition+by+low+molecular+weight+products+in+the+treatment+of+autoimmune+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibition by low molecular weight products in the treatment of autoimmune diseases</span></div><div class="casAuthors">Tanaka, Yoshiya</div><div class="citationInfo"><span class="NLM_cas:title">Saishin Igaku</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3, Zokango</span>),
    <span class="NLM_cas:pages">692-703</span>CODEN:
                <span class="NLM_cas:coden">SAIGAK</span>;
        ISSN:<span class="NLM_cas:issn">0370-8241</span>.
    
            (<span class="NLM_cas:orgname">Saishin Igakusha</span>)
        </div><div class="casAbstract">A review on action mechanism of tofacitinib; a low mol. wt. and Jak3 competitive inhibitor, on autoimmune diseases such as rheumatoid arthritis with clin. efficacy and safety.  Novel Jak3 specific inhibitors, VX-509 or ASP015k, Syk (spleen tyrosine kinase) inhibitor, calcineurin inhibitors, and Jak-Stat signal inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsAMGRmpNsfrVg90H21EOLACvtfcHk0lhUXDn81GTe2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Slurw%253D&md5=2b65a89fba260ef0efad5b1a0bae58ee</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26atitle%3DKinase%2520inhibition%2520by%2520low%2520molecular%2520weight%2520products%2520in%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DSaishin%2520Igaku%26date%3D2013%26volume%3D68%26spage%3D692%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braselmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wicks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossbard, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullard, D. C.</span><span> </span><span class="NLM_article-title">JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">2183</span><span class="NLM_x">â</span> <span class="NLM_lpage">2192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=2183-2192&author=B.+Y.+Changauthor=F.+Zhaoauthor=X.+Heauthor=H.+Renauthor=S.+Braselmannauthor=V.+Taylorauthor=J.+Wicksauthor=D.+G.+Payanauthor=E.+B.+Grossbardauthor=P.+R.+Pineauthor=D.+C.+Bullard&title=JAK3+inhibition+significantly+attenuates+psoriasiform+skin+inflammation+in+CD18+mutant+PL%2FJ+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DBraselmann%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DV.%26aulast%3DWicks%26aufirst%3DJ.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DGrossbard%26aufirst%3DE.%2BB.%26aulast%3DPine%26aufirst%3DP.%2BR.%26aulast%3DBullard%26aufirst%3DD.%2BC.%26atitle%3DJAK3%2520inhibition%2520significantly%2520attenuates%2520psoriasiform%2520skin%2520inflammation%2520in%2520CD18%2520mutant%2520PL%252FJ%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D2183%26epage%3D2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">4123</span><span class="NLM_x">â</span> <span class="NLM_lpage">4134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+novel+inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520novel%2520inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4123%26epage%3D4134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit80b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit80c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle (9<i>E</i>)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2623</span><span class="NLM_x">â</span> <span class="NLM_lpage">2640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201454n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2623-2640&author=A.+D.+Williamauthor=A.+C.+H.+Leeauthor=A.+Poulsenauthor=K.+C.+Gohauthor=B.+Madanauthor=S.+Hartauthor=E.+Tanauthor=H.+Wangauthor=H.+Nagarajauthor=D.+Chenauthor=C.+P.+Leeauthor=E.+T.+Sunauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+%289E%29-15-%282-%28pyrrolidin-1-yl%29ethoxy%29-7%2C12%2C25-trioxa-19%2C21%2C24-triaza-tetracyclo%5B18.3.1.1%282%2C5%29.1%2814%2C18%29%5Dhexacosa-1%2824%29%2C2%2C4%2C9%2C14%2826%29%2C15%2C17%2C20%2C22-nonaene+%28SB1578%29%2C+a+potent+inhibitor+of+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80c&amp;dbid=16384&amp;doi=10.1021%2Fjm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201454n%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%2520%25289E%2529-15-%25282-%2528pyrrolidin-1-yl%2529ethoxy%2529-7%252C12%252C25-trioxa-19%252C21%252C24-triaza-tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255Dhexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-nonaene%2520%2528SB1578%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2623%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">See, C. S.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010â2012</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1517%2F13543776.2013.765862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=449-501&issue=4&author=B.+W.+Dymockauthor=C.+S.+See&title=Inhibitors+of+JAK2+and+JAK3%3A+an+update+on+the+patent+literature+2010%E2%80%932012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span></div><div class="casAuthors">Dymock, Brian W.; See, Cheng Shang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-501</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally implicated in cell signaling processes important in cancer and immune-inflammatory diseases.  Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.  There are many new JAK family enzyme inhibitors in the clinic now with a range of selectivity profiles.  More selective JAK2 or JAK3 compds. are now coming through in considerable nos. and this review attempts to provide an update of the recent patent literature of those new compds.  An overview is given on the diversity of core structures employed for inhibitor design showing that the vast majority of compds. are based on classic ATP-competitive kinase inhibitor heterocycles.Areas covered: This review updates new patents claiming JAK2 and/or JAK3 inhibitors published from 2010 to 2012.  Pre-2010 patents have been extensively covered in previous reviews.  Comments on the context of each chem. series are given where applicable to orient the readers on the bewildering array of mol. designs now available.  This review does not cover JAK1 or TYK2 inhibitors but mention is made of these where they occur within series of JAK2/3 inhibitors.  Given the overlap between many pharmacophores, it was not possible to completely sep. inhibitors of JAK2 from JAK3, hence the material is organized by JAK2, JAK3 and JAK2/3 and within each section by alphabetical order of the patent assignee, some companies having published five or more patents, such as Ambit (10), Incyte (9), Galapagos (7), Almirall (6) and Biocryst (5).  A total of 98 patents are reviewed herein.Expert opinion: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.  Selectivity against the four individual JAK family enzymes, JAK1, 2, 3 and TYK2, is now a key goal since they each play subtly different roles in cytokine-induced cell signaling.  The future looks bright for patients as many new drugs are being developed and now combinations of JAK inhibitors with other targeted agents are being studied in the clinic.  These advances are expected to lead to further significant progress improving patient outcomes and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpx3w37MTHrVg90H21EOLACvtfcHk0liwMsote5hOaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D&md5=a958c185f6c6d500ce19c04eb5665247</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DSee%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520JAK2%2520and%2520JAK3%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202010%25E2%2580%25932012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D449%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">The pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">2205</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1056%2FNEJMra1004965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=22150039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=2205-2219&issue=23&author=I.+B.+McInnesauthor=G.+Schett&title=The+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">The pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Lain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2205-2219</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses key pathogenic advances in rheumatoid arthritis, genetics, environmental factors, immunol. processes, inflammation, and structural damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJslDVaG7MxbVg90H21EOLACvtfcHk0liwMsote5hOaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajsrrM&md5=31a79ccb05bca03f207b15f934b2d52d</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1004965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1004965%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DThe%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26issue%3D23%26spage%3D2205%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit82b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schett, G.</span><span> </span><span class="NLM_article-title">Cytokines in the pathogenesis of rheumatoid arthritis</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">â</span> <span class="NLM_lpage">442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Fjm401490p&amp;key=10.1038%2Fnri2094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=8&amp;doi=10.1021%2Fjm401490p&amp;key=17525752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=32&amp;doi=10.1021%2Fjm401490p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-442&issue=6&author=I.+B.+McInnesauthor=G.+Schett&title=Cytokines+in+the+pathogenesis+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82bR"><div class="casContent"><span class="casTitleNuber">82b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokines in the pathogenesis of rheumatoid arthritis</span></div><div class="casAuthors">McInnes, Iain B.; Schett, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-442</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytokines regulate a broad range of inflammatory processes that are implicated in the pathogenesis of rheumatoid arthritis.  In rheumatoid joints, it is well known that an imbalance between pro- and anti-inflammatory cytokine activities favors the induction of autoimmunity, chronic inflammation and thereby joint damage.  However, it remains less clear how cytokines are organized within a hierarchical regulatory network, and therefore which cytokines may be the best targets for clin. intervention a priori.  Here, we discuss the crucial effector function of cytokines in the immunol. processes that are central to the pathogenesis of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0RdTFn7jhXLVg90H21EOLACvtfcHk0liwMsote5hOaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kgt74%253D&md5=139510ac7d6607fbd46c6d32f781dfc6</span></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1038%2Fnri2094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2094%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DSchett%26aufirst%3DG.%26atitle%3DCytokines%2520in%2520the%2520pathogenesis%2520of%2520rheumatoid%2520arthritis%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26issue%3D6%26spage%3D429%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Martin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towne, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kricorian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klekotka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudjonsson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, C. B.</span><span> </span><span class="NLM_article-title">The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=17-26&author=D.+A.+Martinauthor=J.+E.+Towneauthor=G.+Kricorianauthor=P.+Klekotkaauthor=J.+E.+Gudjonssonauthor=J.+G.+Kruegerauthor=C.+B.+Russell&title=The+emerging+role+of+IL-17+in+the+pathogenesis+of+psoriasis%3A+preclinical+and+clinical+findings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DD.%2BA.%26aulast%3DTowne%26aufirst%3DJ.%2BE.%26aulast%3DKricorian%26aufirst%3DG.%26aulast%3DKlekotka%26aufirst%3DP.%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DRussell%26aufirst%3DC.%2BB.%26atitle%3DThe%2520emerging%2520role%2520of%2520IL-17%2520in%2520the%2520pathogenesis%2520of%2520psoriasis%253A%2520preclinical%2520and%2520clinical%2520findings%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2013%26volume%3D133%26spage%3D17%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="note"><p class="first last">HWB cytokine induced STAT phosphorylation assays procedure: Compounds were prepared as 30 mM stocks in 100% DMSO and then diluted to 5 mM. A 10-point 2.5 dilution series was created in DMSO with a top concentration of 5 mM. Further dilution was done by adding 4 Î¼L of the above test article solutions into 96 Î¼L of PBS with a top concentration of 200 Î¼M. To a 96-well polypropylene plate (VWR 82007-292) 90 Î¼L of HWB was added per well, followed by addition of 5 Î¼L compound solutions prepared above to give a top concentration of 10 Î¼M. The plate was mixed and incubated for 45 min at 37 Â°C. To each well was added 5 Î¼L of IFNÎ± (Universal Type I IFN, R&D Systems catalog no. 11200-2; final concentration of 5000 U/mL) or IL-6 (R&D Systems, catalog no. 206-IL; final concentration of 100 ng/mL) or IL-15 (R&D Systems, catalog no. 247-IL; final concentration of 100 ng/mL) or IL-12 (R&D Systems, catalog no. 219-ILl final concentration of 100 ng/mL) or IL-23 (R&D Systems, catalog no. 1290-IL; final concentration of 100 ng/mL) or D-PBS (unstimulated control), mixed, and incubated for 15 min at 37 Â°C. The reaction was quenched by adding lyse/fix buffer [BD Phosflow 5Ã lyse/fix buffer (BD catalog no. 558049)] to all wells at 1000 Î¼L/well, and the samples were incubated for 20 min at 37 Â°C. After the samples were washed with FACS buffer [D-PBS (Invitrogen catalog no. 14190) containing 0.1% BSA and 0.1% sodium azide], 400 Î¼L of ice cold 90% methanol/water was added to each well and incubated on ice for 30 min. One more wash was done with cold FACS buffer, and all samples were finally resuspended in 250 Î¼L/well of the desired fluorochrome-labeled anti-phospho-STAT antibody (BD) at 1:125 dilution in FACS buffer. After overnight incubation at 4 Â°C all the samples were transferred into a 96-well polypropylene U-bottom plate (Falcon catalog no. 353077) and STATs phosphorylation were analyzed and quantified using a FACS Canto flow cytometer.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401490p&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm401490p%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401490p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0df259a3ad203","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
